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GEnERAl InTRODUCTIOn
Chronic Obstructive Pulmonary Disease (COPD) is currently defined as ‘a common, 
preventable and treatable disease, which is characterized by persistent airflow limita-
tion that is usually progressive and associated with an enhanced chronic inflammatory 
response in the airways and lung to noxious particles and gases. Exacerbations and 
comorbidities contribute to the overall severity in individual patients’.1 
COPD is one of the leading causes of morbidity and mortality and accounts for an 
estimated 3 million deaths a year worldwide.2 COPD occurs around the globe and the 
prevalence is still increasing, mostly due to increased life expectancy.3 In addition to its 
individual impact, the burden for healthcare facilities is substantial and the costs as-
sociated with COPD are estimated to be 50 billion dollars annually in the United States 
alone.4 In The Netherlands, around 760.000 people suffer from COPD, which is 4-5% 
of the overall Dutch population. As COPD develops over years, the reported prevalence 
among the Dutch adults aged ≥ 40 years is considerably higher and ranges between 
11.5% to 24%.5,6 
In order to increase attention for COPD prevention and management, the Global Initia-
tive for Chronic Obstructive Lung Disease (GOLD) was established in 1998.7 Among the 
important objectives of GOLD are to increase awareness of COPD and to help the millions 
of people who suffer from this disease and die prematurely from it or its complications.7 
Common symptoms of COPD are breathlessness, excessive sputum production, and a 
chronic cough, symptoms that generally increase over time and eventually may lead 
to respiratory failure. In addition to these respiratory complaints, patients often suffer 
from comorbidities, such as cardiovascular diseases (CVD), which suggests a common 
denominator in disease pathophysiology.8,9 This has led to the current understand-
ing of COPD as a multisystem disorder.8,10,11 Increased attention to comorbidities has 
emphasized a role for systemic inflammation in its development, as inflammation and 
coagulation are closely linked biological systems.8,10-12 Significant research efforts focus 
on the mechanisms underlying these observations, however, these mechanisms are not 
well defined so far.11
COPD: an inflammatory disease.
COPD develops from an abnormal inflammatory reaction in the lungs in response to 
prolonged exposure to inhaled noxious particles or gases, such as cigarette smoke or 
air pollution.13-16 In response to these irritants, the local immune system initiates an 
inflammatory response in order to eliminate these foreign substances. Under normal 
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circumstances this inflammatory response is well regulated and after elimination of the 
foreign substances, the immune cells will return to a resting state.
In COPD, this inflammatory response is commonly thought to be excessive.14,17 As a 
first response to inhaled irritants, the airway epithelial cells and tissue macrophages 
produce inflammatory mediators, including cytokines.13,14 The cytokines attract various 
cells of the immune system to the site of the inflammation, including (but not restricted 
to) monocytes, neutrophils and dendritic cells. After recruitment of these cells from 
the blood stream into the lung tissue, an innate inflammatory response is orchestrated 
and pro-inflammatory cytokines, reactive oxygen species and proteolytic enzymes are 
released.14,16,17 In COPD this initial response is not well balanced and results in elaborate 
damage of the lungs.14,17 
Accessory release of antigens will subsequently initiate an adaptive immune response. 
Among these adaptive immune cells are cluster of differentiation (CD) 4 positive- and 
CD8 positive T cells that proliferate and differentiate into specific subtypes that establish 
an antigen-specific immune response.14 This process further aggravates the lung dam-
age and results in thickening of the airway wall and disruption of lung parenchyma.14,17 
The prolonged exposure to inhaled noxious particles or gases does not only affect 
inflammation within the lung, but also has a systemic effect on inflammation. Indeed, 
increased inflammatory cytokines such as interleukin-6 (IL-6), C-reactive protein (CRP), 
and also endothelial activation markers have been described in COPD and generally 
increase during acute exacerbations of COPD (AE-COPD).18-20 In addition, various stud-
ies report differences in circulating inflammatory cells in COPD patients compared to 
control subjects and these cells may contribute to COPD pathophysiology as well as the 
development of comorbidities.21,22 
In most cases, COPD develops as a result of prolonged and/or intense tobacco smoke 
exposure. The effects of smoking on immune activation have been extensively studied, 
however, these studies vary greatly in their designs. Some studied specific tobacco 
smoke components,23 whereas others focused on specific diseases or specific immune 
cell subtypes, both in human and non-human species.24-26 Conflicting findings are re-
ported and the exact inflammatory profiles that may eventually progress into COPD are 
not yet identified.
It should be noted, however, that considerable variability is observed within the clinical 
course of COPD and in line with this, possibly also in the related local and/or systemic 
inflammatory responses. Individual variation in immune responses may therefore de-
11
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1termine both susceptibility to COPD and to the development of comorbidities. It is well known, for instance, that not all subjects exposed to inhaled noxious particles or 
gases develop COPD. Around 30-40% of smokers develop COPD,15 suggesting that a 
combination of environmental, genetic and intrinsic individual factors determine COPD 
disease susceptibility and the course of disease.27-29 Studies that improve insight in the 
underlying pathophysiolocal mechanisms and provide opportunities for modulation of 
the immune system are warranted.
Cardiovascular comorbidities in COPD.
In the last two decades, increased interest in the extrapulmonary effects of COPD 
has identified several comorbidities that are more prevalent in COPD in comparison 
to healthy smokers and non-smokers.1,27,30 Among these, cardiovascular comorbidities 
represent an important group, not at the least for their impact on patient outcome.31,32 
Around 50% of hospital admissions in patients with COPD can be attributed to CVD and 
25-27% of deaths.31,32 
Furthermore, several studies show important associations between respiratory func-
tion and the risk for cardiovascular mortality in the general population.33-36 Hole and 
colleagues investigated the relation between forced expiratory volume in one second 
(FEV1) and mortality in 15,411 adults in West Scotland and reported relative hazard 
ratios of 1.56 (1.26-1.92) in men and 1.88 (1.44-2.47) in women for death due to CVD 
in the lowest quintile of FEV1.33 Moreover, in the Baltimore Longitudinal Study of Aging, 
adults with the most rapid decline in FEV1 had a 3 to 5 times increased risk for cardio-
vascular death, compared to those with the slowest decline in FEV1, independent of 
baseline FEV1 and after correction for confounders, such as age, smoking, hypertension 
and body mass index.35 
Emerging data suggests that the link between COPD and CVD cannot be fully explained 
by the risk factor smoking.33,35,37 Myocardial infarction and, to a lesser extent, stroke 
have therefore attracted considerable attention in COPD34,38-41.
Atherosclerosis, a chronic inflammatory condition leading to vascular plaques and 
vessel damage, plays an important role in the development of these vascular events. 
Plaque rupture and arterial thrombosis are acute triggers for acute vascular events, es-
pecially in a high shear environment.42,43 Blood platelets do not only play an important 
role in atherosclerosis, but particularly in thrombus formation44. Anti-platelet therapy is 
therefore the cornerstone of the medication provided to patients with vascular events. 
Apart from its anti-thrombotic effects, anti-platelet therapy may also have immuno-
modulatory effects.45,46 
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Blood platelets may therefore also play an important role in the clinical course of 
disease in COPD. Indeed, thrombocytosis is associated with increased short and long 
term mortality after acute exacerbations of COPD.47 Surprisingly, apart from platelet 
numbers, the function of platelets is scarcely studied in COPD.
Furthermore, it is currently debated whether patients with COPD are also at increased 
risk for venous thromboembolism, such as pulmonary embolism (PE) and deep venous 
thrombosis (DVT). Current research efforts show conflicting results that range from an in-
creased risk of venous thromboembolism to no clear association with COPD at all48-50. The 
pathogenesis of PE and DVT is different from myocardial infarction and stroke as venous 
thrombosis relies more on plasmatic coagulation. Venous thrombi develop in an envi-
ronment with low shear rates or even blood stasis, that develop over hours to days and 
are rich in fibrin and contain a high number of red blood cells, whereas arterial thrombi 
develop in a high shear environment and contain a high number of platelets (Table 1).42 
These different pathophysiological mechanisms have important clinical implications 
and require different therapeutic management.51,52 
Low-grade systemic inflammation is commonly thought to be responsible for the excess 
risk for thromboembolic events in COPD.8,11,34,37,53 This hypothesis is strengthened by the 
fact that the risk of myocardial infarction and stroke further increases during episodes 
of increased inflammation, like during or shortly after AE-COPD.38,40,41 
Interaction between inflammation and coagulation.
Inflammation and coagulation are highly integrated biological systems and extensive 
crosstalk between these systems exists.12,54 Dysregulation of one system may result in 
dysregulation of the other. In critically ill sepsis patients this becomes very evident in 
the case of disseminated intravascular coagulation or when sepsis is complicated by 
Table 1. Pathogenesis of venous thrombi and arterial thrombi
Venous thrombosis Arterial thrombosis
Anatomical region (Large) Veins Arteries
Environment Low shear environment High shear environment
Important trigger(s) Blood stasis Atherosclerotic plaque rupture
Content Fibrin rich, red blood cells Platelets
Time of development Hours to days Minutes to hours
Diseases PE, DVT Myocardial infarction, Stroke
Treatment Anticoagulant treatment Platelet-inhibitors
(Abbreviations: DVT: Deep Venous Thrombosis; PE: Pulmonary Embolism)
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1acute cardiovascular events.
54 Tissue factor (TF), a type I integrin membrane glycoprotein, 
plays a pivotal role in the interaction between these systems. Vascular subendothelial 
cells constitutively express TF, in order to rapidly initiate the coagulation cascade dur-
ing vascular damage.55 In contrast, cells in close contact with blood, such as endothelial 
cells and monocytes, are able to upregulate membrane expression of TF when activated 
by physical or chemical damage or by inflammatory cytokines.54,55 The latter is of great 
interest, as the most important regulator of TF expression seems to be interleukin-6 (IL-6).
Exposure of TF to blood activates the coagulation cascade by complex formation of TF 
with circulating factor VIIa. This complex catalyzes several steps of conversion of dif-
ferent coagulant factors, resulting in the formation of thrombin (factor IIa).12 Thrombin 
enables the conversion from fibrinogen into fibrin which is essential for clot formation 
and thrombin activates platelets via cleavage of protease activated receptors (PAR) 1 
and 4, see figure 1.12,42 This highlights that the processes of arterial and venous throm-
bosis are not mutually exclusive, but are connected.
Platelets are key players in interaction between inflammation and coagulation. These 
small, anucleated cells exhibit important immune functions and can interact both with 
cells from the innate as with the adaptive immune system.56 For example, platelets 
can bind to monocytes to form platelet-monocyte complexes, an early process in 
atherothrombosis.44,57 In addition, platelets can promote activation of monocytes and 
dendritic cells45, thereby enhancing host response.46 Also, recent evidence suggests 
that IL-6 and collagen are able to activate platelets via activation of Signal Transducer 
and Activator of Transcription 3 (STAT3).58,59 STAT3 is important for transduction of a 
variety of cell signals, including signals involved in inflammation.
Another factor that may link inflammation and coagulation is vitamin D. Vitamin D is 
increasingly appreciated for its inflammatory properties,60,61 however, its association 
with coagulation is less investigated. The effects of vitamin D on platelet reactivity are 
currently unknown, while the occurrence of myocardial infarctions and stroke clearly 
show seasonal variation, like vitamin D levels.62-64 Vitamin D is also often prescribed 
in COPD patients, not only as vitamin D deficiencies and corresponding bone loss are 
common in COPD patients, but also because of the presumed favourable effects.
Knowledge on these interactions may provide new targets for modulation of inflammation, 
coagulation and their interaction, as inflammation and coagulation are driven by common 
pathways. Careful study of these pathways is important as therapeutic interventions are 
often based on these studies. Anti-inflammatory drugs are the cornerstone of exacerba-
tion management in COPD, while the use of anti-platelet drugs may be considered as well.
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Aims of the thesis.
The main aim of this doctoral thesis is to investigate the interaction between inflamma-
tion and coagulation in COPD and the potential to modulate their interaction. Therefore, 
the objectives were: 
1. To perform a meta-analysis of the current evidence on the prevalence of pulmonary 
embolism, as an expression of venous thrombosis, in acute exacerbations of COPD 
2. To investigate platelet-monocyte interaction and platelet function in COPD as a 
potential mechanism for arterial thrombosis.
3. To investigate thrombin generation and clotting time in COPD as a potential mecha-
nism for venous thrombosis.
4. To investigate the interaction between inflammation and coagulation in general, 
with a focus on factors that may play a role in COPD 
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Figure 1. Simplified presentation of the interaction between inflammation and coagulation.
During physical damage and/or inflammation tissue factor is released and binds to factor VIIa. Via 
several steps of conversion thrombin is formed. Thrombin converts fibrinogen into fibrin and is also 
able to activate platelets via PAR-1 and Par-4, which results in platelet activation and aggregation. 
These processes are pivotal for thrombus formation. (Abbreviations: ADP: adenosine di-phosphate; 
GPVI: glycoprotein VI; PAR: protease activated receptors; TF-VIIa: Tissue factor –factor VIIa complex)
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Outline of the thesis.
The first chapters of this doctoral thesis describe the presence of pulmonary embolism 
in COPD and the potential mechanisms underlying thromboembolic events in COPD. 
In Chapter 2 a systematic review and meta-analysis on the prevalence of pulmonary 
embolism in patients with unexplained AE-COPD is reported. A thorough literature 
search of MEDLINE and EMBASE databases was performed and an overview of the 
current literature is provided. In Chapter 3, we describe a case-control study in which 
platelet activation and thrombin generation potential was measured in 30 patients 
with moderate to severe stable COPD and in 25 matched control subjects. The patients 
were recruited at the outpatient clinic of Radboud university medical center and control 
subjects were recruited among employees. Since cardiovascular events tend to cluster 
with periods of increased inflammation, platelet function was also assessed in COPD 
patients with an acute exacerbation. The findings of this study are reported in Chapter 
4. In this study, we used a before-after model in which COPD patients were recruited 
during admission for an AE-COPD at the Radboud university medical center. The mea-
surements were performed during the exacerbation and repeated after 6 to 10 weeks 
post-exacerbation.
The next chapters have a more general focus on the interaction between inflammation 
and coagulation. First, the effects of different mutations in transcription factor STAT3 on 
platelets were investigated and the results are described in Chapter 5. Two cohorts were 
investigated, the first cohort concerned patients with autosomal dominant Hyper IgE 
syndrome, a rare immune deficiency disorder. The specific mutations in these patients 
result in non-functional STAT3 activity and was therefore used as a model to study the 
effects on platelets. To determine whether the effects of STAT3 mutations on platelets 
also occur in the general population, data from the 500FG cohort (a large cohort of 
healthy human volunteers) were used. The data from the 500FG cohort were also used 
in the following two chapters. In Chapter 6 we investigated the association between 
different vitamin D single nucleotide polymorphisms (SNPs) and platelet function and 
plasmatic coagulation. Finally, to our current knowledge the best preventive measure 
for COPD is still smoking cessation. Therefore, in Chapter 7 we highlight the association 
between cigarette smoking and immunological phenotype and immune function in the 
500FG cohort. In this study smokers, former smokers and non-smokers were carefully 
matched. To conclude, the most important findings of this thesis and the implications 
are discussed in Chapter 8.
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AbsTRACT
background
COPD patients encounter episodes of increased inflammation, so-called acute exacer-
bations of COPD (AE-COPD). In 30% of AE-COPD no clear etiology is found. Since there 
is a well-known crosstalk between inflammation and thrombosis, the objectives of this 
study were to determine the prevalence, embolus localization and clinical relevance, 
and clinical markers of pulmonary embolism (PE) in unexplained AE-COPD.
Methods 
A systematic search was performed using MEDLINE and EMBASE platforms from 1974 
– October 2015. Prospective- and cross-sectional studies that included patients with an 
AE-COPD and used pulmonary CT-angiography for diagnosis of PE were included.
Results 
The systematic search resulted in 1650 records. Main reports of 22 articles were 
reviewed and 7 studies were included. The pooled prevalence of PE in unexplained 
AE-COPD was 16.1% (95% confidence-interval 8.3%-25.8%) in a total of 880 patients. 
Sixty-eight percent of the emboli found were located in the main pulmonary arteries, 
lobar arteries or inter-lobar arteries. Mortality and length of hospital admission seem 
to be increased in patients with unexplained AE-COPD and PE. Pleuritic chest pain and 
cardiac failure were more frequently reported in patients with unexplained AE-COPD 
and PE. In contrast, signs of respiratory tract infection was less frequently related to PE.
Conclusions
PE is frequently seen in unexplained AE-COPD. Two-thirds of emboli are found at local-
izations that have a clear indication for anticoagulant treatment. These findings merit 
clinical attention. PE should receive increased awareness in patients with unexplained 
AE-COPD, especially when pleuritic chest pain and signs of cardiac failure are present 
and no clear infectious origin can be identified.
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InTRODUCTIOn
Chronic obstructive pulmonary disease (COPD) is currently the third cause of mortality 
and morbidity worldwide.1-3 Acute exacerbations of COPD (AE-COPD) are an important 
aspect of disease as they lead to worsening of respiratory symptoms, deterioration of 
respiratory function and worsening of prognosis.4-7 The majority of AE-COPD develop in 
response to infections, however in about 30% of AE-COPD no clear etiology is found.8 
In AE-COPD, co-existence or development of secondary disorders can significantly de-
termine outcome.5,9 One of these potentially harmful disorders is pulmonary embolism 
(PE). Previous studies suggest a high prevalence of PE in AE-COPD, ranging from 18 - 
25 percent.10-12 This prevalence might be explained by the increase of inflammatory 
markers during AE-COPD.13-15 Population studies, however, have shown either a modest 
excess risk for PE in COPD with odds ratios ranging from 2.51 (Confidence interval (CI) 
1.62-3.87) to 5.46 (CI 4.25-7.02)16-18 or no association at all.19 Since there is a well-
known crosstalk between inflammation and coagulation, patients may be particularly at 
risk for PE during AE-COPD.13,20-22 
Clinical evaluation of PE in AE-COPD might pose some challenges. First, improvements 
in resolution of multislice computed tomography pulmonary angiography (CTPA) has 
led to increased observation of filling defects with a diameter of 2-3mm.23,24 The clinical 
relevance of these isolated subsegmental PE is under debate.25-29 It is unknown how 
often these isolated subsegmental PE are found in AE-COPD. Another important issue is 
the lack of clinical markers for identification of PE in AE-COPD. Early recognition of PE 
is of vital importance, but difficult due to overlap in clinical symptoms.30 This makes it 
challenging to recognize co-incidence of PE in AE-COPD.
Since publication of the previous systematic review on PE in AE-COPD in this journal 
in 2009, several well-performed studies have been published.10,12,23,24,31 The objectives 
of this systematic review are 1) to update the pooled prevalence on PE in unexplained 
AE-COPD, 2) to review the localization and clinical relevance of the filling defects on 
CTPA and 3) to identify clinical markers of PE in unexplained AE-COPD.
METHODs
literature search
The systematic review was performed in accordance with PRISMA guidelines.32 A litera-
ture search for articles written in English was performed using the databases MEDLINE 
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(1946 – October 2015) and EMBASE (1974 – October 2015). The main search terms were 
“Pulmonary Disease, Chronic Obstructive” and “Pulmonary Embolism”. Synonyms of 
“Pulmonary Disease, Chronic Obstructive” resulted in: “Chronic obstructive pulmonary 
disease”, “Chronic Airflow Obstruction”, “COPD”, “Chronic obstructive Airway Disease”, 
“COAD”, “Chronic Obstructive Lung Disease”, “Chronic Airflow Obstruction” , “Obstructive 
Respiratory Disease” as terms. Synonums of “Pulmonary Embolism” resulted in: “Pulmo-
nary thromboembolism”, “PE”, “Chronic Lung Embolism”, “Lung Embolus”, “Lung emboli”, 
“Lung Microembolism”, “Lung Microembolus”, “Lung Thromboembolism”, “Pulmonary 
emboli”, “Pulmonary Embolus”, “Pulmonary Microembolism”. In addition, search term 
“Venous Thromboembolism” and its synonyms were used. All terms were searched in 
title, abstract and as a keyword.
study selection
We included studies that (1) reported on prevalence of pulmonary embolisms in pa-
tients with AE-COPD; (2) provided empirical data; (3) diagnosed PE based on CTPA and 
excluded studies that (4) were performed in stable COPD patients, (5) were performed 
retrospectively or (6) used registries for diagnosis of PE. Title screening was performed 
by one investigator (L.V.). Evaluation of abstracts followed by evaluation of main reports 
was performed independently by two investigators (F.A. and L.V.). Disagreements were 
resolved by consultation with a third investigator (Y.H.). Reference lists of all included 
articles were screened and potentially suitable papers were reviewed.
study outcomes
The primary outcome of this study was the prevalence of PE in unexplained AE-COPD. Sec-
ondary outcome parameters were; prevalence of deep venous thrombosis (DVT), localiza-
tion of pulmonary embolism, clinical outcome and a set of clinical markers. Clinical mark-
ers were divided into patient characteristics, disease characteristics, clinical symptoms, 
physical examination findings, respiratory function, blood gas analysis, laboratory findings, 
other diagnostic measurements, clinical prediction scores and treatment. More detailed 
information on the clinical markers that have been reviewed can be found in e-Table 1.
Data extraction
Two investigators (F.A., L.V.) independently extracted the following data by using a stan-
dardized protocol: title, authors, date of publication, study location, inclusion period, 
number of centers, setting, study design, in- and exclusion criteria, study objectives, 
diagnostic modality, information on D-dimer testing, number of patients, mean age and 
range, gender, prevalence of pulmonary embolism, prevalence of deep venous throm-
bosis (DVT) and localization of pulmonary embolism. Additionally, clinical markers were 
extracted, these can be found in e-Table 1.
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Quality assessment
Two investigators (F.A and L.V.) independently appraised the quality of the included 
studies using the STROBE-score, a quality measure for observational studies. This score 
has a maximum of 22 points and is shown in table 1.
statistical analysis
The primary outcome was the prevalence of PE in patients presenting with an AE-COPD. 
A double arcsine transformation was performed to stabilize data variance.33 Heteroge-
neity among studies was assessed by using the χ2test, defining a significant heteroge-
neity as a P value < 0.10, whereas inconsistency was quantified using the I2statistic.34 As 
significant heterogeneity was observed, a random-effect model was used to calculate 
the overall pooled prevalence of PE and DVT in unexplained AE-COPD. To systemati-
cally ascertain predictors for study heterogeneity, mixed-effects model meta-regression 
analyses was performed for the following potential predictors of heterogeneity; 1) age 
of study population, 2) gender proportions of study population and 3) exclusion of 
pneumonia (as main difference observed in study design between included studies). All 
analyses were conducted using the R statistical software, metaphor package.35,36
The localization of the filling defects on CTPA was determined and categorized into pul-
monary trunk, main pulmonary artery, segmental artery or isolated subsegmental PE. In 
addition, we reviewed whether the presence and localization of PE affected mortality 
and the length of hospital admission. Pooling of data regarding clinical markers was 
not possible as absolute numbers from several studies could not be extracted. Data on 
clinical markers were synthesized.
REsUlTs
study selection 
The literature search resulted in 2997 records in EMBASE- and MEDLINE databases. 
After limits for articles written in English, exclusion of conference abstracts and de-
duplication, 1650 unique records remained. Of these, 1551 records were excluded 
based on title. The remaining 99 abstracts were checked for eligibility, resulting in 
exclusion of 74 abstracts. Twenty-two studies were selected for evaluation of main 
reports. Inter-rater reliability was 0.86, rated as ‘almost perfect agreement’. Interest-
ingly, 2 studies were performed by Akpinar and colleagues in the same hospital and had 
the same inclusion period. One of the studies focused on prevalence of PE in AE-COPD 
and the other focused on D-dimer cut off value in AE-COPD.31,37 As we were unable to 
state that these were separate study populations, the study that focused on D-dimer 
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cut off value in AE-COPD was excluded.37 After evaluation of the other main reports, 
investigators agreed on definitive inclusion of 7 studies.11,12,31,38-41 Study selection and 
main reasons for exclusion are depicted in figure 1.
study characteristics
A total of 880 patients were included in this systematic review. The 7 included stud-
ies were performed in 6 different countries and 2 studies originated from Turkey. One 
study recruited patients at the emergency department, while the other studies included 
hospitalized patients. The mean age and percentage of male patients of included stud-
ies varied from 49.3 to 71.3 years and 68% to 100%, respectively. Characteristics of 
included studies can be found in Table 1.
Pooled prevalence of pulmonary embolism in acute exacerbations of COPD
Overall, 16.1% (95% confidence-interval 8.3%-25.8%) of patients with AE-COPD had 
PE (Figure 2). Variation between included studies was large, with a prevalence ranging 
from 3.3% to 29.1%. Six studies reported on the prevalence of deep venous thrombo-
sis (DVT) in AE-COPD.
Fig 1. Flow diagram of study selection.  
 
 
 
 
 
 
 
 
 
 
 
 
 
a Studies could have fulfilled more than one criterion. 
 
MEDLINE: 
888 records 
EMBASE: 
2109 records 
1650 records 
Step 1. Title screening.  
Titles reviewed by one investigator 
according to the criteria 
99 abstracts 
22 full texts 
8 studies included 
Step 2. Abstract screening.  
Abstracts reviewed by two 
investigators, decisions made by third 
independent investigator 
Step 3. Full text screening.  
Abstracts reviewed by two 
investigators, decisions made by third 
independent investigator 
Reasons for exclusion
a
: 
1) Uncertainty on AE-COPD versus 
stable COPD (n=3) 
2) No prevalence number reported 
(n= 4) 
3) Other technique for diagnosis 
(n=9) 
4) No empirical data (n= 4) 
Fig re 1. Flow diagra  f t e study selection process and numbers of studies identified.
a. studies could have fulfilled more than one criterion. (Abbreviations: AE-COPD: acute exacerbation 
of COPD)
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The pooled prevalence of DVT in AE-COPD was 10.5% (95% confidence interval 4.3%-
19.0%) (Figure 3). Mixed-model meta-regression analyses of age, gender differences 
and exclusion of pneumonia as main difference in study design could not determine the 
main predictors for heterogeneity observed in included studies.
localization and clinical relevance of PE in AE-COPD 
Five included studies documented embolism localization, including a total of 726 COPD 
patients of which 120 patients presented with PE in unexplained AE-COPD.11,31,38,39,41 Of 
PE cases, 39 (32.5%) had isolated subsegmental PE. Other localizations were one of the 
main pulmonary arteries in 42 cases (35.0%), lobar and inter-lobar arteries in 38 cases 
(31.67%), and one patient had an embolism in the pulmonary trunk (0.83%) (Table2).
The relation between isolated subsegmental PE and more proximal localizations of PE 
and clinical outcome was not reported. Three studies assessed length of hospital admis-
sion, two studies found an increase in PE, whereas one could not detect a significant 
difference.31,38,39 In terms of clinical outcome, in-hospital mortality and one-year mortal-
Table 2. Localization of PE found in AE-COPD.
Anatomical region Cases Percent (%)
Pulmonary trunk 1 0.8
Main pulmonary arteries 42 35.0
Lobar- and inter-lobar arteries 38 31.7
Isolated subsegmental arteries 39 32.5
Total 120 100%
(Abbreviations: AE-COPD: acute exacerbations of COPD; PE: pulmonary embolism)
studies was large, with a prevalence ranging from 3.3% to
29.1%. Six studies reported on the prevalence of DVT in
AE-COPD. The pooled prevalence of DVT in AE-COPD
was 10.5% (95% CI, 4.3%-19.0%) (Fig 3). Mixed- odel
meta-regression analyses of age, sex differences, and
exclusion of pneumonia as the main difference in study
design could not determine the main predictors for
heterogeneity observed in includ d studies.
Localization and Clinical Relevance of PE in
AE-COPD
Five included studies documented embolism
localization, including a total of 726 patients with
COPD, 120 of whom presented with PE in unexplained
AE-COPD.11,31,38,39,41 Of PE cases, 39 (32.5%) had
isolated subsegmental PE. Other localizations included
one of the main pulmonary arteries in 42 cases (35.0%)
and lobar and interlobar arteries in 38 cases (31.67%); in
one case, the embolism was located in the pulmonary
trunk (0.83%) (Table 2). The relation between isolated
subsegmental PE and more proximal localizations of PE
and clinical outcome was not reported. Three studies
assessed length of hospital admission: two studies found
an increase in PE, whereas one could not detect a
signiﬁc nt difference.31,38,39 Reg rding clinical outcome,
in-hospital mortality and 1-year mortality was increased
in patients with PE in AE-COPD in one study39 but not
in another (P ¼ 0.26).38 Gunen et al39 additionally
performed a Cox egression analysis and found that
the presence of VTE was the only factor that increased
1-year mortality.
Clinical Markers of PE in AE-COPD
Included studies considered a broad range of clinical
symptoms, biochemical parameters, and patient and
disease characteristics (eg, age, sex, weight, Global
Initiative for Obstructive Lung Disease stage). An
overview of all clinical markers that have been reviewed
is provided in e-Table 1. Clinical markers that show
signiﬁcant differences in patients with AE-COPD in the
presence or absence of PE are shown in Table 3. Studies
Events TotalStudy
50 172
6 103
11 105
14 131
2 123
25 197
0.29
0.06
0.10
0.11
0.02
0.13
(0.22-0.36)
(0.02-0.12)
(0.05-0.18)
(0.06-0.17)
(0.00-0.06)
(0.08-0.18)
17.0%
16.3%
16.3%
16.7%
16.6%
17.1%
0.10 (0.04-0.19)
(0.00-0.48)
100%
Akpinar et al31 (2014)
Choi et al38 (2013)
Kamel et al40 (2013)
Gunen et al39 (2010)
Rutschmann et al41 (2007)
Tillie–Leblond et al11 (2006)
Random effects model 831
Proportion W(random)
Heterogeneity: I2 = 92.2%, tau–squared = 0.021, P < .0001
0 0.1 0.2 0.3 0.4
95% CI
Figure 3 – Prevalence of DVT in patients with AE-COPD. See Figure 1 and 2 legends for expansion of other abbreviations.
Events TotalStudy
Shapira–Rootman et al12 (2015) 9 49
50 172
5 103
30 105
18 131
4 123
49 197
0.18
0.29
0.05
0.29
0.14
0.03
0.25
(0.09-0.32)
(0.22-0.36)
(0.02-0.11)
(0.20-0.38)
(0.08-0.21)
(0.01-0.08)
(0.19-0.32)
12.9%
14.8%
14.2%
14.3%
14.5%
14.4%
14.9%
0.16 (0.08-0.26)
(0.00-0.56)
100%
Akpinar et al31 (2014)
Choi et al38 (2013)
Kamel et al40 (2013)
Gunen et al39 (2010)
Rutschmann et al41 (2007)
Tillie–Leblond et al11 (2006)
Random effects model 880
Proportion W(random)95% CI
Heterogeneity: I2 = 92.2%, tau–squared = 0.0241, P < .0001
0 0.1 0.2 0.3 0.4 0.5
Figure 2 – Prevalence of PE in patients with AE-COPD. PE¼ pulmonary embolism; W ¼ weight. See Figure 1 legend for expansion of other abbreviation.
journal.publications.chestnet.org 549
Figure 2. Prevalence of PE in patients with AE-COPD.
(Abbreviations: AE-COPD: acute exacerbations of COPD; PE: pulmonary embolism; W: weight)
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ity was increased in patients with PE in AE-COPD in one study,39 but not in another (p= 
0.26).38 Gunen and colleagues additionally performed a Cox regression analysis and 
found that presence of venous thromboembolism was the only factor that increased 
one-year mortality.39 
Clinical markers of PE in AE-COPD 
Included studies considered a broad range of clinical symptoms, biochemical param-
eters and patient- and disease characteristics (e.g. age, gender, weight, GOLD stage). 
An overview of all clinical markers that have been reviewed is provided in e-Table 1. 
Clinical markers that show significant differences in AE-COPD patients in presence or 
absence of PE are shown in table 3. Studies that report upon the same clinical marker 
but did not detect a statistically significant difference are also included in the table.
Overall, pleuritic chest pain was reported more frequently in AE-COPD with PE com-
pared to AE-COPD without PE.31,39 Akpinar and Gunen et al. found pleuritic chest pain 
in 81.0% in the PE group versus 40.0% in non-PE patients, and 24.0% in the PE group 
versus 11.5% in non-PE patients, respectively.31,39 However, Tillie-Leblond et al. could 
not show a difference (p-value 0.73).11 Signs of cardiac failure like hypotension, syncope 
and acute right failure on ultrasonography were diagnostic clues associated with PE, 
whereas signs of a respiratory tract infection was seen less frequent in PE cases.31,38,39
In general, age, gender, presence of comorbidities (hypertension, diabetes mellitus 
and coronary artery disease), smoking habits and BMI did not show a relation with risk 
for PE in AE-COPD, as shown in e-Table 1. None of included studies related findings to 
exacerbation frequency, severity of exacerbation or treatment with glucocorticoids in 
included patients.
studies was large, with a prevalence ranging from 3.3% to
29.1%. Six studies reported on the prevalence of DVT in
AE-C PD. The pooled preval nce of DVT in AE-COPD
was 10.5% (95% CI, 4.3%-19.0%) (Fig 3). Mixed-model
meta-regression analyses of age, sex differences, and
exclusion of pneumonia as the main difference in study
design could not determine the main predictors for
heterogeneity observed in included studies.
Localization and Clinical Relevance of PE in
AE-COPD
Five included studies documented embolism
localization, including a total of 726 patients with
COPD, 120 of whom presented with PE in unexplained
AE-COPD.11,31,38,39,41 Of PE cases, 39 (32.5%) had
isolated subsegmental PE. Other localizations included
one of the main pulmonary arteries in 42 cases (35.0%)
and lobar and interlobar arteries in 38 cases (31.67%); in
one case, the embolism was located in the pulmonary
trunk (0.83%) (Table 2). The relation between isolated
subsegmental PE and more proximal localizations of PE
and clinical outcome was not reported. Three studies
assessed length of hospital admission: two studies found
an increase i PE, whereas one could not detect a
signiﬁcant difference.31,38,39 Regarding clinical outcome,
in-hospital mortality and 1-year mortality was increased
in patients with PE in AE-COPD in one study39 but not
in another (P ¼ 0.26).38 Gunen et al39 additi nally
performed a Cox regression analysis and found that
the presence of VTE was the only factor that increased
1-year mortality.
Clinical Markers of PE in AE-COPD
Included studies considered a broad range of clinical
symptoms, biochemical parameters, and patient and
disease characteristics (eg, age, sex, weight, Global
Initiative for Obstructive Lung Disease stage). An
overview of all clinical markers that have been reviewed
is provided in e-Table 1. Clinical markers that show
signiﬁcant differences in patients with AE-COPD in the
presence or absence of PE are shown in Table 3. Studies
Events TotalStudy
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Figu  3. Prevalence of DVT in patients with AE-COPD.
(Abbreviations: AE-COPD: acute exacerbations of COPD; DVT: deep venous thrombosis; W: weight)
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Table 3. Markers for identification of PE in AE-COPD.
Markers significant studies not significant studies
Patient characteristics
Gender Gunen Akpinar, Choi, Tillie-Leblond 
Obesity Akpinar Choi, Gunen, Tillie-Leblond 
Clinical symptoms
No symptoms of RTI Choi  
Increased sputum Choi Akpinar 
Pleuritic chest pain Akpinar, Gunen Tillie-Leblond 
Physical examination
Hypotension Gunen  
Lower leg asymmetry Akpinar Tillie-Leblond 
Syncope Gunen  
Respiratory function
FEV1 Shapira-Rootman Choi 
Arterial blood gas
PaCO2 lower in PE Akpinar Choi, Gunen, Tillie-Leblond 
pH value higher in PE Akpinar  
Decrease in PaCO2 Tillie-Leblond  
Laboratory findings
NT-proBNP Akpinar Choi 
Polycytemia Kamel  
Diagnostics
ECG   
AF Gunen  
Ultrasonography   
Cardiac failure Gunen Tillie-Leblond 
Chest radiograph   
Atelectasis Shapira-Rootman  
Pulmonary artery enlargement Shapira-Rootman  
Wells score 
Previous VTE Tillie-Leblond Akpinar, Gunen 
Malignancy Akpinar, Gunen Tillie-Leblond 
Immobility Gunen  
Outcome measures
Length of stay Akpinar, Gunen Choi 
Mortality Gunen a Choi 
Need for ICU treatment Akpinar 
a Cox regression analyses revealed that VTE was the only factor that significantly increased mortal-
ity.
(Abbreviations: AF: atrial fibrillation; NT-proBNP: N-terminal prohormone of brain natriuretic peptide; 
RTI: respiratory tract infection) 
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DIsCUssIOn
Our review shows that PE is common in unexplained AE-COPD with an estimated preva-
lence of 16% percent. Moreover, two-thirds of these emboli are located in the main 
pulmonary arteries, lobar arteries or inter-lobar arteries, suggesting that the majority 
of these embolisms have important clinical consequences. Included studies reported 
conflicting results regarding clinical markers. Overall, patients with PE in AE-COPD more 
frequently experienced pleuritic chest pain and more frequently had signs of cardiac 
failure. On the contrary, symptoms suggestive of a respiratory tract infection is reported 
less often in patients with PE in AE-COPD. Although clinical outcome could not be re-
lated to embolus localization, patients with PE in unexplained AE-COPD seem to have 
increased mortality and increased length of hospital admission.
This review shows a slightly lower prevalence of PE in unexplained AE-COPD compared 
to previous systematic review that reported an overall prevalence of 19.9%.10 Since 
publication of this systematic review 5 relevant studies have been published. Two stud-
ies from the previous systematic review were excluded since our review solely included 
patients with AE-COPD.42,43 Inclusion of these 2 studies to the analyses would slightly 
increase PE prevalence in AE-COPD (18.5%, 95% CI 10.1%-27.5%). The risk for PE is 
strongly increased in unexplained AE-COPD, especially compared to other inpatient 
populations that show PE prevalence rates of 5.7-6.0%.44,45 PE may be seen in particular 
in exacerbations as systemic inflammation and thrombosis are closely related.13,14,19 
Markers of systemic inflammation, like acute-phase reactants C-reactive protein (CRP) 
and fibrinogen, contribute to development of thrombotic events.13,20,21 Also, tumor ne-
crosis factor-α (TNF-α), a pro-inflammatory cytokine, contributes to a procoagulant state 
by induction of tissue factor and inhibition of anticoagulant protein C.20,22 In AE-COPD 
these mediators are markedly increased systemically, while in stable COPD only a sub-
group of patients show low-grade systemic inflammation.46-48 This may explain lower 
risk estimates found in population studies.16,18,19 Therefore, exacerbation susceptibility 
and exacerbation frequency could be important determinants for development of PE. 
Second, patients with AE-COPD are often treated with glucocorticoids, that increase risk 
for venous thromboembolism, especially after initiation of treatment.49 Others have 
suggested that PE could be a trigger for AE-COPD or mimick exacerbation-like symp-
toms in COPD patients, since vascular occlusion leads to bronchoconstriction30,50-52 This 
could be another potential explanation for the high prevalence found specifically in 
unexplained AE-COPD.11,39,53 In order to fully understand the exact mechanisms involved 
in development of PE in unexplained AE-COPD further mechanistic studies are needed.
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Two thirds of the emboli were clinically relevant PE, located in more proximal than 
subsegmental pulmonary arteries. These more proximally located emboli have a clear 
indication for anticoagulant treatment according to the new ACCP guideline.28 Pulmo-
nary embolism has a general 28-day case fatality rate of 15.1%, which increases to 
32.5% in patients requiring hospitalization for another condition.19,54 Also, we found 
increased hospital stay and mortality in patients with PE. One third of PE in AE-COPD 
is limited to isolated subsegmental pulmonary arteries. Unfortunately, these outcomes 
could not be related to embolus localization. This would have been of great interest, 
as the clinical relevance of these smaller filling defects found on CTPA is not well de-
fined.25,55 In isolated subsegmental PE anticoagulant treatment may be withheld and 
clinical surveillance is preferred under certain circumstances.28 
Several clinical markers seem to be related to PE in AE-COPD, in particular pleuritic chest 
pain and signs of cardiac failure. Similarly, symptoms suggestive of a respiratory tract 
infection would argue against PE in AE-COPD. Though formal logistic regression analysis 
was not possible owing to the lack of raw data, our study suggests that these findings 
merit clinical attention and should be taken into account in patients with unexplained AE-
COPD. It might add to the clinical decision making in patients with an AE-COPD, because 
it would be undesirable to perform a CTPA in every patient with an AE-COPD. Unintended 
adverse effects such as renal failure and allergic reactions to iodinated contrast agents 
should be taken into account. Also, the liberal use of CTPA in AE-COPD poses the risk of 
unnecessary radiation exposure and could increase the costs of the health care system. 
Currently, efforts are made to safely withhold CTPA.55 Very recent work by van Es and col-
leagues shows that age-adjustment of D-dimer may improve exclusion of PE in order to 
safely withhold imaging in suspected cases.56 These findings need further confirmation, 
but may have important potential to address this issue in COPD patients.
The present study has several limitations. First and most important limitation is the 
heterogeneity of findings observed between included studies, with prevalence rates of 
PE ranging from 3.3% to 29.1%. This makes the mean estimate of 16.1% less stable 
and this estimate should be seen in conjunction with the CI of 8.3%-25.8%. The low 
prevalence found by Choi and colleagues might be explained by ethnicity as Asians 
have a lower risk for development of venous thromboembolism (Risk Ratio=0.2, (95% 
CI 0.1-0.5)).57 Yet, the study with the lowest prevalence was performed in a predomi-
nantly white population.41 PE was excluded in patients with a negative D-dimer, which 
is generally accepted as safe.58-60 Also, small sample sizes may influence the overall es-
timate and although the random-effects model takes sample size into account, findings 
of individual studies may be skewed. A meta-regression analysis of potential predictors; 
age, gender and exclusion of pneumonia (as difference observed in study design), was 
CHAPTER 2
34
unable to determine the main sources for heterogeneity. Since all included studies 
applied comparable criteria for acute exacerbations and used CTPA for detection of 
PE we cannot completely explain differences observed between included studies. This 
heterogeneity requires that the findings, and mean prevalence in particular, should be 
interpreted with caution.
Second limitation is the risk of publication bias. Studies with findings near the extremes, 
such as a very high or very low prevalence, might be easier published due to newswor-
thiness.61 Also in this review very low and relatively high prevalence rates are found in 
included studies. Although publication bias seems less relevant for prevalence studies, 
since findings are not criticized based on p-value, the potential influence publication 
bias should not be underestimated.62 Additionally, studies that have not been included 
in MEDLINE and EMBASE databases may be overlooked.
Last, all studies in this systematic review included a relatively large proportion of male 
subjects. One of the included studies found that male gender is associated with PE in 
their study, while 3 other studies did not detect significant differences.11,31,38,39 Male 
gender has been shown to be an independent risk factor for venous thromboembolism 
in the general population, however our meta-regression analysis could not identify 
gender as potential predictor of the findings.63
COnClUsIOns 
PE is seen in 16% of patients with AE-COPD and two-thirds of these emboli are found 
at localizations that have a clear indication for anticoagulant treatment. These findings 
merit clinical attention. PE should receive increased awareness in patients with unex-
plained AE-COPD, especially when pleuritic chest pain and signs of cardiac failure are 
present and no clear infectious origin can be identified.
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e-Table 1. Clinical markers associated with PE in AE-COPD.
Clinical Markers significant studies 
(p < 0.05) 
not significant studies
(p > 0.05)
Patient characteristics
Age Akpinar, Choi, Gunen, Kamel, 
Tillie-Leblond
Gender (male) Gunen Akpinar, Choi, Tillie-Leblond
Body Mass Index Choi, Gunen
Obesity Akpinar Tillie-Leblond
Comorbidities Akpinar, Choi
Smoking Status Choi
Pack Years Choi, Gunen
Disease characteristics
Gold classification Akpinar, Gunen, Tillie-Leblond
Clinical symptoms
Lower extremity 
complaints
Gunen
Absence of symptoms 
of respiratory tract 
infection
Choi
Increased sputum Choi Akpinar 
Purrulent sputum Choi
Pleuritic chest pain Akpinar, Gunen Tillie-Leblond
Cough Akpinar, Tillie-Leblond
Hemoptysis Akpinar, Gunen, Tillie-Leblond
Palpitations Gunen, Tillie-Leblond
Dyspnea Tillie-Leblond, Akpinar 
Physical examination
Fever Choi, Akpinar 
Tachycardia Akpinar, Tillie-Leblond
Hypotension Gunen
Lower leg asymmetry Akpinar Tillie-Leblond
Signs congestive heart 
faillure
Gunen
Syncope Gunen
Respiratory function
FEV1 Shapira-Rootman Choi
FEV1/VC Choi
Arterial blood gas
PaO2 Choi, Gunen, Tillie-Leblond
PaCO2 lower in PE Akpinar Choi, Gunen, Tillie-Leblond
Pa(A-a)O2 Choi
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e-Table 1. Clinical markers associated with PE in AE-COPD. (continued)
Clinical Markers significant studies 
(p < 0.05) 
not significant studies
(p > 0.05)
pH value higher in PE Akpinar 
Decrease in paCO2 
of > 5mmHg from 
baseline
Tillie-Leblond
laboratory findings
NT-proBNP Akpinar Choi
White blood cell count Choi, Gunen
Erythrocyte 
sedimentation rate
Choi
C-reactive protein Choi
procalcitonin Choi
Creatine kinase - MB Choi
Troponines Choi
serum albumin Choi, Gunen
Glucose Gunen
Urea Gunen
Creatinine Gunen
Polycytemia Kamel
Diagnostics
ECG
Atrial fibrillation Gunen
S1Q3T3 pattern Gunen
Ultrasonography
signs of acute right 
heart failure 
Gunen Tillie-Leblond
CTPA findings
Atelectasis Shapira-Rootman
Pulmonary artery 
enlargement
Shapira-Rootman
Emphysema Shapira-Rootman
Bronciectasis Choi, Shapira-Rootman
Ground glass opacities 
/ Consolidations
Choi, Shapira-Rootman
Noduli Shapira-Rootman
Interstitial changes Shapira-Rootman
Fibrosis Choi, Shapira-Rootman
Pleural effussion Choi, Shapira-Rootman
Pulmonary edema Shapira-Rootman
Peribronchial cuffing Shapira-Rootman
Granulomas Shapira-Rootman
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e-Table 1. Clinical markers associated with PE in AE-COPD. (continued)
Clinical Markers significant studies 
(p < 0.05) 
not significant studies
(p > 0.05)
Wells criteria
Previous venous 
thromboembolism
Tillie-Leblond Akpinar, Gunen
Surgery <4 weeks Akpinar, Tillie-Leblond
Malignancy Akpinar, Gunen Tillie-Leblond
Immobility Gunen
Travel < 3 days
Hemoptysis Akpinar, Gunen, Tillie-Leblond
Treatment
Long term oxygen 
treatment
Gunen
Outcome measures
Length of hospital 
admission 
Akpinar , Gunen Choi
Mortality Choi
Need for ICU 
treatment 
Akpinar 
In-hospital mortality Gunen
One-year mortality Gunen
3-month mortality Akpinar 
Predefined clinical markers that have been reviewed, but have not been reported by included studies
Treatment 
Use of medication 
All medication 
Specific use of glucocorticoids
Exacerbation frequency
Exacerbation severity 
(Abbreviations: AE-COPD: acute exacerbations of COPD; CTPA: computed tomography pulmonary an-
giography; FEV1: forced expiratory volume in 1 second; FEV1/VC: forced expiratory volume in 1 sec-
ond divided by vital capacity; PE: pulmonary embolism; NT-proBNP, N-terminal pro b-type natriuretic 
peptide)
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AbsTRACT
background
COPD is well known for its cardiovascular co-morbidities. Increased platelet-monocyte 
interaction may reflect altered platelet function and a potential role for anti-platelet 
therapy.
Objectives
The objectives were to investigate platelet-monocyte interaction, platelet activation 
and reactivity and plasmatic coagulation in stable COPD.
Methods
Platelet-monocyte interaction and platelet activation were determined by flow cy-
tometry in 30 stable COPD patients and 25 controls. Platelet activation was measured 
by binding of fibrinogen to the activated fibrinogen receptor and platelet P-selectin 
expression at baseline and after platelet stimulation with platelet agonists. Plasmatic 
coagulation was measured by D-dimer and thrombin generation.
Results
Platelet-monocyte interaction was increased in stable COPD (median fluorescence 
intensity of platelet CD61 was 19.8 (IQR 14.0 – 33.2) versus 10.0 (IQR 8.7 – 16.7), 
p=0.002). In contrast, platelet activation and reactivity, reflected by fibrinogen binding 
and P-selectin expression, was equal between groups. Plasma P-selectin and Inter-
leukin-6 were increased in COPD (p=0.01 and p=0.02, respectively), whereas soluble 
fibrinogen, D-dimer and thrombin generation were similar.
Conclusions
Increased platelet-monocyte interaction was found in absence of platelet hyper-
reactivity and activation of plasmatic coagulation in stable COPD. Future clinical evalu-
ation of the effects of different anti-platelet drugs in COPD is warranted, as anti-platelet 
therapy may interfere with platelet-monocyte interaction.
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InTRODUCTIOn
Chronic obstructive pulmonary disease (COPD) is not only recognized as the third 
leading cause of death worldwide, but also known for development of cardiovascular 
co-morbidities.1-5 Most cardiovascular diseases (CVD) in COPD result from arterial 
thrombosis.2-4 However, the risk for venous thrombosis should not be underestimated.6,7 
A further increase in thrombotic complications is seen during or shortly after episodes 
of acute exacerbations of COPD (AE-COPD).8,9 A recent meta-analysis indicates a higher 
risk of myocardial infarction during AE-COPD compared to stable disease,9 and similar 
results have been reported for stroke.10 Low-grade systemic inflammation in COPD is 
commonly thought to play an important role, both in COPD pathophysiology, as in the 
development of its cardiovascular complications.4,11,12 
Extensive crosstalk between inflammation and coagulation exists, and platelets, mono-
cytes and their interaction play a pivotal role in chronic inflammation and development 
of CVD.13,14 When activated, platelets secrete a variety of biologically active substances 
including cytokines and chemokines. Platelet degranulation leads to increased expres-
sion of P-selectin on the platelet membrane, whereas a conformational change in the 
integrin αIIbβ3 results in increased fibrinogen binding.15 P-selectin facilitates binding to 
P-selectin glycoprotein ligand-1 (PSGL-1) expressed on monocytes, resulting platelet-
monocyte complexes (PMCs), an early process in atherothrombosis13,16. Fibrinogen 
binding results in platelet aggregation, clot formation and adhesion of platelets to the 
vascular endothelial surface.13,14 Compelling evidence shows that platelet hyper-reactiv-
ity and increased PMC formation contribute to development of CVD.13,17,18 Anti-platelet 
therapy is the cornerstone of treatment to prevent thrombotic cardiovascular morbidity.
Surprisingly, platelet function is scarcely studied in COPD. Some evidence indicates 
that platelet function may be altered.19-22 Maclay and colleagues showed that stable 
COPD patients have increased circulating PMCs that increase further during AE-COPD.21 
Increased PMC formation is often considered to be a result of platelet hyper-reactivity, 
however, platelets and monocytes can interact in various ways.15 To the best of our 
knowledge, no direct assessment of platelet function in stable COPD has been per-
formed to date. These data add to the current debate on whether COPD patients may 
benefit from anti-platelet therapy in order to prevent CVD.20,21,23
We hypothesized that COPD patients have increased platelet-monocyte interaction 
due to increased platelet activation and hyper-reactivity upon platelet stimulation. 
Therefore, we determined: 1) platelet-monocyte interaction 2) platelet activation and 
reactivity, and 3) plasmatic coagulation in stable COPD patients and control subjects.
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METHODs
Patients selection
Thirty stable COPD patients and 25 controls were included in the study. The inclusion 
criteria for COPD patients were irreversible expiratory airway obstruction according to 
the ATS/ERS criteria24 (FEV1/FVC ratio < 70% and post-bronchodilator FEV1<80% (COPD 
Gold II-IV)) and clinical diagnosis of COPD confirmed by a pulmonologist. General exclu-
sion criteria were use of platelet function inhibitors, asthma, malignancies or chronic 
inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease. 
Patients were considered stable when they had not experienced an AE-COPD, as defined 
by the Anthonisen criteria,25 in the preceding 6 months. Patients were recruited between 
October 2015 and February 2016 at the outpatient clinic of our respiratory department 
and controls were recruited among employees at Radboud University Medical Center. 
Spirometry was performed in the control group to exclude underlying lung disease. This 
study was approved by the Ethical Committee of Radboud University Nijmegen and was 
conducted according to the principles of the Declaration of Helsinki (version Oct 2008) 
and in accordance with the Dutch Medical Research Council working under the Human 
Subjects Act. All participants gave written informed consent. Blood was collected in 
EDTA and 3.2% sodium citrate vacutainer tubes (Becton Dickinson, Plymouth, UK) and 
processed immediately. Blood counts were measured with a haematology analyzer 
(Sysmex XN-450, Kobe, Japan).
Platelet reactivity and platelet-monocyte interaction 
Platelet activation and reactivity were measured by a flow cytometry-based assay that 
has previously been described and that is able detect both platelet hyper-reactivity 
and thrombopathie in different clinical settings.26-28 In short, whole blood samples were 
stained with antibodies for the platelet identification marker CD61 and for two platelet 
activation markers. The platelet activation markers used were the binding of fibrinogen 
to the activated fibrinogen receptor αIIbβ3 (GPIIb/IIIa complex) and the expression of 
alpha-granule protein P-selectin (CD62P) on the platelet surface, representing platelet 
aggregation and degranulation, respectively. Platelet reactivity was defined as the 
expression of these markers after stimulation of the samples with platelet agonists.27 
The samples were measured unstimulated (at baseline) and after ex vivo stimulation 
with the following agonists; adenosine 5’ diphosphate (ADP) (Sigma-Aldrich, Saint 
Louis, Missouri, USA), cross linked collagen-related peptide (CRP-XL) (kind gift from 
Prof. Dr. R. Farndale, Cambridge, UK) and thrombin receptor-activating peptide-6 (TRAP) 
(Sigma-Aldrich, Saint Louis, Missouri, USA). The staining of the samples was performed 
with antibodies for CD61 (PC7-conjugated) (Beckman Coulter, Brea, California, USA), 
anti-human fibrinogen (fluorescein isothiocynate (FITC)-conjugated) (Dako, Santa Clara, 
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California, USA) and P-selectin (CD62P, phycoerythrin (PE)-conjugated) (Biolegend, Bio-
legend, San Diego, California, USA) and the samples were co-incubated with the platelet 
agonists or medium control for 20 minutes. After stimulation, the samples were fixated 
with 0.2% paraformaldehyde and measured by flow cytometry (FC500 flow cytometer, 
Beckman Coulter, Brea, California, USA). Gating of platelets was performed based on 
forward and sideward scatter and additionally for of CD61 positivity. The mean fluo-
rescence intensity (MFI) of the human fibrinogen and human P-selectin antibodies on 
the platelet surface was used as quantification of the platelet activation marker signal. 
The MFI is a measure for the mean intensity of the fluorescence signal of the labeled 
antibody that is detected in the corresponding flow cytometry fluorescence channel.
For measurement of platelet-monocyte interaction, samples were incubated with 
monoclonal antibodies to CD14 (PE-conjugated) (Becton Dickinson, Franklin Lakes, New 
Jersey, USA) and CD61 (PC7-conjugated) (Beckman Coulter, Brea, California, USA) for 
20 minutes. Erythrocytes were lysed with optilyse B (Beckman Coulter, Brea, California, 
USA) and the reaction was stopped by dilution with distilled water. Gating of monocyes 
was performed based on forward and sideward scatter and additionally for of CD14 
positivity. The degree of platelet-monocyte interaction was quantified by the MFI of 
platelet marker CD61 on monocytes (CD14 positive cells).
Plasmatic coagulation
Tissue factor (TF) triggered thrombin generation was measured in platelet-poor plasma 
using the automated thrombogram method as described previously.29 In this assay, 
the thrombin generation curve was evaluated based on parameters that describe the 
initiation, propagation and termination phases of thrombin generation expressed as lag 
time, endogenous thrombin potential (ETP) and thrombin peak, respectively. Plasma 
was obtained after centrifugation of blood tubes at 3800 RPM for 10 minutes. Samples 
were measured unstimulated and after stimulation with tissue factor (1pM).
soluble markers of platelet activation, coagulation and inflammation 
Soluble fibrinogen and soluble P-selectin levels were determined in plasma using the 
human Fibrinogen ELISA kit and human P-selectin/CD62P duoset ELISA kit (R&D sys-
tems, Minneapolis, Minnesota, USA), respectively. D-dimer and high-sensitive Interleu-
kin-6 (hsIL-6) and C-reactive protein were determined with the human D-dimer ELISA 
kit (Abcam, Europe, Cambridge, UK),human high sensitive IL-6 Quantikine ELISA kit (R&D 
systems, Minneapolis, Minnesota, USA) and human C-Reactive Protein ELISA kit (R&D 
systems, Minneapolis, Minnesota, USA), respectively. For platelet content whole blood 
was centrifugated for 15 minutes at 156 g without break to obtain platelet-rich-plasma 
(PRP). Platelet concentration was adjusted to 300x109/L by addition of autologous 
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plasma. Samples were freeze-thawed for 3 cycles to fragment the platelets, followed 
by ultra-centrifugation for 5 minutes at 5000 RPM to spin down large particles and 
supernatants were taken for ELISA. Platelet fibrinogen and P-selectin were determined 
with the ELISA kits described above.
Data analyses
Statistical analysis was performed with Graphpad Prism 5.0 (San Diego, California, USA) 
and IBM SPSS statistics 22.0 (New York, New York, USA). Non-normally distributed data 
was analyzed with Mann-Whitney U tests and results are presented as median with the 
interquartile range (IQR). Normally distributed data was analyzed by Student’s T tests 
(two-sided) and results are presented as mean with the standard error of the mean 
(SEM). Two-way ANOVA analyses were performed for repeated measures. Haematologi-
cal data were analyzed using Student’s T test for continuous variables and presented 
as mean with the standard deviation (SD). For expected counts less than 5 a Fisher’s 
Exact test was performed. Associations between inflammation and platelet markers 
were determined using Spearman’s rank correlation coefficient. The differences were 
considered significant if p value < 0.05.
REsUlTs
The study population demographics can be found in table 1. Control subjects were 
slightly younger and had less tobacco smoke exposure, as reflected by pack years. 
Haematological parameters were not different, including platelet counts and platelet 
characteristics (table 2). Notably, mean platelet volume (MPV), a commonly used mea-
sure for platelet activation, was not different between groups.
Interaction between platelet and monocytes was increased in stable COPD patients 
compared to controls, median MFI for platelet marker CD61 on CD14 positive cells was 
19.8 (IQR 14.0 – 33.2) in COPD patients versus 10.0 (IQR 8.7 – 16.7) in controls, p=0.002 
(Figure 1A). In addition, in the population of CD14/CD61 double positive cells, the inten-
sity of the CD61 fluorescence signal was significantly higher in COPD patients, median 
MFI 24.6 (IQR 19.6 – 37.7) versus 19.3 (IQR 16.6 - 24.2), p=0.006 (Figure 1B), suggesting 
that more platelets were bound to the monocyte surface. After exclusion of outliers both 
parameters were still statistically significant (p=0.005 and p=0.01, respectively).
Next, we investigated platelet activation by measurement of fibrinogen binding to the 
activated fibrinogen receptor and expression of P-selectin both in unstimulated sam-
ples and after ex vivo stimulation by ADP, CRP-XL and TRAP. In unstimulated samples, 
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no differences in these two parameters were observed between stable COPD patients 
and controls (the median MFI for fibrinogen was 5.11 (IQR 3.8 – 6.2 ) versus 5.68 (IQR 
5.2 – 6.3), p=0.20 and the mean MFI for P-selectin was 7.018 ± 0.26 versus 7.194 ± 0.24, 
p=0.71)(Figure 2).
In stimulated samples, platelet reactivity was similar for ADP, CRP-XL and TRAP in 
COPD patients and controls, for both markers (Figure 3). Soluble P-selectin and soluble 
fibrinogen, markers for platelet degranulation, were measured in plasma. Plasma P-
selectin concentrations were found to be increased in COPD patients (median 31.07 ng/
ml (IQR 26.3 – 40.5) versus 25.25 ng/ml (IQR 24.3 – 32.3), p=0.03) in controls, whereas 
Table 1. Demographics.
COPD patients Control subjects
number of participants 30 25
Age, years 61.6 ± 10.0 53.0 ± 11.7
Male 14 (46.7%) 9 (36.0%)
Current smokers 6 (20.0%) 2 (8.0%)
smoking history, pack years 50.7 ± 27.8 1.6 ± 4.3
GOlD classification N/A
I 1 (3.3%) 
II 11 (36.7%) 
III 15 (50.0%) 
IV 3 (10.0%) 
Respiratory function
FEV1, l 1.36 ± 0.6 3.12 ± 0.89 
FEV1% predicted 48.9 ± 17.5 98.0 ± 13.9 
FVC, l 3.31 ± 0.73 3.94 ± 1.08 
FEV1/FVC ratio 42.9 ± 12.9 80.4 ± 5.5 
Values are mean ± SD or n (%). (Abbreviations: COPD: Chronic Obstructive Pulmonary Disease; FEV1: 
forced expiratory volume in 1 second; FVC: forced vital capacity; GOLD: Global Initiative for Chronic 
Obstructive Lung Disease; N/A: not applicable; SD: Standard deviation)
Table 2. Haematological Parameters.
COPD patients Control subjects p-value
Leukocytes (x 109/L) 7.0 ± 2.3 6.5 ± 1.2 0.399
Platelets (x 109/L) 273 ± 103 261 ± 66 0.876
Mean platelet volume (fL) 10.2 ± 0.8 10.2 ± 0.7 0.958
Platelet distribution width (fL) 11.7 ± 1.8 12.0 ± 1.6 0.526
Platelet-large cell ratio (%) 26.6 ± 6.7 26.8 ± 5.9 0.931
Values are mean ± SD. (Abbreviations: COPD: Chronic Obstructive Pulmonary Disease; SD: Standard 
deviation)
CHAPTER 3
52
  


 




 












 


   


 




 












 


Figure 1. Platelet-monocyte interaction.
Patients with stable COPD show A. increased platelet-monocytes complexes compared to controls, 
median MFI for platelet marker CD61 on CD14 positive cells 19.8 (IQR 14.0 – 33.2) in stable COPD 
patients versus 10.0 (IQR 8.7 – 16.7) in controls, p=0.002. b. In addition, in CD14/CD61 double 
positive cells, CD61 expression was higher in COPD patients compared to controls, median MFI 
24.6 (IQR 19.6 – 37.7) versus 19.3 (IQR 16.6 - 24.2), p=0.006. Lines represent medians with IQR. 
(Abbreviations: COPD: Chronic Obstructive Pulmonary Disease; IQR: Interquartile Range; MFI: Mean 
Fluorescence Intensity)
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Figure 2. Platelet activation in COPD patients and control subjects.
Flow cytometric analyses of platelet fibrinogen binding and platelet P-selectin expression. A. The 
median MFI of fibrinogen binding in COPD was 5.11 (IQR 3.8 – 6.2) versus 5.68 (IQR 5.2 – 6.3) in 
controls, p=0.20 and b. The mean* MFI of P-selectin expression in COPD was 7.018 ± 0.26 versus 
7.194 ± 0.24 in controls, p=0.71. Lines represent median with IQR (A) and mean with SEM (B). 
(Abbreviations: COPD: Chronic Obstructive Pulmonary Disease; IQR: Interquartile Range; MFI: Mean 
Fluorescence Intensity; SEM: Standard error of the mean) *normally distributed data is presented as 
mean ± SEM
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plasma fibrinogen levels were similar (mean 3314 µg/ml ± 259 versus 3051 µg/ml ± 
245, p=0.53) (Figure 4).
Since fibrinogen is rapidly stored intracellular after binding to the receptor, we mea-
sured platelet fibrinogen content to investigate fibrinogen internalization. However, no 
differences in both platelet fibrinogen and platelet P-selectin content could be detected 
(data not shown).
In summary, increased platelet-monocyte interaction was observed, in absence of 
increased platelet activation and platelet hyper-reactivity. Since considerable variation 
in platelet fibrinogen binding (Figure 2A) and soluble P-selectin (Figure 4) was observed 
between patients, a correlation with systemic inflammation was explored. Plasma 
levels of high sensitive interleukin-6 (hsIL-6) were determined and were found to be 
higher overall in stable COPD patients compared to controls (median 313.5 pg/ml (IQR 
265 – 465) versus 258.3 pg/ml (IQR 310 – 316), p=0.02)(Figure 5). No correlations could 
be detected between hsIL-6 and platelet activation and platelet reactivity, neither for 
platelet-monocyte interaction, in stable COPD patients (data not shown).
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Figure 3. Platelet reactivity in COPD patients and controls.
Platelet reactivity was measured after stimulation of with two concentrations of different platelet 
agonists. Data are presented as mean ± SD. A. Reactivity after stimulation with ADP was not dif-
ferent, fibrinogen binding p=0.91, P-selectin expression p=0.56, b. The same applies to stimula-
tion with CRP-XL, fibrinogen binding p=0.39, P-selectin expression p=0.95, and C. stimulation with 
TRAP, fibrinogen binding p=0.39, P-selectin expression p=0.26. (Abbreviations: ADP: adenosine 5’ 
diphosphate; COPD: Chronic Obstructive Pulmonary Disease; CRP-XL: Cross linked Collagen-Related 
Peptide; SD: Standard deviation; TRAP: thrombin receptor-activating peptide; MFI: Mean Fluorescence 
Intensity)
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Additionally, we determined CRP and similarly, no significant correlations could be 
detected with the platelet parameters. A trend towards a positive correlation was seen 
for CRP and platelet-monocyte interaction, although not statistically significant (Spear-
man’s rho 0.264, p=0.095) when examining the entire cohort (supplementary figure).
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Figure 4. Soluble markers for platelet activation in COPD patients and controls.
Soluble markers for platelet activation were measured in platelet poor plasma. A. Soluble P-selec-
tin was higher in COPD patients, median 31.07 ng/ml (IQR 26.3 – 40.5) versus 25.25 ng/ml (IQR 
24.3 – 32.3) in controls, p=0.03. b. Fibrinogen was not statistically different, mean* 3314 µg/ml 
± 259 versus 3051 µg/ml ± 245, p=0.53. Lines represent median with IQR (A) and mean with SEM 
(B). (Abbreviations: COPD: Chronic Obstructive Pulmonary Disease; IQR: Interquartile Range; SEM: 
Standard error of the mean). *normally distributed data is presented as mean ± SEM
   


 




 











Figure 5. Systemic inflammation in stable 
COPD patients and controls.
HsIL-6 was higher in COPD patients, however 
only a subgroup shows increased systemic 
inflammation. Median 313.5 pg/ml (IQR 265 
– 465) in stable COPD, versus 258.3 pg/ml 
(IQR 310 – 316) in controls, p=0.02. Lines 
represent medians with IQR. (Abbreviations: 
COPD: Chronic Obstructive Pulmonary Dis-
ease, hsIL-6: high sensitive Interleukin-6, IQR: 
Interquartile range) 
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To further investigate the underlying mechanisms we determined activation of plas-
matic coagulation. D-dimer, a measure for fibrinolysis, was not different between stable 
COPD patients and controls (median 636.8 ng/ml (IQR 293 – 535) versus 294.3 ng/ml 
(232 – 455), p=0.16). An automated thrombin generation assay was used to investigate 
hypercoagulable phenotypes. Thrombin generation was measured in the presence and 
absence of TF. Clotting time (Lag time), total amount of thrombin generated (ETP) and 
maximum thrombin concentration (thrombin peak) was not different between stable 
COPD patients and controls (Table 3).
DIsCUssIOn
The present study shows that stable COPD patients have increased platelet-monocyte 
interaction in absence of increased platelet activation, platelet hyper-reactivity and 
activation of plasmatic coagulation. Increased expression of platelet marker CD61 
was observed on monocytes in stable COPD patients compared to controls. The lack 
of platelet hyper-reactivity was reflected by platelet fibrinogen binding and platelet 
P-selectin expression in unstimulated samples and after stimulation with 3 different 
platelet agonists. Though a minority of COPD patients had a certain degree of systemic 
inflammation, this could not be related to platelet-monocyte interaction and platelet 
activation. Also, no differences in D-dimer and thrombin generation were detected 
between stable COPD patients and control subjects.
COPD patients are at increased risk for CVD and studies that improve insight in the 
underlying pathophysiological mechanisms are warranted.3,30-32 We hypothesized that 
platelet-monocyte interaction would be increased in COPD, in concurrence with in-
creased platelet activation and platelet hyper-reactivity. In contrast to our hypothesis, 
no alterations in platelet function were found. We confirm previous findings by Maclay 
Table 3. Thrombin generating capacity of stable COPD patients and control subjects.
lag time (min) ETP (nM.min) Peak (nM)
Stable COPD 5.24 ± 1.72 1110 ± 334 216.9 ± 99.8
0 pM TF Control subjects 5.59 ± 3.37 1068 ± 423 1.92.2 ±100.2
p = 0.79 p=0.96 p=0.55
Stable COPD 13.39 ± 5.64 1327 ± 392 298.3 ± 75.8
1 pM TF Control subjects 14.90 ± 6.77 1276 ± 402 285.3 ± 94.6
p=0.33 p=0.85 p=0.68
No statistical significant differences were seen in terms of clotting time (Lag time), total amount 
of thrombin generated (ETP), and maximum thrombin concentration (Peak). Values are mean ± SD. 
(Abbreviations: COPD: Chronic Obstructive Pulmonary Disease; ETP: Endogenous thrombin potential; 
SD: Standard deviation; TF: Tissue Factor)
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and colleagues showing that COPD patients have increased platelet-monocyte interac-
tion,21 however in absence of platelet hyper-reactivity. PMC formation is often used 
as a surrogate marker for platelet activation, as platelet and monocytes can interact 
via platelet P-selectin and PSGL-1 on monocytes and through platelet GPIIb/IIIa and 
monocyte-activating complex-1 (MAC-1) via binding of fibrinogen, interactions that are 
facilitated by platelet activation.33 These interactions seem less relevant in COPD, as 
platelet activation and response to stimulation was not different.
Platelets and monocytes can interact in multiple ways13,15,16 and monocyte-related fac-
tors, such as monocyte activation, may play an important role. Platelets constitutively 
express GPIbα, a receptor that directly interacts with MAC-1 on monocytes.34 MAC-1 
expression increases with monocyte activation, thereby promoting this interaction.34,35 
Our data suggests that not primarily platelet activation, but monocyte activation may 
be a key factor in their interaction. This is supported by the trend that was observed 
between platelet-monocyte interaction and plasma CRP levels. CRP is thought to 
play an important role in atherosclerosis36 and studies have shown that CRP induces 
monocyte-endothelial cell adhesion, an early event in atherosclerosis.37 Moreover, 
increased plasma CRP levels are linked in plaque instability, that may be explained by 
monocyte activation.36,38,39
These findings add to the current debate on whether COPD patients would benefit from 
anti-platelet therapy. At first sight, the benefits of anti-platelet therapy in COPD patients 
seem limited. Increased platelets-monocyte interaction, however, is thought to play a 
key role in cardiovascular disease pathogenesis as it augments development of athero-
sclerotic lesions and is involved in plaque instability.13,40,41 P2Y12 receptor blockers, 
such as Clopidogrel, Prasugrel and Ticagrelor, are known to decrease platelet-monocyte 
interaction and systemic inflammation, partially via reduced monocyte activation,42-45 
whereas these effects are less clear for the COX-inhibitor Aspirin.44,45 Our data suggests 
that P2Y12 receptors may have a beneficial effect in COPD and clinical confirmation is 
warranted.
Interestingly, a small increase in soluble plasma P-selectin levels was observed in COPD 
patients. P-selectin can be released by endothelial cells during endothelial inflamma-
tion, a mechanism that has been previously described for COPD.46,47 This may explain 
our observation. In addition to platelet function, we assessed markers for plasmatic 
coagulation. Risk for venous thrombosis, especially pulmonary embolism, is increased 
in COPD.2,3,6,7 Pulmonary embolism often results from thrombus dislocation from deep 
venous thrombosis, a mechanism dependent on blood stasis and plasmatic coagula-
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tion.48 We found that COPD patients did not show a hypercoagulable phenotype in 
stable disease, as reflected by D-dimer and thrombin generation.
An important, yet unresolved question to address is whether platelet function is af-
fected during and after acute exacerbations. Harrison and colleagues showed that 
thrombocytosis during AE-COPD is associated with increased 1-year mortality (OR 1.53 
(95% CI 1.03-2.29, p=0.030) and patients on anti-platelet therapy showed improved 
survival, although no explanation was given.20 Data on platelet function and platelet-
monocyte interaction during and after AE-COPD is crucial to assess future implications 
for specific anti-platelet therapy in COPD.
This study has several limitations; first limitation is the heterogeneity in COPD patients 
which makes our findings less robust and adds to the difficulty to extrapolate our 
findings. Tremendous research efforts focus on identification of different COPD ‘phe-
notypes’, however today we are not able to differentiate clinically relevant subgroups 
from an immunological perspective. A second limitation is the difference between COPD 
patients and controls in terms of tobacco smoke exposure and age. Tobacco smoke ex-
posure and ageing may increase platelet hyper-reactivity. However, these factors would 
have resulted in platelet hyper-reactivity in the COPD group which was not shown by 
our data. Lastly, data on risk factors for CVD were not collected and therefore no strati-
fication for cardiovascular risk factors could be performed. It was recently shown that 
comorbidities in COPD tend to cluster in different phenotypes49 and therefore it would 
have been of great interest to investigate the effects of these factors on our findings 
from a mechanistical point-of-view.
In summary, we demonstrated that stable COPD patients have increased platelet-mono-
cyte interaction in absence of increased platelet activation, platelet hyper-reactivity 
and activation of plasmatic coagulation. The mechanisms underlying cardiovascular 
risk in COPD may be more dependent on platelet-monocyte interaction than platelet 
function alterations. The benefits of common anti-platelet therapy may differ for the 
COX-inhibitor Aspirin, compared to P2Y12 receptor blockers, as the latter interferes 
with platelet-monocyte interaction. Further confirmation of the effects of anti-platelet 
therapy in COPD is warranted.
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supplementary figure. The relation between plasma CRP and platelet-monocyte interaction in the 
study cohort.
In the entire study cohort, a trend for a modest positive correlation was found between plasma 
CRP and platelet-monocyte interaction (Spearman’s rho= 0.264, p=0.095). (Abbreviations: CRP: C-
reactive protein).
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AbsTRACT
Cardiovascular risk is increased during acute exacerbations of COPD (AE-COPD). In-
creased platelet-monocyte complex (PMC) formation is suggested to contribute this 
this increased risk and may be associated with platelet function alterations. This study 
investigates platelet function in exacerbated COPD patients. PMCs and platelet reactiv-
ity were determined by flow cytometry in 22 exacerbated COPD patients during and 
post-exacerbation. PMCs decrease in AE-COPD, median 10.6% (IQR 8.5-13.6%) versus 
11.9% (IQR 10.2-15.3%), p= 0.04, without platelet function alterations. Monocyte 
MAC-1 expression was increased during AE-COPD (p=0.005) and inversely correlated 
with PMCs. This study suggests that platelet function alterations may not explain car-
diovascular risk during AE-COPD.
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InTRODUCTIOn 
COPD patients are at increased risk for cardiovascular diseases (CVD) and around 50% 
of hospital admissions in COPD patients can be attributed to CVD and 25% of deaths.1 
Myocardial infarction and stroke are the most commonly observed CVD in COPD.2 Acute 
exacerbations of COPD (AE-COPD) are characterized by increased inflammation and fur-
ther increase the cardiovascular risk.2,3 Inflammation and hemostasis are closely linked 
biological systems and interact in many ways.4 Blood platelets function at the cutting 
edge and play a pivotal role in development of cardiovascular disease.
A previous publication by Maclay and colleagues in Thorax suggested increased platelet 
activation in AE-COPD.5 This implicates that COPD patients may benefit from anti-
platelet therapy as preventive measure for CVD. We have shown that no clear platelet 
function alterations were present in stable COPD patients, but confirm increased 
platelet-monocyte complexes (PMCs). PMCs augment the development of atheroscle-
rosis and plaque instability, thereby contributing to CVD.6 
The presence of platelet function alterations during AE-COPD has not yet been studied. 
Moreover, the mechanisms by which platelet and monocytes interact in COPD are not 
known. Recent evidence suggested that macrophage receptor 1 (MAC-1) on monocytes 
may play a role in their interaction.7 This study investigated platelet-monocyte inter-
action, platelet reactivity and MAC-1 expression on monocytes in AE-COPD and post-
exacerbation.
METHODs
See the Online supplement for a detailed description of the methods.
In summary, COPD patients admitted for an exacerbation (as defined by the Anthonisen 
criteria) were included. The study was approved by the Ethical Committee of Radboud 
University Nijmegen, the Netherlands. Blood samples were taken during hospital admis-
sion and after 6 – 10 weeks post-exacerbation.
PMCs were determined by flow cytometry after incubation of samples with monoclonal 
antibodies to monocyte marker CD14 and platelet marker CD61. Erythrocytes were 
lysed and the reaction was stopped by dilution with distilled water.
The binding of fibrinogen to the activated fibrinogen receptor αIIbβ3 and the expression 
of P-selectin (CD62P) on the platelet surface were used to determine platelet reactivity. 
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Platelet reactivity was defined as the expression of these markers after stimulation of 
whole blood with platelet agonists, as previously reported.8 Samples were incubated 
with antibodies for CD61, anti-human fibrinogen and P-selectin and the platelet ago-
nists. After stimulation, cells were fixated with 0.2% paraformaldehyde.
To measure MAC-1, whole blood samples were stained with monoclonal antibodies to 
CD14, CD45 and CD11b, after which the erythrocytes were lysed. After lysis, samples 
were measured within 10 minutes on the flow cytometer. The gating strategies and 
information on the statistical analysis can be found in the online supplement.
REsUlTs
Twenty-two patients were included in this study Two patients died during hospital 
admission and one patient retracted consent. PMCs were decreased during AE-COPD 
compared to post-exacerbation, median PMCs 10.6% IQR 8.5-13.6% during AE-COPD 
versus 11.9% IQR 10.2-15.3% post-exacerbation, p = 0.04, (Figure 1A). In contrast, ex-
pression of MAC-1 by monocytes was higher during AE-COPD (MFI 26.01 IQR 20.1-34.8 
versus 19.54 IQR 18.3-24.6 post-exacerbation versus, p=0.005)(Figure 1B). There was 
an inverse correlation between monocyte MAC-1 expression and platelet-monocyte 
interaction post-exacerbation, Pearon’s r = -0.534, p=0.03, however this association 
was not found during AE-COPD, Pearson’s r = -0.289, p=0.217 (Figure 1C).
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Figure 1. Platelet-monocyte complexes, MAC-1 and their relation.
A. Patients with AE-COPD had less PMCs compared to post-exacerbation, the median percentage 
PMCs of the total monocyte population was 10.6% IQR 8.5-13.6% during AE-COPD compared to 
11.9% IQR 10.2-15.3% post-exacerbation, p=0.04. B. MAC-1 expression on monocytes was higher 
during AE-COPD compared to post-exacerbation, median MFI 26.01 IQR 20.1-34.8 during AE-COPD 
versus median MFI 19.54 IQR 18.3-24.6 post-exacerbation, p=0.005. C. The correlation between 
monocyte MAC-1 expression and platelet-monocyte interaction post-exacerbation (Pearon’s r = 
-0.534, p=0.03). (Abbreviations: AE-COPD: acute exacerbations of COPD; IQR: Inter-quartile range; 
MAC-1: macrophage-1 antigen; MFI: mean fluorescence index; PMC: Platelet-monocye complex)
69
PLATELET-MONOCYTE INTERACTION IN AE-COPD
4
The binding of fibrinogen to platelets in unstimulated samples showed higher fibrinogen 
binding during AE-COPD, whereas P-selectin expression on platelets was not different. 
Upon stimulation of platelets with 3 different platelet agonists, ADP, CRP-XL and TRAP, 
in 2 concentration we did not observe any differences in platelet fibrinogen binding, nor 
did we observe changes in platelet P-selectin expression (Figure 2).
DIsCUssIOn
PMCs were lower in exacerbated COPD patients compared to post-exacerbation, 
whereas MAC-1 expression on monocytes was increased. Additionally, PMCs and MAC-1 
were inversely correlated post-exacerbation. Platelet reactivity was similar during AE-
COPD and post-exacerbation.
Clinical studies suggest that anti-platelet therapy may have a beneficial effect in COPD 
patients.5,9 We, and others, reported increased PMCs in patients with COPD.5 Platelet-
monocyte interaction is often used as a surrogate marker for platelet activation, how-
ever, no clear platelet function alterations were detected in stable COPD patients.
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Figure 2. Platelet reactivity in response to stimulation with platelet agonists.
No differences in fibrinogen and P-selectin expression were found after stimulation with platelet 
agonists ADP (A), CRP-XL (B) and TRAP (C). (Abbreviations: ADP: Adenosine di-phosphate; AE-COPD: 
Acute Exacerbations of COPD; CRP-XL: cross-linked collagen-related peptide; MFI: mean fluorescence 
index; TRAP: Thrombin receptor activating peptide)
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It has been suggested that PMCs further increase during AE-COPD.5 This has led to our 
hypothesis that platelet-monocyte interaction may be driven by monocyte activation, 
rather than platelet activation. Platelets and monocytes can interact in many ways 
and recent evidence suggests that MAC-1 is involved in PMC formation via binding to 
platelet GPIb, a mechanism dependent on monocyte activation.7 This may be relevant 
as different platelet inhibitors can interfere with PMC formation.10 
In contrast to the previous study,5 we observed less PMCs during AE-COPD. An important 
difference is that we used a before-after model in which platelet-monocyte interac-
tion was assessed during and after AE-COPD. Second, this cohort was slightly larger. 
Together this may explain the contradictory nature of the observations.
MAC-1 expression was higher during AE-COPD, however, had an inverse relationship 
with PMCs post-exacerbation. These data indicate that MAC-1 may not be crucially 
involved in platelet-monocyte interaction in COPD.
Similar to our previous study, no alterations in platelet function were found in exacer-
bated patients. This does not necessarily imply that anti-platelet therapy may not be 
beneficial in COPD. Some platelet-inhibitors, such as P2Y12 inhibitors, interfere with 
PMCs and may decrease systemic inflammation. Platelets also exhibit immunological 
functions, and these may influence COPD disease pathophysiology. Interestingly, COPD 
patients treated with platelet-inhibitors showed increased survival post-exacerbation, 
while this was not related to cardiovascular deaths.9
Our study has some limitations. The first limitation of our study is the small sample size. 
COPD is a heterogeneous disease and this makes our findings less robust. We assessed 
the effects of smoking, FEV1 and frequent versus infrequent exacerbator phenotype, 
and these had no influence. Second, we cannot state that the post-exacerbation 
measurement after 6 to 10 weeks resembles stable disease, as it may be period of 
convalescence.
In conclusion, this study reports increased platelet-monocyte interaction post-exacer-
bation of COPD, in absence of platelet hyper-reactivity. The increased cardiovascular 
risk during AE-COPD may therefore not be explained by platelet function alterations.
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study design.
Patients admitted for an AE-COPD were included in the study. The inclusion criteria 
were; patients above 40 years of age, spirometry confirmed diagnosis of COPD (i.e. 
post-bronchodilator FEV1/FVC < lower limit of normal) and clinical diagnosis of COPD 
confirmed by a pulmonologist and > 10 pack years of smoking. General exclusion crite-
ria were use of anti-coagulation or platelet function inhibitors, asthma, malignancies or 
chronic inflammatory diseases, such as rheumatoid arthritis, psoriasis and inflammatory 
bowel disease. An exacerbation is defined as sustained worsening of respiratory symp-
toms during 48 hours. Respiratory symptoms include at least one of the Anthonisen 
criteria, which are increased dyspnoea, sputum volume or sputum purulence, with or 
without minor symptoms such as cough, fever, common cold, wheezing or sore throat.1
Patients were recruited between January and April 2017 after admission at the depart-
ment of Respiratory Medicine at Radboud university medical center, Nijmegen, The 
Netherlands. This study was approved by the Ethical Committee of Radboud University 
Nijmegen and was conducted according to the principles of the Declaration of Helsinki 
(version Oct 2008) and in accordance with the Dutch Medical Research involving Human 
Subjects Act. All participants gave written informed consent before blood was drawn. 
Blood samples were taken at two time points; first time point was within 96 hours after 
admission to the hospital and the second time point was after 6 to 10 weeks at a follow 
up visit at the outpatient clinic. Blood was collected in EDTA and 3.2% sodium citrate 
vacutainer tubes (Becton Dickinson, Plymouth, UK) and processed immediately. Blood 
counts were measured with a haematology analyzer (Sysmex XN-450, Kobe, Japan).
Platelet-monocyte interaction and platelet reactivity.
For measurement of platelet-monocyte interaction, samples were incubated with 
monoclonal antibodies to monocyte marker CD14 (phycoerythrin (PE)-conjugated) 
(Becton Dickinson) and platelet marker CD61 (PC7-conjugated) for 20 minutes. Optilyse 
B (Beckman Coulter) was used to lyse the erythrocytes and after 10 minutes the reac-
tion was stopped by dilution with distilled water. Gating of monocytes was performed 
based on forward and sideward scatter and additionally for of CD14 positivity, followed 
by positivity for CD61.
The binding of fibrinogen to the activated fibrinogen receptor αIIbβ3 (GPIIb/IIIa com-
plex) and the expression of P-selectin (CD62P) on the platelet surface were used to 
determine platelet activation, as these markers reflect platelet aggregation and degran-
ulation, respectively. Platelet reactivity was defined as the expression of these markers 
after stimulation of whole blood with platelet agonists, as previously reported.2,3 Whole 
blood samples were measured unstimulated and after stimulation with the agonists 
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adenosine 5’ diphosphate (ADP) (Sigma-Aldrich), cross linked collagen-related peptide 
(CRP-XL) (kind gift from Prof. Dr. R. Farndale, Cambridge, UK) and thrombin receptor-
activating peptide-6 (TRAP) (Sigma-Aldrich). Samples were incubated with antibodies 
for CD61 (PC7-conjugated) (Beckman Coulter), anti-human fibrinogen (fluorescein 
isothiocynate (FITC)-conjugated) (Dako) and P-selectin (CD62P, phycoerythrin (PE)-
conjugated) (Biolegend) and two concentrations of the platelet agonists for 20 min-
utes. After stimulation cells were fixated with 0.2% paraformaldehyde. Expression of 
activation markers was measured by flow cytometry (FC500 flow cytometer, Beckman 
Coulter). Gating of platelets was performed based on forward and sideward scatter and 
additionally for of CD61 positivity.
MAC-1 expression on monocytes.
MAC-1 is a monocyte receptor that is upregulated during monocyte activation and is 
able to bind to platelets via platelet receptor GPIb and to platelet receptor GPIIb/IIIa 
via concurrent binding of fibrinogen.4,5 To measure monocyte activation, whole blood 
samples were stained with monoclonal antibodies to CD14 (PE, Beckman coulter), CD45 
(PC7) and CD11b (FITC) for 15 minutes, after which the erythrocytes were lysed with BD 
Pharm Lyse (BD Biosciences) for 10 minutes. After lysis, samples were measured within 
10 minutes on the flow cytometer.
soluble markers of platelet activation and inflammation.
High-sensitive Interleukin-6 (hsIL-6) was determined with human high sensitive IL-6 
Quantikine kit (R&D systems, Minneapolis, USA). For platelet content whole blood was 
centrifugated for 15 minutes at 156 g without break to obtain platelet-rich-plasma 
(PRP). Platelet concentration was adjusted to 300x109/L by addition of autologous 
plasma. In order to lyse the platelets in PRP, samples were 1:1 diluted with triton X-100 
2%, followed by ultra-centrifugation for 5 minutes at 10,000 RPM to spin down large 
particles and supernatants were taken for ELISA.
Data analyses
Statistical analysis was performed with Graphpad Prism 5.0 (San Diego, CA, USA) and 
IBM SPSS statistics 22.0 (New York, NY, USA). Data was tested for normality by use of 
the Shapiro-Wilkinson test and assessed in Q-Q plots. Normally distributed data were 
analyzed by paired T tests (two-sided) and results are presented as mean with the 
standard error of the mean (SEM). Non-normally distributed data were analyzed with 
the Wilcoxon-Rank sum test and data are presented as median with interquartile range 
(IQR). Correlations between inflammation and platelet markers were determined us-
ing Pearon’s r when data were normally distributed and Spearman’s rank correlation 
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coefficient when data were non-normally distributed. The differences were considered 
significant if the p-value < 0.05.
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AbsTRACT
Involvement of STAT3 in inflammation is well-known. Recently, a role for STAT3 in plate-
let activation and platelet production has been suggested. Platelets exhibit important 
immune functions and engagement of STAT3 in platelet physiology may link inflam-
mation and hemostasis. This study investigated the effects of STAT3 loss-of-function 
mutations and SNPs in STAT3 on Glycoprotein VI (GPVI)-mediated platelet activation 
and platelet numbers in humans. Two cohorts were studied. The first cohort concerned 
patients with STAT3 loss-of-function mutations. Platelet numbers were investigated in 
8 patients and GPVI-mediated platelet activation was functionally tested in 4 patients. 
Additional experiments were performed to investigate underlying mechanisms. The 
second cohort concerned 334 healthy volunteers and investigated the consequences of 
SNPs in STAT3 on GPVI-mediated platelet activation and platelet numbers. Platelet acti-
vation was lower in STAT3 loss-of-function patients at baseline and after stimulation of 
the GPVI receptor, reflected by decreased P-selectin expression. This was independent 
of gene transcription. Blockade of the ADP pathway resulted in a further decrease of P-
selectin expression, particularly in STAT3 loss-of-function patients. In contrast, the SNPs 
in STAT3 did not influence GPVI-mediated platelet activation. Also, platelet numbers 
were not affected by STAT3 loss-of-function mutations, nor was there an association 
with the SNPs. In conclusion, STAT3 signaling does not seem to play a major role in 
thrombopoiesis. We confirm that STAT3 is involved in GPVI-mediated platelet activa-
tion in humans, independent of gene transcription. GPVI-mediated platelet activation is 
highly dependent on secondary ADP release. Our findings suggest that STAT3 modula-
tion may affect inflammation, hemostasis and their interaction.
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InTRODUCTIOn
Signal Transducer and Activator of Transcription 3 (STAT3) is important for transduction 
of a variety of cell signals, including signals involved in inflammation.1,2 In response to 
cytokines and growth factors, STAT3 is phosphorylated and translocated to the nucleus 
for transcription of specific genes.1 Differentiation of T helper-17 (Th-17) cells is depen-
dent on STAT3 and is essential for host defense against fungal infections.3,4 Conversely, 
increased STAT3 activity results in hyperinflammation and disease, and contributes to 
the pathogenesis of certain types of cancer.4-8 Therefore, a delicate balance of STAT3 
activation is crucial to prevent disease.
In addition to regulation of inflammatory responses, recent evidence suggests that 
STAT3 is also involved in hemostasis. More specific, STAT3 was shown to play a role 
in platelet activation9-11 and in thrombopoiesis.12 Zhou and colleagues reported that 
platelet activation via surface receptor Glycoprotein VI (GPVI) is impaired in platelet 
STAT3-knockout mice.9 Additionally, ex vivo STAT3 inhibition by pharmacological 
inhibitors resulted in decreased platelet activation and less thrombus formation after 
stimulation of GPVI with platelet agonist collagen-related peptide (CRP) in humans.9 
Grozovsky and colleagues showed involvement of STAT3 in platelet production.12 Bind-
ing of desialylated platelets to the Ashwell-Morell receptor induced hepatic thrombo-
poietin (TPO) via a mechanism dependent on STAT3 in mice.12 These studies suggest 
that STAT3 may be involved in primordial platelet physiology, however, most evidence 
is derived from mouse models and cell lines: further validation of its importance in 
humans is therefore warranted.
This study investigated involvement of STAT3 in platelet activation and platelet numbers 
in humans. Two independent cohorts were studied. The first cohort concerned patients 
with STAT3 loss-of-function mutations. STAT3 loss-of-function is rare but nonetheless 
observed in humans and results in the Hyper IgE syndrome, an immune deficiency 
disorder associated with recurrent infections, eczema, mucocutaneous candidiasis and 
extreme elevations of serum IgE.13,14 Patients with STAT3 loss-of-function are deficient 
in STAT3-dependent cytokines, such as Interleukin (IL)-17. It is unknown whether 
thrombopoiesis and platelet function are affected in humans with mutations in STAT3. 
The second cohort concerned healthy human volunteers and investigated the effects 
of Single Nucleotide Polymorphisms (SNPs) in STAT3 on platelet activation and platelet 
numbers. These data are important to understand its function on a population level. We 
demonstrate that both mutations and SNPs in STAT3 do not influence platelet numbers 
in humans, whereas STAT3 loss-of-function mutations do affect GPVI-mediated platelet 
activation by CRP. Additionally, we observed that GPVI-mediated platelet activation was 
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largely dependent on secondary stimulation by adenosine di-phosphate (ADP), thereby 
partially restoring the defect observed in STAT3 loss-of-function patients.
METHODs 
Patients selection.
Cohort 1. Subjects with STAT3 loss-of-function mutations.
Autosomal dominant cases of hyper IgE syndrome (AD-HIES) are caused by specific 
mutations that results in non-functional STAT3 activity.15 Most mutations are found 
at positions that are well known for STAT3 function, such as the Src homology (SH2) 
domain that enables recruitment and binding of STAT3 to the activated receptor and 
the DNA-binding domain that enables binding of STAT3 to DNA target sites.14 The vast 
majority of AD-HIES cases are due to these heterozygous mutations resulting in absent 
STAT3 activity, however, several other mutations have been described.13,16 To examine 
the effects of STAT3 loss-of-function mutations on platelet numbers, medical records of 
8 confirmed heterozygous AD-HIES patients were consulted. Additionally, we were able 
to functionally assess GPVI-mediated platelet activation in 4 of these patients and in 
10 control subjects. Interleukin-17 production has been previously tested in peripheral 
blood mononuclear cells (PBMCs) of these patients and the interleukin-17 (IL-17) defi-
ciency served as a further confirmation of the STAT3 loss-of-function.17 Control subjects 
were healthy individuals that were age- and gender matched with AD-HIES patients. 
No genotyping for specific STAT3 mutations was performed in control subjects because 
the incidence is exceptionally low and severe medical complaints manifest early in life. 
The control subjects did not experience any medical complaints during recruitment. 
Subjects were recruited under a protocol approved by the Institutional Review Board of 
Radboud University Nijmegen Medical Center. AD-HIES patients are referred to as STAT3 
loss-of-function patients.
Cohort 2. STAT3-related SNPs in healthy subjects.
Several SNPs in STAT3 that are associated with inflammatory diseases were identified 
from literature.18-20 In contrast to the STAT3 loss-of-function mutations, the SNPs in 
STAT3 are associated with inflammatory diseases that are accompanied by increased 
IL-17 levels. Differentiation of Th-17 cells is dependent on STAT3, which suggests in-
creased STAT3 activity.20 We determined these SNPs using DNA from the 500 Functional 
Genomics (FG) cohort and correlated these with GPVI-mediated platelet activation and 
platelet numbers. This cohort consists of 534 healthy individuals of Caucasian origin 
and is part of the Human Functional Genomics Project (HFGP) aimed at characterizing 
variations in immune function.21,22 More detailed information on the study design and 
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the characteristics of study participants can be found in previous publications.22,23 
Individuals were recruited under a protocol approved by the Institutional Review Board 
of Radboud University Nijmegen Medical Center.
Experiments cohort 1.
Platelet activation and responsiveness assay.
Blood from STAT3 loss-of-function patients during stable disease and healthy subjects 
was collected in 3.2% sodium citrate vacutainer tubes (Becton Dickinson, Franklin 
Lakes, New Jersey, USA). Whole blood was centrifugated for 15 minutes at 156 g 
without break to obtain platelet-rich-plasma (PRP). Platelet concentration was adjusted 
to 300x109/L by addition of autologous platelet-poor plasma (PPP). PPP was obtained 
after centrifugation of whole blood at 3800 RPM for 10 minutes. PRP was rested for 1 
hour before platelet functions were assessed.
Platelet expression of activation marker P-selectin was measured in PRP at baseline and 
after incubation for 20 minutes with different concentrations of platelet agonist cross 
linked collagen-related peptide (CRP) (kind gift from Prof. Dr. R. Farndale, Cambridge, 
UK) to stimulate the GPVI surface receptor. Thrombin Receptor Activating Peptide-6 
(TRAP) (Sigma-Aldrich, Saint Louis, Missouri, USA), an agonist for the thrombin receptor 
proteinase-activated receptor-1 (PAR-1), served as a positive control. Samples were 
incubated with 9 concentrations of CRP (range 1.3 – 320ng/ml) and two concentrations 
of TRAP (9.78µm and 156µm) together with antibodies for flow cytometry. The reaction 
was stopped by addition of 0.2% paraformaldehyde. P-selectin expression was mea-
sured with a Becton Dickinson flow cytometer. In order to identify platelets, platelets 
were gated based on forward and sideward scatter (FSC/SSC) and additional gating was 
performed based on expression of platelet surface marker CD61 (PC7 labeled anti-
CD61, Beckman Coulter, Brea, California, USA). To determine platelet activation, the 
mean fluorescence intensity (MFI) exceeding that of the matched isotype of P-selectin 
(PE labeled anti-CD62P, Bio-legend, San Diego, California, USA) was determined.
Inhibition of ADP pathway with apyrase.
Activation via the GPVI surface receptor results in platelet degranulation of dense 
granules thereby releasing biologically active substances, most notably ADP. ADP can 
activate platelets via a secondary pathway. In order to avoid skewing of the responses 
by platelet activation via this positive feedback loop, additional experiments were 
performed after pre-incubation with apyrase, to block the ADP pathway. Apyrase was 
purchased from Sigma-Aldrich (Saint Louis, Missouri, USA). For experiments a final 
concentration 5 U/ml was used. After incubation with apyrase, PRP samples were stimu-
lated with CRP at concentrations 320 ng/ml, 80 ng/ml, 20ng/ml in combination with the 
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antibodies for flow cytometry. The same protocol and gating strategies as described 
above were used.
Inhibition of transcription during platelet activation.
STAT3, as a transcription factor, regulates DNA transcription and exerts its effects after 
phosphorylation, dimerization and translocation to the nucleus.24 Platelets do not have 
a nucleus and exclusively contain mitochondrial DNA. Experiments with transcription 
blocker actinomycin were performed to investigate the role of DNA transcription in this 
process. Actinomycin was purchased from Sigma-Aldrich (Saint Louis, Missouri, USA) 
and dissolved in DMSO, stock concentration 6270ug/ml. PRP was pre-incubated with 
actinomycin D in two concentrations (50ug and 5ug) and DMSO control, before samples 
were stimulated with CRP. The CRP concentration of 40ng/ml was chosen as it was esti-
mated that platelet responses would be in the steep part of the platelet reactivity curve. 
The same protocol for stimulation and similar gating strategies as described above were 
used for measurement of P-selectin expression.
Platelet content and plasma markers.
Soluble plasma markers and platelet content of P-selectin, fibrinogen were determined 
by ELISA. For platelet content, PRP (concentration 300x109 platelets/ml) were freeze-
thawed for 3 cycles to fragment the platelets. Samples were centrifugated at room tem-
perature 5 for minutes at 5000 RPM in an ultracentrifuge to spin down large particles. 
Supernatants were used for ELISA. PPP was used for plasma markers. Soluble P-selectin 
and soluble fibrinogen were measured using a human P-selectin/CD62P duoset ELISA 
kit (R&D systems, Europe, Abingdon, UK) and a human Fibrinogen ELISA kit (Abcam, Eu-
rope, Cambridge, UK), respectively. Thrombopoietin (TPO) was measured with a human 
thrombopoietin Quantikine ELISA kit (R&D systems, Europe, Abingdon, UK).
Experiments cohort 2.
Single Nucleotide Polymorphisms (SNPs) in STAT3.
Genotyping of the SNPs was performed using a commercially available SNP chip, Il-
lumina HumanOmniExpressExome-8 v.1.0, methods previously reported by Li et al.23 In 
short, genotype calling was performed using Optical 0.7.0.25 Call rates less than ≤0.99 
were excluded from the dataset, as were samples with a Hardy-Weinburg equilibrium 
(HWE) ≤0.0001, call rate ≤0.99 and MAF ≤0.001. In total, 483 samples were included for 
further imputation, as described previously. Data was extracted for the following SNPs: 
rs744166, rs3816769 and rs4796793. Presence of the SNP was related to platelet 
activation in response to CRP and to platelet numbers.
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Platelet activation and responsiveness assay.
For assessment of platelet activation and responsiveness, platelet P-selectin expression 
was measured in whole blood at baseline and after incubation for 20 minutes with 7 dif-
ferent concentrations of platelet agonists CRP, together with an antibody-mix for flow 
cytometry. The same protocol and gating strategies as described above were used for 
measurement of P-selectin expression. The area under the curve (AUC) of the P-selectin 
expression after stimulation (MFI) was correlated with the SNP data. In total, data was 
available for 334 healthy human volunteers.
statistical analysis.
Cohort 1. Quantitative data are expressed as median with interquartile range (IQR) and 
were analyzed with GraphPad Prism 5. Repeated measures like platelet responsiveness 
upon stimulation was analyzed using a two-way ANOVA in order to correct for the mul-
tiple independent observations. To compare singular measurements between groups 
Mann-Whitney U tests were performed for non-normally distributed data.
Cohort 2. Platelet numbers were normally distributed, in contrast to P-selectin expres-
sion. To normalize P-selectin expression (AUC), data was log transformed. Formal cor-
rection for age- and gender effects in both outcome parameters was performed. SNP 
genotypes were coded 0, 1 and 2, before linear regression analyses was performed with 
SPSS with use of dummy variables.
P values < 0.05 were considered statistically significant.
REsUlTs
Characteristics of study participants.
Main characteristics of the two study cohorts are presented in table 1. The first cohort 
concerned 8 STAT3 loss-of-function patients, five patients had a mutation in the DNA-
binding domain, two in the SH2-domain and one patient had a mutation in the Linker-
domain of STAT3. The second cohort involved 483 healthy human volunteers for which 
of 334 participants data on SNPs and GPVI-mediated platelet activation was available. 
A more detailed description of the specific mutations in the STAT3 loss-of-function 
patients can be found in table 2.
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less platelet activation and GPVI-mediated platelet responsiveness in sTAT3 
loss-of-function patients.
To investigate the involvement of STAT3 in platelet activation, we determined baseline 
platelet activation in STAT3 loss-of-function patients. Platelet activation, determined 
by P-selectin expression, was significantly lower in STAT3 loss-of-function patients 
compared to healthy subjects (median MFI 3.03 (IQR 2.62 – 3.84) versus 4.82 (IQR 3.53 
– 5.67), p=0.01) (Figure 1A). Next, we investigated whether collagen induced platelet 
activation by stimulation of GPVI surface receptor with CRP was affected. Stimulation of 
the GPVI receptor with different concentrations of CRP (range 1.3 – 320 ng/ml), resulted 
in significantly lower P-selectin expression in STAT3 loss-of-function patients compared 
to healthy subjects (p<0.001)(Figure 1B). To examine whether this observation was due 
to an intrinsic platelet defect or whether it resulted from the theoretical possibility of 
defective production of factors that prime platelets, platelets were stimulated with 
another agonist, TRAP, as a control. Although platelet responses were slightly lower with 
TRAP (Figure 1C), this effect was not statistically significant after correction for lower 
baseline P-selectin expression, suggesting a largely intrinsic defect in platelets.
Table 1. Patient characteristics.
Cohorts sTAT3 loss-of-function Cohort snP Cohort 
AD-HIES Control subjects Healthy individuals
number (n) 8 10 483
Age (mean, sD) 38 ± 10.5 32 ± 9.2 28.5 ± 13.7
Gender (% male) 37.5% 40% 44.3%
Mutation domain (n) N/A N/A
DnA binding domain 5   
sH2-domain 2   
linker-domain 1   
snP frequency* N/A N/A
rs744166   31.5/48.4/20.1% 
rs3816769   58.6/37.0/4.4% 
rs4796793   37.7/48.9/13.4% 
Medication Anti-fungal therapy, 
prophylactic 
antibiotic treatment
No medication No medication
Clinical complications Recurrent RTIs, 
eczema, ‘cold 
abscesses’
None None
Characteristics of the two study cohorts. (Abbreviations: AD-HIES: Autosomal-Dominant Hyper IgE 
Syndrome; N/A: Not Applicable; RTI: respiratory tract infection; SH2: Src Homology 2; SNP: Single 
Nucleotide Polymorphism) *homozygous for common allele / heterozygous / homozygous for rare 
allele
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Figure 1. Functional assessment of GPVI-mediated platelet activation in STAT3 loss-of-function 
patients.
A. Platelet P-selectin expression in unstimulated samples (median MFI 3.03 (IQR 2.62 - 3.84) in 
STAT3 loss-of-function versus 4.82 (IQR 3.53 - 5.67) in control subjects, p=0.01). b. Platelet P-
selectin expression in GPVI-mediated platelet activation by CRP stimulation (P<0.001). C. Platelet 
P-selectin expression in PAR-1 mediated platelet activation by TRAP (p=0.054). D. P-selectin ex-
pression in GPVI-mediated platelet activation by CRP after blockade of the ADP pathway by apy-
rase. Data are presented as median with IQR. (Abbreviations: ADP: adenosine 5’ diphosphate; CRP: 
Collagen-related Peptide; GPVI: Glycoprotein VI; MFI: Mean Fluorescence Intensity; TRAP: Thrombin 
Receptor Activating Peptide-6)
Table 2. STAT3 loss-of-function mutations.
Protein domain site of mutation DnA sequence
change
Predicted amino
acid change 
number of
patients
DnA-binding Exon 13 1144C→T R382W 2* (1)
Exon 13 1145G→A R382Q 1 
Exon 16 1387 deletion GTG V463 deletion 1 
Intron 11 1110-2A→G G380 deletion 1* 
sH2 Exon 21 1909C→G V637L 1
Exon 21 1909G→A V637M 1* 
linker domain Exon 19 1679-1681 deletion S560 deletion 1*
Specification of the STAT3 loss-of-function mutations. (Abbreviations: DNA: Deoxyribonucleid acid; 
SH2: Src Homology 2). Patients indicated with an asterisk (*) were functionally assessed.
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Inhibition of the ADP pathway further attenuates platelet responsiveness in 
sTAT3 loss-of-function patients.
GPVI-mediated platelet activation results in platelet degranulation, thereby releasing 
biologically active substances, in particular ADP from dense granules.26 In order to in-
vestigate dependency of the GPVI-mediated platelet activation pathway on secondary 
ADP release, we incubated samples with apyrase to block this pathway. Stimulation of 
the GPVI receptor by different concentrations of CRP after incubation of samples with 
apyrase resulted in considerably lower P-selectin expression in both groups. Inhibition 
of the ADP pathway seems to have a more profound effect in STAT3 loss-of-function 
patients than in healthy subjects, as the relative increase from baseline to the highest 
CRP concentration was 5.7 fold in STAT3 loss-of-function patients compared to 11.4 fold 
in control subjects (Figure 1D).
sTAT3 signaling in GPVI-mediated platelet activation is independent of gene 
transcription.
Platelets do not have a DNA containing nucleus, however platelets do possess functional 
mitochondrial DNA.26 In order to exclude the theoretical possibility of involvement of 
novel DNA transcription in platelet activation in response to CRP stimulation, transcrip-
tion was inhibited by general transcription blocker actinomycin D. After incubation of 
PRP samples with actinomycin D, samples were stimulated with CRP. No changes in 
expression of P-selectin was seen after inhibition of transcription in both patients and 
healthy subjects (data not shown).
no differences in platelet content and soluble markers were found in sTAT3 
loss-of-function patients.
Previous experiments suggest an intrinsic platelet defect in patients with STAT3 loss-of-
function mutations. In addition, inhibition of the ADP pathway had a relatively higher 
impact on GPVI-mediated platelet activation in STAT3 loss-of-function patients. To 
examine whether these observations were a result of alterations in granule content, 
we measured P-selectin and fibrinogen in platelet lysates. No differences were seen in 
platelet content for P-selectin and fibrinogen (327.0 ng/ml (IQR 153.9 – 523.5) versus 
261.1 ng/ml (IQR 204.3 – 325.5), p-value 0.84 and 2420 µg/ml (IQR 1786 – 3813) and 
2092 µg/ml (IQR 1038 – 2938), p-value 0.52, respectively). This suggests that previ-
ous observations are more likely due to lower platelet granule release in response to 
stimulation than alterations in granule content.
Lastly, P-selectin and fibrinogen in plasma was determined as a measure for platelet 
granules release. Interestingly, no significant differences were found in soluble plasma 
P-selectin and fibrinogen between patients and healthy subjects, (median 41.7 ng/ml 
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(IQR 27.0 – 47.3) versus 27.9 ng/ml (21.9 – 44.2), p-value 0.45 and mean 2513 µg/ml 
(IQR 1826 – 3016) versus 2640 µg/ml (IQR 2240 – 3114), p-value 0.74, respectively).
snPs in sTAT3 do not correlate with GPVI-mediated platelet activation in 
healthy volunteers.
To investigate the involvement of STAT3 on platelet activation on a population level, 
several SNPs in STAT3 that are associated with inflammatory diseases were investigated. 
The 3 SNPs; rs744166, rs3816769 and rs4796793, were determined in the second 
cohort, concerning healthy volunteers. These SNPs are known from literature to be 
functional and are likely to influence STAT3 activity in relation to several diseases, such 
as Crohn’s disease, ulcerative colitis and autoimmune thyroid disease.18-20 The minor 
allele frequencies (MAF) of rs744166, rs3816769, rs4796793 were C=0.439/964, 
C=0.254/964 and C=0.378/964, respectively. The MAFs were similar to the MAFs re-
ported in the NCBI database (http://www.ncbi.nlm.nih.gov/SNP), except for rs3816769 
with a MAF of C=382/1912 in the NCBI database.
Linear regression analysis was performed for SNP genotype and platelet activation in 
response to GPVI stimulation (AUC). No significant correlations could be detected for 
rs744166, rs3816769, and rs4796793 with GPVI-mediated platelet activation (p>0.05). 
The SNP characteristics and the relation between the SNPs and GPVI-mediated platelet 
activation is shown in Figure 2. In contrast to previous observations, SNPs in STAT3 do 
not seem to affect GPVI-mediated platelet activation.
 
Figure 2. SNPs rs744166, rs3816769 and rs4796793 and P-selectin expression (AUC).
SNP characteristics are shown in the upper figure. P-selectin expression (AUC of MFI) after GPVI-
mediated platelet activation by 7 concentrations of CRP is shown in the lower figure. Data are 
presented as median with IQR. (Abbreviations: AUC: Area Under the Curve; CRP: Collagen-related 
Peptide, GPVI: Glycoprotein VI; IQR: Interquartile range; MAF: Minor Allele Frequency; MFI: Mean Fluo-
rescence Intensity; SNP: Single Nucleotide Polymorphism)
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Platelet numbers are not influenced by sTAT3 mutations and sTAT3 snPs.
Lastly, we studied platelet production. Platelet production is primarily regulated by TPO 
concentrations in blood and it has recently been suggested that hepatic TPO production 
is dependent on signaling via STAT3.12 Platelet numbers retrieved from medical records 
of 8 confirmed STAT3 loss-of-function patients were mostly within the normal range 
(Table 3). Interestingly, thrombocytosis was observed in two patients during an acute 
infection. Thrombocytopenia was not observed in STAT3 loss-of-function patients. In 
addition, plasma TPO levels were determined in the 4 functionally assessed STAT3 loss-
of-function patients and the 10 healthy subjects. Although most values were below the 
detection limit of 15.6 pg/ml, two STAT3 loss-of-function patients had detectable TPO 
levels (24.0 pg/ml and 79.7 pg/ml) (Figure 3A).
Several studies suggest that IL-6 stimulates thrombopoiesis.27,28 Therefore, we deter-
mined IL-6 levels in plasma. A trend for higher IL-6 was observed in STAT3 loss-of-
function patients (Figure 3B).
Also the effects of the SNPs in STAT3 were examined. Consistently with the observation 
in the STAT3 loss-of-function patients, no significant influence of the SNPs on platelet 
numbers were observed in 334 healthy subjects (Table 3). Importantly, both thrombo-
cytopenia and thrombocytosis were rarely observed.
Table 3. Median platelet numbers (range).
sTAT3 loss-of-function 
cohort
Highest (platelets 
x109/l)
lowest (platelets 
x109/l)
1. ♀ , 46 yrs. 264 229
2. ♀, 46 yrs.* 247 160
3. ♀, 23 yrs.* 505 231
4. ♂, 47 yrs.* 317 168
5. ♂, 26 yrs. 242 133
6. ♀, 34 yrs. 314 205
7. ♀, 32 yrs.* 431 175
8. ♀, 50 yrs. 257 206
snP cohort Wild type Heterozygous Homozygous for snP
rs744166 274 (132-470) 257 (132-491) 268 (133-488)
rs3816769 276 (132-470) 263 (132-491) 266 (133-488)
rs4796793 280 (159-401) 275 (132-491) 261 (132-488)
Platelet numbers from STAT3 loss-of-function patients, platelets x 109/L, and platelet numbers 
from the SNP cohort, median platelet numbers x109/L (range). Patients indicated with an asterisk 
(*) were functionally assessed. (Abbreviations: ♀: female; ♂: male; SNP: Single Nucleotide Polymor-
phism) 
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DIsCUssIOn
The present study investigated the involvement of STAT3 in GPVI-mediated platelet 
activation and platelet numbers in humans. Our findings indicate that GPVI-mediated 
platelet activation is affected by STAT3 loss-of-function mutations confirming its in-
volvement in platelet function in humans. In contrast, neither clinically relevant STAT3 
loss-of-function mutations, nor SNPs in STAT3 affected platelet numbers in humans.
Further experiments were performed to increase our understanding of its function. 
GPVI-mediated platelet activation was shown to be largely dependent on secondary 
stimulation by platelet ADP release, both in patients and in healthy subjects. Blockade 
of this mechanism strongly attenuated platelet responses, particularly in STAT3 loss-
of-function patients. These observations were independent of gene transcription, as 
previously reported.9 Although STAT3 is commonly known as a transcription factor, 
its involvement in platelet activation appears to be non-transcriptional and few non-
transcriptional properties of STAT3 have been previously described.29,30 SNPs in STAT3 
did not directly affect GPVI-mediated platelet activation in a healthy population. In 
some inflammatory diseases the effects of SNPs in STAT3 on platelet activation may 
become apparent, however, in healthy individuals robust mechanisms seem to balance 
inflammation and hemostasis.
Interestingly, P-selectin levels in plasma were not different between STAT3 loss-of-
function patients and control subjects, whereas platelet degranulation was decreased 
in patients. Another source for soluble P-selectin is the vascular endothelium.31 Both 
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Figure 3. TPO and IL-6 levels in plasma.
A. Plasma TPO levels in STAT3 loss-of-function patients and control subjects, B. Plasma IL-6 expres-
sion in STAT3 loss-of-function patients and control subjects. (Abbreviations: IL-6: Interleukin-6; TPO: 
Thrombopoietin)
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vascular abnormalities and endothelial dysfunction are common in Hyper IgE syndrome 
and may explain this observation.32
With the lack of an effect on platelet numbers we report an opposite effect compared 
to a previous study that suggests an important role for STAT3 in the hepatocytic produc-
tion of TPO, the most important regulator of platelet formation by megakaryocytes.12 
In addition to a mouse model, it was shown that desialylated platelets are taken up by 
a human HepG2 cells and these cells subsequently produce TPO in a Janus Kinase-2/
STAT3-dependent manner.12 In contrast, we did not find a decrease in platelet numbers 
in patients with defective STAT3 signaling, moreover thrombocytosis was observed in 
STAT3 loss-of-function patients during acute infections. TPO levels were detectable in 
plasma in two patients, whereas these were low or undetectable in control subjects. A 
direct comparison between groups is limited by the fact that TPO was undetectable in 
most subjects and these results should be interpreted with caution. A trend was seen 
for increased IL-6 in patients and this may also stimulate thrombopoiesis.27,28 Our find-
ings suggest that in vivo other mechanisms also regulate platelet production in humans.
The observation that STAT3 is involved in GPVI-mediated platelet activation further 
validates that the mechanism reported by Zhou and colleagues may be functional and 
relevant in humans too.9 Involvement of STAT3 in platelet activation may provide a 
relevant link between inflammation and hemostasis. Increased activation of the STAT3 
signaling pathway has been described in cancer and many inflammatory diseases, 
including cardiovascular diseases.4-8,33 Cardiovascular disease is the leading cause of 
death worldwide and interestingly, risk for cardiovascular diseases is strongly increased 
in many inflammatory diseasese.34 To examine whether GPVI-mediated platelet activa-
tion was affected by SNPs in STAT3 we studied a cohort of healthy human volunteers, 
however, no relation was observed. The role of STAT3 activation in inflammatory dis-
eases and its consequences for platelet activation needs further exploration. Especially 
since it is unknown if the SNPs in STAT3 affect STAT3 function in healthy subjects, or 
whether aberrant STAT3 function becomes apparent in inflammatory diseases.
Blockade of STAT3 is currently being explored as a new therapy for cancer.35,36 Several 
STAT3-inhibitors have recently proceeded into clinical trials and also drugs that block 
Janus Kinase 2 (JAK2), such as Ruxolitinib.35,37,38 It is important that involvement of STAT3 
in platelet activation is recognized. Bleeding complications may occur, especially in pa-
tients that are concurrently treated with platelet inhibitors that target other pathways 
such as Ticagrelor and Clopidogrel, targets of the ADP receptor, P2Y12. GPVI-mediated 
platelet activation is highly dependent on secondary activation via ADP and suppres-
sion of both pathways may have important consequences in terms of bleedings.39-41
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The relevance of the functional impairment in patients with AD-HIES seems to be 
limited due to the positive feedback loop by ADP, which partially restores platelet 
responses. Although severe bleeding complications are reported, they mostly coincide 
with opportunistic infections in AD-HIES patients that often have bronchiectasis, both 
features known to provoke pulmonary hemorrhages.42,43 Interestingly, in one AD-HIES 
patient a spontaneous bleeding was recorded that could not be explained from a clini-
cal perspective. The bleeding occurred in the iliopsoas muscle and was not preceded 
by any kind of trauma. Examination of the medical history of the other patients did not 
reveal any unexplained spontaneous bleedings.
Our study has a few limitations. The first limitation is that we were unable to relate 
platelet responses directly to STAT3 function and different STAT3 isoforms. STAT3 has 
several isoforms that mostly result from alternative mRNA splicing. These isoforms can 
have distinct functions, STAT3β, for example, lacks the Ser727 phosporylation site and 
is thought to be a negative regulator.44 The exact mechanisms by which STAT3 mutations 
cause STAT3 loss-of-function are still largely unknown.14 It would have been of great 
interest to directly relate STAT3 isoforms and STAT3 activity to GPVI-mediated platelet 
responses. Also the question whether there is an compensatory increase in other STATs 
needs further investigation, as STATs can both form homodimers and heterodimers with 
different functions.44 The second limitation is the limited sample size of STAT3 loss-of-
function patients (AD-HIES patients). This makes our findings less robust. AD-HIES is 
a very rare disease with an estimated prevalence of 1:100.000.14,45 It has to be noted 
that the effects observed were consistent in patients and in different concentrations of 
CRP. Lastly, STAT3 loss-of-function patients are treated with prophylactic antimicrobial 
therapy and we were unable to correct for those differences in the healthy subjects. 
Therefore, we cannot completely exclude a potential effect of medication on our find-
ings.
In conclusion, our findings indicate that STAT3 is involved in GPVI-mediated platelet ac-
tivation by CRP in humans. Additionally, GPVI-mediated platelet activation was shown 
to be largely dependent on secondary stimulation by ADP. In contrast, neither clinically 
relevant STAT3 loss-of-function mutations, nor SNPs affecting STAT3 activity influence 
platelet numbers in humans. These data improve our understanding on the interaction 
between inflammation and hemostasis and suggest that STAT3 modulation may affect 
both inflammation and hemostasis and their interaction in humans.
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AbsTRACT
background
Cardiovascular events are often associated with low vitamin D concentrations, although 
the underlying mechanisms are poorly understood. This study investigated associations 
between 25-hydroxyvitamin D concentrations, single nucleotide polymorphisms (SNPs) 
in genes influencing vitamin D biology and platelet function in the 500 Functional 
Genomics (500FG) cohort.
Methods
The 500FG cohort consists of approximately 500 healthy participants of Western-Eu-
ropean ancestry and is part of the Human Functional Genomics Project (HFGP). Among 
other immunological and metabolic parameters, this observational study measured 
platelet activation and function by binding of fibrinogen to the activated fibrinogen 
receptor integrin αIIbβ3 and platelet expression of P-selectin, markers of platelet ag-
gregation- and degranulation, respectively, by flow cytometry. The platelet function pa-
rameters were correlated to serum 25-hydroxivitamin D and genotyping was performed 
to investigate SNPs in genes important for vitamin D biology.
Results
25-hydroxyvitamin D circulating concentrations were inversely correlated with base-
line platelet binding of fibrinogen to integrin αIIbβ3 (Pearson’s r = -0.172, p=0.001) 
and platelet responses to platelet agonist CRP-XL (Pearson’s r = -0.196 p=0.001). 
No differences in platelet fibrinogen binding were observed between subjects with 
normal 25-hydroxyvitamin D concentrations (>75nmol/L) and a 25-hydroxyvitamin D 
insufficiency (50-75 nmol/L), while there was an effect in comparison to vitamin D de-
ficient subjects (≤50nmol/L). There were no correlations between 25-hydroxyvitamin 
D concentrations and platelet P-selectin expression. Several SNPs in the GC region of 
the vitamin D binding protein (VDBP)-gene were associated with platelet responses to 
CRP-XL.
Conclusions
Low circulating vitamin D concentrations are associated with increased platelet fibrino-
gen binding to integrin αIIbβ3 in unstimulated samples and after stimulation with CRP-
XL and ADP. These findings may partially explain the higher incidence of cardiovascular 
events in vitamin D deficient patients and its seasonal variation. Further studies are 
needed to investigate causality.
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InTRODUCTIOn
Cardiovascular diseases, such as myocardial infarction, are the leading causes of global 
mortality and morbidity.1 A seasonal variation of its incidence is observed, with a higher 
rate of events in the winter and a nadir in the summer.2-5 Vitamin D concentrations 
show a similar seasonal pattern as vitamin D concentrations are influenced by skin 
exposure to sunlight.6 Many studies have shown associations between low vitamin D 
concentrations and cardiovascular diseases7-11 and the majority of patients with acute 
myocardial infarction are vitamin D deficient.12,13 However, the underlying mechanisms 
remain poorly understood.
Vitamin D has many functions beyond its traditional role in bone health, including a 
regulatory role in inflammation and infection.14-16 Inflammation and hemostasis are 
closely linked biological systems17,18 and during episodes of increased systemic in-
flammation, thrombotic complications are more frequently observed.19 Platelets play 
a pivotal role in this process and platelet activation, degranulation and aggregation 
are essential steps in arterial thrombus formation.20 Interestingly, it has been reported 
that both platelets and their megakaryocyte precursors express the vitamin D receptor 
(VDR).21 However, the direct association between vitamin D and platelet function in 
humans is poorly studied.
The vitamin D pathway is a complex metabolic pathway that has many steps before the 
substrate 25-hydroxyvitamin D is converted in its active metabolite 1,25-dihydroxyvi-
tamin D.6,14 As a result, there is a large variation of genetic inter-individual factors that 
influence vitamin D homeostasis.22-25 Single nucleotide polymorphisms (SNPs) in genes 
of several key factors influencing vitamin D biology, such as vitamin D binding protein 
(VDBP), cytochrome P2R1 (CYP2R1) and VDR are reported to influence 25-hydroxyvita-
min D concentrations, but may also influence 1,25-dihydroxivitamin D bio-availability 
and thereby its physiological effects.22-24,26-28 
For this study, data from the 500 Human Functional Genomics Project (500FG) were 
used. The 500FG is part of the Human Functional Genomics Project (HFGP) that is aimed 
to characterize of variations of immune cell function and platelet function in healthy 
human volunteers29 and thereby provided an unique opportunity to study the associa-
tion between 25-hydroxyvitamin D and platelet function. The objective of this study 
was to investigate whether 25-hydroxyvitamin D concentrations and SNPs in genes 
encoding for proteins important for vitamin D biology influence platelet function in 
healthy human volunteers.
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METHODs
study design and population.
The 500FG cohort consists of 534 healthy volunteers and is part of the HFGP (http://
www.humanfunctionalgenomics.org/site/) aimed at characterizing variations in im-
mune function.30 The study design and population have been previously described.29,31 
In summary, between August 2013 and December 2014 a total of 534 healthy human 
subjects of Caucasian origin were recruited in the Radboud university medical center, 
Nijmegen, the Netherlands. Participants were scheduled for a study visit between 8-10 
am to donate blood. After their visit, participants received an online questionnaire on 
dietary habits, lifestyle and disease history.
Ethics.
This study was approved by the local Ethical Committee (NL42561.091.12, 2012/550) 
and was conducted according to the principles of the Declaration of Helsinki (version 
Oct 2008) and in accordance with the Dutch Medical Research involving Human Subjects 
Act. All participants gave written informed consent before blood was drawn.
blood sampling and 25-Hydroxyvitamin D measurement.
Blood was drawn in sterile EDTA, serum and 3.2% sodium citrate vacutainer tubes (Bec-
ton Dickinson, Plymouth, UK). 25-Hydroxyvitamin D3 was measured with liquid chro-
matography tandem mass spectrometry (LC- MS/MS) after precipitation of the protein 
and solid-phase extraction as described in further detail by ter Horst et al.29 In summary, 
an internal standard of 2H3] 25OH-vitamin D3 was added before 50ul NaOH (2M) was 
added to release protein-bound 25-OH vitamin D3 and a combination of Acetonitrile/
Methanol (9:1) was added for protein precipitation. H2O was added followed by solid 
phase extraction (Oasis HLB 1cc, Waters). The eluate (300 µL methanol/isopropanol 
95:5) was diluted with H2O (3:1) and injected (10 µL) into an Agilent Technologies 1290 
Infinity VL UHPLC-system (Agilent Technologies, Santa Clara, CA), equipped with a BEH 
C18 (1.7 µm 2.1 × 50mm) analytical column (Waters) at 45°C. An Agilent 6490 tandem 
mass spectrometer (Agilent Technologies) was operated in the electrospray positive ion 
mode, with a capillary voltage 3.5 kV, fragmentor voltage 380 V, sheath gas temperature 
350°C and gas temperature 100°C with N2 collision gas. Both 25OH-vitamin D3 and 
25OH-vitamin D3 [-H2O] (in-source fragmentation) were used for quantification (results 
were averaged) with both two transitions (qualitative and quantitative) monitored. An 
8-point calibration curve was used and absolute concentration of the calibrator (Sigma-
Aldrich) was assessed by spectrophotometry (264nm). The method was linear assessed 
by CLSI EP6 protocol and recovery rates were within 90-109%.
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Platelet activation and function assessment.
Platelet activation was defined by the binding of fibrinogen to the activated fibrinogen 
receptor integrin αIIbβ3 (GPIIb/IIIa complex) and the expression of P-selectin (CD62P) 
on the platelet surface, markers of platelet aggregation and degranulation, respectively. 
Platelet activation was measured in whole blood samples at baseline and after incu-
bation with different platelet agonists, to assess its functional capacity. The agonists 
used were adenosine 5’ diphosphate (ADP) (Sigma-Aldrich, Saint Louis, Missouri, USA) 
and cross-linked collagen-related peptide (CRP-XL) (kind gift from Prof. Dr. R. Farndale, 
Cambridge, UK). The blood samples were incubated for 20 minutes with 7 different con-
centrations of the agonists in combination with anti-bodies for flow cytometry at room 
temperature, followed by fixation with 0.2% paraformaldehyde. Staining of samples 
was performed with antibodies for CD61 (PC7-conjugated) (Beckman Coulter Brea, 
California, USA), anti-human fibrinogen (fluorescein isothiocynate (FITC)-conjugated) 
(Dako) and P-selectin (CD62P, phycoerythrin (PE)-conjugated) (Biolegend, San Diego, 
California, USA). Expression of these markers was measured by flow cytometry (FC500 
flow cytometer, Beckman Coulter, Brea, California, USA). Gating of platelets was per-
formed based on forward and sideward scatter and additionally for of CD61 positivity. 
The area under the curve (AUC) of fibrinogen binding and P-selectin expression after 
stimulation (MFI) was used for correlations with 25-hydroxyvitamin D concentrations 
and SNPs.
Genotyping.
The DNA samples of the participants were genotyped with a commercially available 
SNP chip, Illumina HumanOmniExpressExome-8 v.1.0, methods previously reported by 
Li et al.31 In short, genotype calling was performed using Optical 0.7.0. Call rates less 
than ≤0.99 were excluded from the dataset, as were samples with a Hardy-Weinburg 
equilibrium (HWE) ≤0.0001, call rate ≤0.99 and MAF ≤0.001. A total of 483 samples 
were left for the genetic analysis, as described previously.31 Of the 39 SNPs involved 
in the vitamin D pathway that were identified from literature,25,32-35 thirty-one SNPs 
were available in our dataset, i.e.: rs10741657, rs10877012, rs2134095, rs2282679, 
rs3829251, rs10766197, rs218174, rs1155563, rs12785878, rs12794714, rs2762933, 
rs7041, rs6599638, rs10500804, rs7975232, rs4588, rs6055987, rs7116978, 
rs3755967, rs12800438, rs1562902, rs17467825, rs3794060, rs1993116, rs7968585, 
rs4945008, rs2060793, rs222020, rs4944957, rs2298849 and rs1801222.
statistical analyses.
Statistical analysis was performed with IBM SPSS statistics 22.0 (New York, NY, USA) 
and Graphpad Prism 5.0 (San Diego, CA, USA). All data was tested for normality with 
the Shapiro-Wilkinson test and assessed in corresponding Q-Q plots. Non-normally 
CHAPTER 6
104
distributed data were log transformed before further analyses. Pearson’s R correlation 
coefficients were calculated in R using the standard cor.test.routine. Multiple regression 
analyses were performed to assess the effects of covariates age and gender. The nominal 
p value < 0.05 was used as significance threshold. Correction for multiple comparisons 
was applied using False Discovery Rate (FDR).
REsUlTs
The demographics of the study population can be found in table 1. Most participants 
were in their early adulthood and had a normal BMI. The Netherlands has a strong annual 
variation in terms of sunlight exposure and as participants were included throughout 
the year, we found an absolute vitamin D deficiency (≤ 50nmol/L) in 105 participants. 
The variation in vitamin D concentrations during recruitment was previously published 
by ter Horst and colleagues.29 
low 25-hydroxyvitamin D3 concentrations correlate to platelet binding of 
fibrinogen to integrin αIIbβ3.
A small, but statistically significant inverse correlation was observed between 
25-hydroxyvitamin D concentrations and platelet binding of fibrinogen to the acti-
vated fibrinogen receptor integrin αIIbβ3 in unstimulated samples, Pearson’s r = -0.172, 
p=0.002, n= 393 (Figure 1). Platelet fibrinogen binding in response to platelet stimula-
tion of GPVI receptor by CRP-XL also inversely correlated to vitamin D concentrations, 
Pearson’s r = -0.196 p=0.002, n= 299, (Figure 1). These data show higher platelet activa-
tion and reactivity in participants with low vitamin D concentrations. No difference was 
Table 1. Demographics of study participants 
Characteristics N = 533
Gender (% male) 44,5%
Mean age, years (SD) 28,5 (13.9)
BMI (SD) 22.7 (2.9)
Oral contraceptive use (% of women) 53.0%
Current smoking (% of whole cohort) 13.3%
25-Hydroxyvitamin D concentrations, n (% of whole cohort)
> 75nmol/L 206 (38.6%) 
50 – 75 nmol/L 174 (32.6%) 
≤ 50 nmol/L 105 (19.7%) 
Missing value 48 (9.1%) 
(Abbreviations: BMI: body mass index; SD: standard deviation)
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seen between platelet reactivity in response to stimulation with platelet agonist ADP 
(Pearson’s r -0.097, p = 0.08, n= 393) (Figure 1). Interestingly, P-selectin expression, 
a marker of platelet degranulation, was not affected by vitamin D concentrations in 
unstimulated samples (Pearson’s r = 0.037, p= 0.52, n= 467, nor was there a correlation 
in stimulated CRP-XL and ADP stimulated samples (Pearson’s r= -0.12, p= 0.08, n= 299 
and Pearson’s r = 0.02, p= 0.66, n= 486, respectively) (Figure 2).
25-Hydroxyvitamin D deficiency (≤ 50 nmol/l), but not insufficiency, seems 
to be correlated to platelet integrin αIIbβ3 activation.
Next, study participants were grouped according to the commonly used cut-off values 
for 25-hydroxyvitamin D concentrations; vitamin D concentrations >75 nmol/L were 
considered sufficient, vitamin D concentrations from 50-75 nmol/L were considered 
insufficient, and the threshold for vitamin D deficiency was ≤ 50 nmol/L. A significant 
increase was found in platelet fibrinogen binding to integrin αIIbβ3 in unstimulated 
samples and in response to stimulation with CRP-XL in vitamin D deficient participants 
compared to sufficient and insufficient participants (Figure 3). Importantly, no signifi-
cant differences were observed between vitamin D sufficient and vitamin D insufficient 
participants in terms of fibrinogen binding.
When applying the commonly used conservative threshold of 50 nmol/L, fibrinogen 
binding in unstimulated samples was statistically different between groups (mean of 
participants with vitamin D > 50nmol/L 0.44 ± 0.005 versus 0.49 ± 0.009 in partici-
pants with vitamin D ≤ 50nmol/L, p<0.0001). This difference was also observed after 
stimulation with CRP-XL and after stimulation with ADP (mean fibrinogen binding of 
participants with vitamin D > 50nmol/L 1.997 ± 0.01 versus 2.088 ± 0.02 in partici-
pants with vitamin D ≤ 50nmol/L, p=0.0002, and mean of participants with vitamin D > 
50nmol/L 1.696 ± 0.01 versus 1.744 ± 0.02 in participants with vitamin D ≤ 50nmol/L, 
p=0.021, respectively), supplementary figure 1. Together, these data suggest that the 
association between 25-hydroxyvitamin D and platelet fibrinogen binding to integrin 
αIIbβ3 is stronger in vitamin D deficient participants. Interestingly, a significant differ-
ence was seen in P-selectin expression after CRP-XL stimulation (mean of participants 
with vitamin D > 50nmol/L 269 ± 4 versus mean 301 ± 9 in participants with vitamin D 
≤ 50nmol/L, p= 0.02), whereas this was not observed in unstimulated samples (mean 
of participants with vitamin D > 50nmol/L 0.71 ± 0.004 versus mean 0.70 ± 0.010 in 
participants with vitamin D ≤ 50nmol/L, p=0.32), nor after stimulation with ADP (mean 
of participants with vitamin D > 50nmol/L 1.82 ± 0.01 versus mean 1.83 ± 0.01 in par-
ticipants with vitamin D ≤ 50nmol/L, p=0.58), supplementary figure 2.
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The influence of snPs in key players of the vitamin D pathway on platelet 
activation and function.
The vitamin D pathway is a complex metabolic pathway that is regulated on many lev-
els. SNPs in key players, such as VDBP, CYP2R1 and VDR, were determined and related 
to platelet activation and platelet function. Thirty-nine functional SNPs in the vitamin 
D pathway were identified through thorough literature search, of which 31 SNPs were 
available in the dataset. In total, 9 SNPs had a significant influence on fibrinogen bind-
ing to integrin αIIbβ3 in unstimulated samples and after stimulation with CRP-XL or ADP, 
table 2.
Six out of 9 associated SNPs were present in the GC region of VDBP, among 5 that were 
associated to platelet fibrinogen binding to integrin αIIbβ3 in response to stimulation 
with CRP-XL, indicating that there may be crosstalk in these signaling pathways. Next, 
we examined whether these SNPs exerted their effects on platelet activation and func-
tion through vitamin D concentrations or in an independent manner by performing 
causality test.36,37 The analyses on each SNP-vitamin D- platelet triple result in “inde-
pendent” model, suggesting that the genetic effect on both phenotypes are statistically 
independent, or there is a limited power to detect the actual causal relationship using 
the dataset available.
Figure 3. Vitamin D status and platelet fibrinogen binding.
Fibrinogen binding at baseline and after stimulation with CRP-XL and ADP in vitamin D sufficient 
(>75 nmol/L), insufficient (50-75 nmol/L) and deficient (≤ 50 nmol/L) participants. (Abbreviations: 
ADP: adenosine 5’diphosphate; AUC: area under the curve; CRP-XL: cross-linked collagen-related pep-
tide; MFI: mean fluorescence intensity; Vit D: 25-hydroxyvitamin D)
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DIsCUssIOn
This is the first study that investigated the correlation between 25-hydroxyvitamin D 
concentrations and platelet activation and reactivity in a large cohort of healthy human 
subjects. We found an inverse correlation between 25-hydroxyvitamin D concentrations 
and platelet fibrinogen binding to the activated fibrinogen receptor integrin αIIbβ3 in 
unstimulated samples and after stimulation with the platelet agonist CRP-XL, which 
activates platelets through the collagen pathway, showing increased platelet activation 
and reactivity in those with low vitamin D concentrations. 
This association was stronger for 25-hydroxyvitamin D concentrations ≤ 50nmol/L, 
and, when this concentration was used as a cut-off value, platelet fibrinogen binding 
to integrin αIIbβ3 in response to agonist ADP was also significantly associated. No 
differences were observed between 25-hydroxyvitamin D insufficiency and normal 
25-hydroxyvitamin D concentrations, further supporting the presence of a threshold. 
Several SNPs in key genes contributing to the vitamin D pathway were significantly 
associated with platelet fibrinogen binding to integrin αIIbβ3 at baseline and/or in 
response to stimulation. Five out of 9 SNPs in the GC region of VDBP, were associated 
with fibrinogen binding in response to CRP-XL. Several associations between the SNPs, 
25-hydroxyvitamin D and platelet function parameters were found, however, causality 
could not be formally confirmed.
We report a modest, but significant effect of vitamin D concentrations on platelet 
fibrinogen binding to the activated fibrinogen receptor integrin αIIbβ3. However, on 
a population level, small effects may have considerable impact. Myocardial infarction 
and stroke are the leading causes of death worldwide with 8 million deaths a year.38 
Cardiovascular diseases are multifactorial in origin and a combination of factors, such 
as atherosclerosis, plaque instability and platelet reactivity contribute to its develop-
ment.39 Associations with vitamin D concentrations exist, although these are poorly 
understood.11 
Previously, only few studies investigated direct associations between vitamin D con-
centrations and platelet parameters in different diseases.40-42 An association between 
low vitamin D concentrations and high-residual platelet reactivity in patients with 
cardiovascular diseases receiving anti-platelet therapy has been reported, as well as 
antithrombotic activities of vitamin D supplemented to hemodialysis patients.40,42 
These findings, together with our observations, may point out specific pathways that 
are functionally involved.
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The strongest association with 25-hydroxyvitamin D was found for platelet fibrinogen 
binding in response to CRP-XL stimulation. Interestingly, 5 of the investigated SNPs in 
the GC region, coding for VDBP, also showed an association with platelet responses to 
CRP-XL. The platelet agonist CRP-XL signals through the collagen pathway to activate 
platelets and is dependent on phosphorylation of Signal Transducer and Activator of 
Transcription 3 (STAT3).43 Interactions between vitamin D and JAK-STAT signaling path-
ways have been reported.44,45 Olson and colleagues showed that vitamin D decreases 
STAT3 phosphorylation and this may explain increased platelet fibrinogen binding in 
response to CRP-XL in vitamin D deficient participants.45 On the other hand, VDBP may 
also play a key role as it has been suggested that VDBP is involved in aspirin-resistant 
platelet activation.46
In contrast to platelet fibrinogen binding, platelet P-selectin expression was only 
associated with 25-hydroxyvitamin D in response to stimulation with CRP-XL in the 
individuals in which vitamin concentrations was below 50nmol/L. Moreover, there was 
no association between P-selectin expression upon CRP-XL stimulation and any of the 
SNPs. The potential involvement of P-selectin seems far less than fibrinogen, and it is 
likely that the study is underpowered to detect such small effects. Others have sug-
gested that platelet functional responses may be differentially regulated, which may be 
a plausible explanation for the different observations.47 
A causal relationship between the SNPs studied here, vitamin D concentrations and 
platelet function parameters could not be confirmed, and caution is warranted as it may 
be suggested that vitamin D concentrations are merely a reflection of overall health 
status. People with a low health status stay may have a more sedentary lifestyle, may 
stay more indoors, and, in combination with a poor dietary variation, this results in low 
vitamin D concentrations. Therefore, vitamin D could be an epiphenomenon and may 
not be causally involved. This is further strengthened by supplementation studies that 
yield little to no effect on cardiovascular diseases to date.48-50
In order to increase our understanding of the involvement of vitamin D in hemostasis, 
future studies should focus on the underlying pathways. A combination of many factors 
ultimately determines disease susceptibility and progression. It may be worthwhile to 
investigate the effects of vitamin D supplementation on specific factors such as platelet 
reactivity. An example is the ongoing PRECOVID trial, which investigates the effects of 
vitamin D supplementation on immune responses and platelet function in vitamin D 
deficient COPD patients.51 Furthermore, causal inference analyses should be pursued 
in large cohorts as it is pivotal to know whether vitamin D acts as a mediator or is just 
an epiphenomenon. Insight in the exact mechanisms is important to further understand 
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the clinical consequences of vitamin D deficiency as well as to identify effective thera-
peutic opportunities.
Our study has a few limitations. One important limitation is the observational design of 
the study and this study must therefore be seen as a hypothesis-generating study. This 
cohort was relatively large and we tried to perform formal causal inference analyses, 
however as the effect is relatively small, the study may be underpowered to detect 
these subtle differences and causality could not be shown. 
In conclusion, this study shows increased platelet fibrinogen binding to integrin αIIbβ3 
in healthy volunteers with low vitamin D concentrations, particularly below 50 nmol/L. 
This observation may partially explain the association with thrombotic diseases and its 
seasonal variation. Further studies are needed to investigate the underlying mecha-
nisms and causality of vitamin D in platelet function.
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AbsTRACT
background
Tobacco smoking is still common and contributes to a variety of illnesses with signifi-
cant mortality worldwide. A comprehensive analysis of the systemic effects of tobacco 
smoke on immune cell populations and function in humans is lacking.
Objectives
We investigated the association between smoking and the innate and adaptive immune 
cell populations in peripheral blood and its association with immune cell function and 
systemic inflammation in human subjects.
Methods
Cases (current- and former smokers) and controls (non-smokers) were identified among 
500 healthy volunteers from the 500 Functional Genomics Cohort. Immune cell popula-
tions were determined in blood. Ex vivo cytokine production upon stimulation of whole 
blood and peripheral blood mononuclear cells and levels of circulating inflammatory 
mediators were compared between groups.
Results
Sixty-three current and 57 former smokers were matched to non-smokers. Current 
smokers showed increased numbers of circulating monocytes, mostly classical mono-
cytes, and these correlated with pack years. Neutrophils, NK cells and B cells were not 
affected by smoking. Within the adaptive arm of the immune system, increased CD4 and 
CD8 positive central memory (CM) cells, CD4 positive effector memory (EM) cells and 
increased regulatory T cells were observed in smokers. Production of monocyte-derived 
cytokines after ex vivo lipopolysaccharide challenge was lower. Circulating concentra-
tions of IL-6 and C-reactive protein positively correlated with pack years. No differences 
were observed in former smokers.
Conclusion
In healthy volunteers, tobacco smoking leads to a defective capacity of immune cells 
to respond upon microbial stimulation, yet it induces inappropriate systemic inflam-
mation.
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InTRODUCTIOn
Despite global initiatives for tobacco regulation, smoking is still common with an 
estimated 1 billion smokers worldwide.1-3 Smoking impacts nearly every organ of the 
human body and contributes to numerous diseases with significant morbidity and mor-
tality.4-6 The most common diseases that are caused by smoking are chronic obstruc-
tive pulmonary disease (COPD), lung cancer, and cardiovascular diseases (CVD), most 
notably myocardial infarction.5 Immune dysregulation by smoking is thought to play 
an important role in the development of these diseases. Moreover, strong associations 
between smoking and auto-immune diseases such as rheumatoid arthritis and Crohn’s 
disease further emphasise the immune effects of smoking.7-9
Tobacco smoke consists of approximately 5,000 chemical components, some of which 
are very toxic, such as benzo-α-pyrenes and nitrogen oxides.10-12 Many studies showed 
that tobacco smoke influences the human immune system, reviewed by,13-15 affecting 
both innate and adaptive immunity.16-20 Some tobacco smoke components have immu-
nosuppressive effects, whereas other components induce inflammation.7,21-23 Together, 
these factors determine the overall impact of tobacco smoke on the human immune 
system.
The aims of the various studies that investigated the effects of smoking vary widely, some 
aim to study specific tobacco smoke components,23 some explore specific local and/or 
systemic immune cell lineages,24-26 whereas others analyze effects in specific diseases in 
humans or in experimental models.13,22 These studies often reported opposite effects of 
tobacco smoke, including up and down-regulation of natural killer cells,18,27,28regulatory 
T cells,29,30 and release of pro- and anti-inflammatory cytokines.17,19,31
To the best of our knowledge, a comprehensive analysis of the systemic effects of 
tobacco smoking in healthy subjects, where smokers, former smokers and non-smokers 
are carefully matched, is lacking. These data are needed to identify and further study 
those pathways that are involved in the pathophysiology of smoking-related diseases 
at a systemic level.
The objectives of this study were: 1) to perform comprehensive analyses of the associa-
tion between smoking and the variation of innate and adaptive immune cell populations 
in peripheral blood, and 2) to investigate its association with immune cell function and 
systemic inflammation in healthy human subjects. Pack years were used to investigate 
the effects of prolonged tobacco smoke exposure.
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METHODs
study design.
In this cross-sectional study, cases (current smokers and former smokers) and controls 
(non smokers) were identified among participants of the 500FG cohort.32 This cohort 
is part of the Human Functional Genomics Project (HFGP) aimed at characterizing 
variations in human immune function.33 The study design and population have been 
published previously.32,34 In short, between August 2013 and December 2014 a total of 
534 healthy human subjects of Caucasian origin were recruited at the Radboud univer-
sity medical center, Nijmegen, the Netherlands. Forty-five participants were excluded, 
mainly because of the use of medication. Participants were scheduled for a study 
visit between 8-11 am to donate blood. After their visit, participants received an online 
questionnaire on dietary habits, lifestyle and disease history. Current smokers, former 
smokers and non-smokers were identified based on the answers to smoking-related 
questions in the questionnaire.
The study received ethical approval from the local Ethical Committee (NL42561.091.12, 
2012/550) and was conducted according to the principles of the Declaration of Helsinki 
(version Oct 2008) and in accordance with the Dutch Medical Research Council involv-
ing Human Subjects Act. All participants gave written informed consent before blood 
was drawn.
Experimental procedures.
A detailed description of the experimental study procedures has been previously 
published.32,34,35 In summary, myeloid and lymphoid immune cell populations were 
measured within 2-3 hours by 10-color flow cytometry (10-color Navios Flow cytom-
eter, Beckman Coulter, Brea, California, USA). Cellular functional capacity in terms of 
cytokine production was measured in PBMCs and in whole blood. PBMCs were isolated 
by density centrifugation of diluted whole blood samples over Ficoll-Paque (Pharmacia 
Biotech, Uppsala, Sweden), followed by two washing steps in saline and final resuspen-
sion in RPMI 1640 medium supplemented with gentamicine, L-glutamine and pyruvate. 
Cells were stimulated for 24 hours or 7 days for measurement of cytokines.34 For whole 
blood experiments, heparin blood was added to 48-wells plates and stimulated 1:5 
with different stimuli for 48-hours. PBMCs were stimulated with LPS (Toll-like receptor 
(TLR) 4 ligand), Pam3Cys (TLR2 ligand), poly I:C (TLR3 ligand) for 24 hours or 7 days. 
Culture supernatants were stored in -20 Celsius degrees until ELISA measurements 
were performed. The concentrations of IL-1β, IL-6 and TNFα were determined in cell 
culture supernatants of the 24 hours PBMC stimulation assays. IL-17, IL-22 and IFNγ 
concentrations were determined in the 7 days PBMC culture supernatants. In addition, 
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the circulating concentrations of hsCRP, hsIL-6 and alpha-1-antitrypsin (AAT) were mea-
sured in EDTA plasma using ELISA.
Definition of cell subsets.
A comprehensive analysis was performed on different immunophenotypes of innate 
and adaptive immune cell populations. The cluster of differentiation (CD)-markers that 
were used for the identification of the different immune cell populations are described 
in Table E1 in the online data supplement.
statistical analyses.
All statistical analyses were performed in the R programming language and on absolute 
cell numbers and not on ratios.
Paired analyses
Control samples were matched as closely as possibly to the smokers and ex-smokers 
based on age and gender. P-values were calculated using the two-sided Wilcoxon 
signed-rank test. This test was preferred over the parametric t-test since the cell counts 
were not always normally distributed.
Calculation of the effect of pack years
The rank-based regression method “Rfit”,36 implemented as a package in the R program-
ming language, was used to evaluate the association between pack years and cell counts 
and cytokine production. The results were corrected for age, gender, body mass index 
(BMI), season and usage of oral contraceptives.
Multiple testing correction
P-values were corrected with multiple testing each time multiple p-values were evalu-
ated simultaneously. This correction was achieved by calculating a False Discovery Rate 
(FDR) using the Benjamini-Hochberg FDR-correction.37
REsUlTs
Within the 500FG cohort, 63 subjects were classified as current smokers and 57 subjects 
as former smokers. These subjects were individually matched for age and gender with 
non-smokers. Demographics of the study participants can be found in Table 1. Smokers, 
former smokers and non-smokers were similar in terms of age, gender, BMI and oral 
contraceptives use in women.
CHAPTER 7
126
Monocyte and lymphocyte populations are associated with current tobacco 
smoking.
Phenotypic analysis revealed that CD14 positive monocytes, including classical mono-
cytes (CD14 high, CD16 negative), lymphocytes, including T cells (CD3 positive, CD56 
negative), and double negative αβ cells (CD4 and CD8 negative) were increased in 
smokers, see Figure 1.
No differences between current smokers and non-smokers were observed in terms 
of neutrophils (median 3.99 x10^6 IQR 3.0x10^6 versus median 3.98 x10^6 IQR 2.6 
x 10^6 p=0.37), natural killer (NK) cells (median 6700 IQR 7473 versus median 5730 
IQR 4148, p=0.58), B cells (median 135224 IQR 127513 versus median 142069 IQR 
100230 p=0.58) and several other immune cell populations (see Table E2 in the online 
data supplement). The increased monocyte population in current smokers seems to be 
primarily driven by the classical monocytes, since no significant differences were ob-
served in the non-classical monocytes (CD14 high, CD16 positive) and the intermediate 
monocytes (CD14 and CD16 positive), see Figure 1. Regression analysis showed a posi-
tive correlation between CD14 positive monocytes and pack years, and this observation 
was similar for classical monocytes, suggesting a dose-effect relationship, see Figure 2.
Increased CD4 and CD8 positive Central Memory (CM) T cells and CD4 
positive Effector Memory (EM) T cells in current smokers.
Further differentiation of specific subtypes of adaptive immune cells showed an 
important association with ‘antigen experienced’ T cells in current smokers. CM T cell 
numbers were higher in smokers in both CD4 and CD8 positive lineages (CD3+ CD4+ 
CD45RA- CD27+, and CD3+ CD8+ CD45RA- CD27+, respectively). Additionally, CD8 
positive CM cells showed dose-effect relationships with pack years, while this was not 
seen in CD4 positive CM cells, see Figure 3. Central memory cells are known for their 
‘reactive’ memory and are able to rapidly proliferate and differentiate into effector 
cells upon antigenic stimulation.38 Also, an increase of CD4 positive EM (CD3+ CD4+ 
Table 1. Demographics of study participants 
Characteristics smokers
n= 63
Controls
n= 63
Former smokers
n= 57
Controls 
n= 57
Gender, % male 42.9 42.9 56.1 56.1
Age, mean years (SD) 28 (12) 28 (12) 38 (17) 36 (15)
Pack years smoking, mean (SD) 5.2 (9) 0 (0) not available 0 (0)
Oral contraceptive use, % of women 48.1 44.4 34.4 34.5
BMI, mean (SD) 22.7 (3.5) 23.2 (3.0) 22.8 (3.7) 23.2 (3.5)
Characteristics of study participants. (Abbreviations; BMI: Body mass Index, IQR: Inter-quartile range, 
SD: Standard Deviation) 
127
ASSOCIATION BETWEEN SMOKING AND IMMUNE FUNCTION
7
CD45RA- CD27-) was observed in smokers, while this was not observed for CD8 positive 
EM cells (CD3+ CD8+ CD45RA- CD27-), see Figure 3. No correlation with pack years 
was observed for these T cell populations. Furthermore, an increase was seen in CD4 
positive naive cells (CD3+ CD4+CD45RA+ CD27+) in smokers, data not shown.
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Figure 1. Several distinct immune cell populations are increased in smokers.
A. The increased numbers of monocytes in smokers (median 540897 IQR 316965 compared to non-
smokers median 386200 IQR 263107, p=0.005) were mostly driven by increased classical mono-
cytes (median 384952 IQR 260110 compared to median 301847 IQR 185030 in non-smokers, 
p=0.02), whereas no significant difference was observed between intermediate and non-classical 
monocytes (median 24782 IQR 21828 in smokers compared to non-smokers, median 22357 IQR 
12477, p=0.37 and median 47683 IQR 28863 versus median 34301 and 36477, p=0.27, respec-
tively) B. Smokers showed increased numbers of lymphocytes (median 2544103 IQR 1752675 
compared to non-smokers median 1978454 IQR 1101036, p=0.036), primarily driven by T cells 
(median 1917035 IQR 1415245 compared to non-smokers median 1367745 IQR 751611, p=0.02). 
B-cells were not different between smokers and non-smokers (median 135224 IQR 127513 com-
pared to non-smokers median 142069 IQR 100230, p=0.58). C. Increased alpha-beta double nega-
tive cells were increased in smokers (median 105769 IQR 113959 compared to non-smokers me-
dian 70087 IQR 55644, p=0.02)
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Increased regulatory T-cells in current smokers compared to non-smokers.
Immune responses are delicately balanced in order to avoid infections on one hand and 
hyper-infl ammation on the other. In addition to increased CM cells and increased CD4 
positive EM cells in current smokers, an increase in regulatory T cells (CD3+ CD4+ CD25+ 
FOXp3+) was observed. Although controversial, regulatory T cells may be divided into 
thymic and peripherally diff erentiated regulatory T cells by expression of Helios. Both 
Helios positive and Helios negative regulatory T cells were increased in current smokers 
compared to controls, see Figure 4A.
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Figure 2. Monocyte populations according to pack years.
Both monocytes, and classical monocytes, were positively correlated with pack years suggesting 
a dose-eff ect relationship (regression, p=0.04 for both population). The data are categorized for 
display purposes only and were not categorized in the primary analyses).
Figure 3. CD4 and CD8 positive central memory (CM) T cells and CD4 positive eff ector memory 
(EM) T cells. See page 131.
A. Increased diff erentiation of CD4 positive CM and EM T cells in smokers compared to non-smok-
ers (median 456462 IQR 421656 compared to non-smokers median 308106 IQR 200941, p=0.008 
and median 54969 IQR 43178 versus 48221 IQR 27171, p=0.02, respectively). B. Increased dif-
ferentiation of CD8 positive CM T cells (median 142537 IQR 121569 versus median 100849 IQR 
72364, p=0.008), whereas no diff erence was observed in CD8 positive EM T cells (median 16410 
IQR 14810 versus median 14227 IQR 13450, p=0.41) C. CM T cells showed a positive correlation 
with pack years, while this was not observed in EM T cells. The data on pack years are categorized 
for display purposes only and were not categorized in the primary analyses.
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Figure 3. CD4 and CD8 positive central memory (CM) T cells and eff ector memory (EM) T cells.
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Further examination of the regulatory T cell compartment showed an increase in regula-
tory T cells positive for the activation marker Human Leukocyte Antigen - antigen D related 
(HLA-DR) in current smokers, and a positive correlation between this marker and pack years, 
see Figure 4B. Similarly, expression of proliferation/maturation marker Ki-67 on regulatory 
T cells was increased in current smokers and also showed a positive correlation with pack 
years, see Figure 4B. Together, these data show that in addition to increased CM and EM 
cells, also the regulatory T cell compartment is associated with current tobacco smoking.
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Figure 4. Increased expression of markers for activation and proliferation in regulatory T cells in 
smokers.
A. Increased expression of activation marker HLA-DR on regulatory T cells in smokers compared to 
non-smokers (median 10142 IQR 5971 versus 5309 IQR 4371, p=0.0003). B. Also, increased expres-
sion of proliferation marker Ki-67 was found in healthy smokers compared to healthy non-smokers 
(median 4342 IQR 3815 versus median 2581 IQR 2050, p=0.003) and both markers correlated with 
pack years (p=0.02 for HLA-DR positive regulatory T cells and p=0.009 for expression of Ki-67). The 
data are categorized for display purposes only and were not categorized in the primary analyses. (Ab-
brevations: HLA-dr: Human Leukocyte Antigen - antigen D related; IQR inter-quartile range)
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b cells are not affected by smoking.
In contrast to monocytes and T cells, B cells were not associated with smoking in terms of 
absolute cell counts. The B cell compartment was divided in transitional B cells (CD19+ 
CD24++ CD38++), naive and memory B cells (CD19+ IgD+ IgM+ CD27- and CD19+ IgD+ 
IgM+ CD27+, respectively), and plasmablasts / plasma cells (CD19+ IgD- IgM- CD38++). 
Also several specific subsets of memory B cells were investigated, based on their dif-
ferential expression of Ig-heavy chain isotypes, such as IgM and IgD.39 No differences in 
these populations were observed between current smokers compared to non-smokers, 
see Figure 5. In contrast, regression analysis showed that class-switched memory B cells 
(IgD- IgM- CD38+ and CD27+) were positively correlated with pack years (p=0.01). The 
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Figure 5. The effects of smoking on B cell populations.
No differences were observed with regards to naïve B cells (median 39390 IQR 46589
in smokers versus 44179 IQR 39594 in non-smokers, p=0.76), transitional B cells (median 1470 
IQR 1786 in smokers versus median 2602 IQR 2731 in non-smokers, p=0.13), and memory B-cells 
(median 10983 IQR 8745 in smokers versus 8581 IQR 6816 in non-smokers, p=0.28) and plasma 
blasts/plasma cells (median 2296 IQR 2417 in smokers versus 2850 IQR 3048 in non-smokers, 
p=0.28). (Abbreviations: CD: Cluster of differentiation; Ig: Immunoglobulin; IQR: inter-quartile range)
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lack of important effects is remarkable, as B cells have an important role in antigen 
specific adaptive responses.40 Further definition and results on the different subpopula-
tions that were investigated, including B cells, can be found in Table E3 in the online 
data supplement.
Tobacco smoking is associated with defective cytokine responses.
Several distinct innate and adaptive immune cell populations were upregulated in cur-
rent smokers. In order to further investigate the association of smoking with immune 
cell function, we measured the cytokine production capacity upon stimulation and we 
measured the concentrations of several circulating mediators in cases and controls. 
Whole blood and PBMCs were stimulated with several TLR ligands and subsequently 
analysed for cytokine production. Whole blood samples and PBMCs were stimulated 
with LPS (TLR4 ligand) and Pam3Cys (TLR 2 ligand) for 48 hours (whole blood) and 24 
hours and 7 days (PBMCs). In the whole blood LPS stimulation model, smokers had a 
trend towards lower TNFα production compared to non-smokers (2,92 pg/ml IQR 0,28 
versus 3,00 pg/ml IQR 0,30, p=0.09 in the analyses corrected for multiple testing and 
p=0.010 in the uncorrected analysis). We also observed this trend in TNFα production 
in response to LPS stimulation of PBMCs from current smokers (TNFα 2,33 pg/ml IQR 
0,44 versus 2,47 pg/ml IQR 0,40, p=0.09 in the corrected analyses and p= 0.015 in the 
uncorrected analyses).
The trend towards a decrease in the production of TNFα in current smokers was surpris-
ing since this is a monocyte-derived cytokine. Monocytes, including classical mono-
cytes, were increased in current smokers, and these data may suggest that the decrease 
in cytokines results from a change in the function of monocytes.
We corrected cytokine levels for monocyte numbers and indeed lower production of 
the innate cytokine TNFα was observed in response to LPS stimulation in current smok-
ers (p=0.0003 in whole blood and p=0.002 in PBMCs). Moreover, our analyses revealed 
that the production of IL-6, IFNγ and IL-1β was also decreased in whole blood from 
current smokers upon LPS challenge (p-values were all p=0.002), whereas in PBMCs 
this was only seen for Il-6 and IL-1β (p=0.01 and p=0.004, respectively). In response 
to stimulation with Pam3Cys, only TNFα was significantly lower in current smokers 
(p=0.01). These findings were further confirmed by the regression analysis of pack 
years and cytokines corrected for monocyte numbers that showed that both TNFα and 
IFNγ production capacity inversely correlate with pack years (both p=0.04), see Figure 6, 
while there was no significant impact on IL-6 and IL-1β production.
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Lastly, we determined plasma levels of circulating inflammatory mediators in cases 
and controls. No significant differences were detected for IL-6 (median 0,026 pg/ml 
IQR 0,54 versus 0,017 pg/ml IQR 0,25, p=0.82), hsCRP (median 2,76 pg/ml IQR 0,75 
versus 2,86 pg/ml IQR 0,76, p=0.92), and AAT (median 9,10 pg/ml IQR 0,40 versus 9,17 
IQR 0,18, p=0.41) in the paired analyses between smokers and non-smokers, see Figure 
7A. Interestingly, a positive correlation between both IL-6 and hsCRP and pack years 
was observed in the regression analyses, p=0.03 and p=0.02, respectively, see Figure 
7B. These data suggest that prolonged and/or intense smoking behaviour results in 
increased systemic inflammation.
Former smokers do not show the immune dysregulation that was observed 
in current smokers.
Interestingly, none of the observations above were found when former smokers were 
compared to non-smokers. Tables E4 – E6 in the online data supplement provides an 
overview of all the analyses that were performed and their findings. These findings may 
suggest that the immunodysregulation observed in current smokers normalizes after 
smoking cessation.
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Figure 6. Relation between whole blood TNFα and IFNγ production in response to ex vivo LPS chal-
lenge and pack years.
A decrease in TNF-alpha and IFN-gamma was observed with increasing pack years. (Abbreviations: 
IFN: Interferon; LPS: lipopolysaccharide; TNF: Tumor necrosis factor).
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DIsCUssIOn
The present study provides a comprehensive analysis of the association between tobac-
co smoking and the variation of innate and adaptive immune cell populations, and its 
association with immune cell function in healthy human subjects. We report increased 
numbers of monocytes, mostly classical monocytes, in current smokers, whereas the 
production of the monocyte-derived cytokines after ex vivo LPS challenge was lower 
in this population. Furthermore, production capacity of TNFα and IFNγ were inversely 
correlated to pack years. Dysregulation of the adaptive arm of the immune system was 
reflected by increased CD4 and CD8 positive CM T cell populations, increased CD4 posi-
tive EM T cell populations and increased regulatory T cells in current smokers. Except 
for CD4 positive EM cells, these populations correlated with pack years. Interestingly, 
plasma IL-6 and hsCRP concentrations, markers for systemic inflammation, were not 
different between current smokers and non-smokers, but showed a positive correlation 
with pack years in the current smokers. B cells, on the contrary, showed no clear as-
sociation with tobacco smoking. These findings indicate that tobacco smoking leads to a 
defective capacity of immune cells to respond upon microbial stimulation, yet it induces 
inappropriate systemic inflammation. No differences in immune cell populations were 
observed in former smokers, underlining the importance of smoking cessation.
Tobacco smoking is the second-leading risk factor for attributable mortality3,5 and 
smoking-related diseases are not limited to the respiratory tract, but also develop 
at a distant level, like myocardial infarction.4,6 In the present study, some intuitively 
conflicting observations co-occur that require further exploration. The previous publi-
cation on the 500FG cohort by our group32 reported that smoking does not significantly 
affect host immune responses. In this previous study, however, only current smoking 
status (current-, former-, non-smokers) was taken into account, and subjects were not 
individually matched based on smoking. In addition, an in-depth analysis based on the 
number of pack-years has not been previously performed in the earlier study. In the 
present study, in which we carefully matched cases and controls, we report important 
systemic effects of smoking on the immune system.
In current smokers, increased numbers of monocytes, mostly classical monocytes, 
were observed that produce less pro-inflammatory cytokines, suggesting a defective 
capacity of monocytes to produce cytokines upon challenge with microbial ligands. 
This supports a previous publication by Noakes and colleagues, who compared immune 
response from cord blood of neonates between of maternal smokers and non-smokers 
during pregnancy, and report decreased TNFα, IL-6 and IL-10 in cord blood of neonates 
from maternal smokers.41 Others investigated the effects of the tobacco component 
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nicotine and reported decreased cytokine production by monocytes via a mechanism 
dependent on nuclear factor-kappa B transcriptional activity.42,43
In addition, increased populations of double negative αβ cells and regulatory T cells 
were found in smokers. Αβ cells are mostly known from transplantation medicine where 
they act as suppressors of T cell proliferation and inducers of apoptosis.44 Regulatory T 
cells, another suppressive cell type, showed increased activation and maturation in cur-
rent smokers. Opposite effects regarding regulatory T cell numbers and function have 
been reported in the context of smoking, including up- and down-regulation of regula-
tory T cells.13,45-47 These findings seem dependent on the tissue investigated (peripheral 
blood, bronchial alveolar lavage fluid) and the studied population, such as healthy (non) 
smokers or COPD patients.
T cell differentiation follows along a continuum from naive T cells to antigen experi-
enced CM and EM T cells.38,48,49 In smokers, CM T cells were increased both in CD4 and 
CD8 positive cell lineages and confirm previous studies that report an increase in these 
specific T cell populations in humans,26,50,51 whereas this was not found in mice.52 The 
correlation with pack years suggests that prolonged exposure contributes to their de-
velopment. Upon antigenic stimulation, CM T cells can rapidly proliferate into effector 
T cells that migrate to the tissues to exert their pro-inflammatory effects.38 The CD4 
positive EM T cell population was higher in current smokers, but was not correlated to 
pack years. Increased EM T cell populations may result from antigenic stimulation of CM 
T cells in current smokers and seem less dependent on prolonged tobacco exposure.
Previous studies suggest that T cell differentiation is driven by antigen load and per-
sistence in infectious diseases.53-55 Indeed, several studies found alterations in airway 
colonization caused by tobacco smoke.56,57 An important, yet unanswered, question is 
whether the defective capacity of immune cells in current smokers that was observed in 
this study contributes to these alterations and this requires further exploration.
In contrast, positive correlations between pack years and circulating concentrations 
of both IL-6 and hsCRP suggest that during prolonged and/or intense tobacco smoke 
exposure, progression into inappropriate systemic inflammation occurs.
These data are important as they contribute not only to our understanding of the sys-
temic immunological consequences of smoking, but may help to identify pathophysi-
ological mechanisms that result in smoking-related diseases. It is well known that not 
all subjects that are exposed to tobacco smoke will develop smoking-related diseases. 
Around 30-40% of smokers develop COPD,58 suggesting that a combination of environ-
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mental, genetic and intrinsic individual factors determine disease susceptibility and the 
clinical course of disease.59-61
Many of our observations show important similarities with studies in smoking-related 
diseases. In COPD circulating CD4 and CD8 positive cell populations have shown to be 
increased30,62,63 and correlated with GOLD stage and disease exacerbations. Increased 
CD4 positive EM T cell populations have also been reported to correlate with markers of 
atherosclerosis, such as intima-media thickness and low-density lipoproteins, and these 
EM cells were higher in patients with stable angina and acute myocardial infarction.64 
Comprehensive analysis of immune cells in these diseases is pivotal to identify which 
mechanisms prevail in the development of smoking-related diseases and may identify 
those at risk.
Our study has also limitations. First, the design of the study is cross-sectional and must 
be seen as a hypothesis-generating study. Second, many participants are relatively 
young and have a low number of pack years. This may result in missing some of the 
true effects of tobacco smoke exposure on immune responses. Lastly, we do not know 
what substances our participants exactly smoke, especially since the Netherlands has a 
tolerance policy on cannabis. Despite these limitations, important conclusions can be 
drawn from this comprehensive analysis and these require further exploration.
In conclusion, smoking affects monocyte and T-cell populations and monocyte-derived 
cytokine production in healthy human smokers. The upregulation of pro-inflammatory 
cells and systemic inflammation is, however, associated by a defective response to 
bacterial stimulation, which suggest a deleterious combination of low-grade chronic 
inflammation and immunodeficiency. Comprehensive analyses of immune cell popula-
tions in smoking-related diseases may identify those pathways involved in pathophysi-
ology of smoking-related diseases at a systemic level.
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supplementary table 1. Definition of peripheral immune cell populations.
Immune cell phenotype CD markers 
Monocytes CD3+ CD14+
Classical monocytes CD3+ CD14++ CD16 -
Intermediate monocytes CD3+ CD14++ CD16+
Non-classical monocytes CD3+ CD14+ CD16++
T cells CD3+ CD56-
Double negative αβ cells CD3+ CD4- CD8-
Neutrophils Based on FSC and SSC
NK cells CD3- CD56+ CD16-
NKT cells CD3+ CD56+
B cells CD3+ CD19+
CD4+ central memory (CM) T cells CD3+ CD4+ CD45RA- CD27+
CD8+ central memory (CM) T cells CD3+ CD8+ CD45RA- CD27+
CD4+ effector memory (EM) T cells CD3+ CD4+ CD45RA- CD27-
CD8+ effector memory (EM) T cells CD3+ CD8+ CD45RA- CD27-
CD4+ naive T cells CD3+ CD4+CD45RA+ CD27+
CD8+ naive T cells CD3+ CD8+CD45RA+ CD27+
Regulatory T cells Helios+ CD3+ CD4+ CD25+ FOXp3+ Helios +
Regulatory T cells Helios- CD3+ CD4+ CD25+ FOXp3+ Helios - 
Activated regulatory T cells CD3+ CD4+ CD25+ FOXp3+ HLA-DR+
Proliferating regulatory T cells CD3+ CD4+ CD25+FOXp3+ Ki-67+ 
Transitional B cells CD19+ CD24++ CD38++
Naive B cells CD19+ IgD+ IgM+ CD27-
Memory B cells CD19+ IgD+ IgM+ CD27+
Plasmablasts CD19+ IgD- IgM- CD38++
The different CD-markers that were used to phenotype the peripheral immune cells are sum-
marised. (Abbreviations: CD; Cluster of differentiation, FOXp3: Forkhead box P3, FSC: Forward-scat-
tered light, HLA-DR: Human Leukocyte Antigen – antigen D Related, Ig: Immunoglobulin, NK: Natural 
killer; NKT: Natural killer T; SSC: Side-scattered light)
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supplementary table 2. Immune cell populations.
Population
smokers non-smokers
P-value median IQR median IQR
Monocytes 540897 316965 386200 263107 0,005
CD4 Positive T cells 1302550,5 957422 849018 596037 0,020
T cells (CD3+ CD56-) 1917035 1415245 1367745 751611 0,020
Classical monocytes 384951,5 260111 301847 185030 0,020
Double negative ɑβ cells 105768,5 113959 70087 55644 0,021
Regulatory T cells 37812 34141 22947 22124 0,021
Lymphocytes 2544103 1752675 1978454 1101036 0,036
CD8 Positive T cells 520268 350565 448882 249713 0,092
NK bright (CD56++ CD16-) 8098 5892 8778 6847 0,166
Non-classical monocytes 47682,5 28863 34301 36477 0,270
Intermediate monocytes 24781,5 21828 22357 12477 0,373
Neutrophils 3985093 3029764 3984660 2618607 0,373
NKT cells 60769,5 97716 82038 80770 0,540
B cells 135224 127513 142069 100230 0,583
NK (CD56+ CD16-) 6699,5 7473 5730 4148 0,583
Double Positive cells (CD4+ CD8+) 9681 9582 9789 6710 0,981
NK diminished (CD56+ CD16+) 235317,5 189931 212292 158187 0,981
NK cells (CD3- CD56+) 249162 199997 239360 167915 0,981
The different immune cell populations in the general immune cell panel. (Abbreviations: CD; Cluster 
of differentiation, IQR: inter-quartile range; NK: Natural killer; NKT: Natural killer T)
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supplementary table 3. The different B-cell populations investigated in this analysis of peripheral 
blood immune cell phenotypes.
Population
smokers non-smokers
P-value median IQR median IQR
IgM+ CD38++ CD27+ 414 349 788 835 0,10
Transitional B cells (CD24++ CD38++) 1470 1786 2602 2731 0,13
Plasmablast (IgD- IgM- CD38++) 1290 1670 1899 2379 0,13
Transitional B cell (CD27- IgM+ CD24+ CD38high) 2391 2696 3420 3778 0,13
Class switched memory (IgD- IgM- CD38+ CD27+) 15178 14635 10320 13242 0,14
IgD+ CD5++ 4964 5824 6939 8013 0,23
CD19+ CD20- Plasma blasts/cells 2296 2417 2850 3048 0,28
Natural effector (CD24+ CD38+ IgD+ IgM+) 10257 8403 8003 6407 0,28
Memory B cells (IgD+ IgM+ CD27+) 10983 8745 8581 6816 0,28
Class non switched memory (IgM+ CD38+ CD27+) 13200 9996 11097 9486 0,28
IgD- IgM- CD27- 3776 4495 3336 2853 0,28
IgD- IgM- 20970 21347 18257 15853 0,29
IgD- CD5+ 23982 17375 20261 17641 0,29
CD19+ CD20+ B cells 84530 70335 69757 58504 0,44
IgD- IgM+ CD27- 1006 1140 711 862 0,44
CD24+ CD38+ 75449 61197 61820 51338 0,46
IgD+ CD5+ 55164 51446 49090 43257 0,46
IgM- 17275 16640 15025 17675 0,46
IgD+ IgM- 3398 5202 4733 5457 0,46
CD24+ CD38+ CD27+ IgM+ 2604 2409 2197 1881 0,53
IgD+ IgM+ 53628 49239 48701 46564 0,54
IgM+ CD27- 40884 46810 44334 39413 0,75
IgD- CD5++ 799 1058 855 641 0,76
Naive B cells (IgD+ IgM+ CD27-) 39390 46589 44179 39594 0,76
Mature naive CD24+ CD38+ 31530 43359 34519 31107 0,77
IgD- IgM+ 4270 4625 3373 3902 0,80
IgM only memory (IgD- IgM+ CD27) 3018 3057 2640 2748 0,87
The different immune cell populations in the general immune cell panel. (Abbreviations: CD: Cluster 
of differentiation; Ig: Immunoglobulin; IQR: inter-quartile range)
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supplementary table 4. The different cell populations investigated in peripheral blood from for-
mer smokers.
Population
former smokers non-smokers
p-value median IQR median IQR
B cells (CD19 +) 130634 88886 141481 120926 0.90
CD19 + CD20 - Plasma blasts/cells 1645 1659 1628 2937 0.84
CD19 + CD20 + B cells 69943 54755 70713 75796 0.84
CD24 + CD38 + 63031 47385 65458 74677 0.84
CD24 + CD38 + CD27 + IgM + 2002 1778 2069 2481 0.84
CD4 + CD25high Regulatory T cells 36057 19650 27773 30618 0.81
CD4 + CM CD45RA - CD27 + 429826 236528 388827 313478 0.32
CD4 + Effector CD45RA + CD27 - 2157 5395 822 4331 0.48
CD4 + EM CD45RA - CD27 - 57894 40525 49066 33294 0.26
CD4 + Naive CD45RA + CD27 + 500186 541467 414912 439557 0.28
CD4 + T cells 1046763 682681 1036096 704738 0.81
CD8 + CM CD45RA - CD27 + 124367 88474 110615 103452 0.52
CD8 + Effector CD45RA + CD27 - 23960 41265 13399 23746 0.26
CD8 + EM CD45RA - CD27 - 24092 29187 15911 22293 0.46
CD8 + Naive CD45RA + CD27 + 227739 248943 241166 190799 0.46
CD8 + T cells 455006 265260 419251 210053 0.90
Class non switched memory (IgM + CD38 + 
CD27 +)
10127 7051 10902 10077 0.84
Class switched memory (IgD - IgM - CD38 + 
CD27 +)
13311 9000 8500 14388 0.84
Classical monocytes (CD14 + +CD16 -) 359651 290790 269060 351510 0.90
Double Negative (CD4 - CD8 -) 60466 71999 65237 53607 0.90
Double Positive (CD4 + CD8 +) 11404 6173 8925 9047 0.90
IgD - CD5 + 21222 13307 17322 21142 0.84
IgD - CD5 + + 671 525 807 990 0.84
IgD - IgM - 19029 12761 14516 19208 0.84
IgD - IgM - CD27 - 3448 2089 2615 3336 0.84
IgD - IgM + 3372 1802 3226 3903 0.87
IgD - IgM + CD27 - 903 989 803 1298 0.84
IgD + CD5 + 45417 33608 49439 51794 0.84
IgD + CD5 + + 3625 4844 4469 7324 0.84
IgD + IgM - 4344 4648 3798 4736 0.84
IgD + IgM + 43549 38880 50164 55577 0.84
IgM - 17727 10998 14105 15412 0.84
IgM + CD27 - 36104 31556 40790 48444 0.84
IgM + CD38 + + CD27 + 416 443 478 740 0.84
IgM only memory (IgD - IgM + CD27) 2482 1615 2413 2725 0.84
Intermediate monocytes (CD14 +CD16 +) 25489 18681 26359 19204 0.90
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supplementary table 4. The different cell populations investigated in peripheral blood from former 
smokers. (continued)
Population
former smokers non-smokers
p-value median IQR median IQR
Lymphocytes 2177388 1013214 2150268 1320234 0.90
Mature naive CD24 + CD38 + 28319 24272 28796 41820 0.84
Memory B cells (IgD + IgM + CD27 +) 7902 6225 8352 7226 0.87
Monocytes (CD14 +) 439566 297493 402252 432023 0.90
Naive B cells (IgD + IgM + CD27 -) 35235 32190 40455 39012 0.84
Natural effector (CD24 + CD38 + IgD + IgM +) 7319 6421 7605 6907 0.84
Neutrophils 4641964 2362811 4446735 2683722 0.90
NK (CD56 + CD16 -) 6396 6477 5102 5706 0.81
NK bright (CD56 + + CD16 -) 10243 7118 10315 8834 0.90
NK cells (CD3 - CD56 +) 247562 163109 242405 175158 0.90
NK dim (CD56 + CD16 +) 228522 159153 211024 166369 0.90
NKT cells (CD3 + CD56 +) 75971 88490 82165 120920 0.92
Non-classical monocytes (CD14 + +CD16 +) 41958 38604 42701 36467 0.90
Plasmablast (IgD - IgM - CD38 + +) 1009 1443 1255 1964 0.84
Ki-67 + CD4 + Tconv 16489 12279 13617 16984 0.31
Ki-67 + CD4 + Regulatory T cells 3857 3833 3353 2122 0.31
Ki-67 + CD8 7388 5350 6778 9017 0.77
Ki-67 + DN(CD4 -CD8 -) 40089 54792 42096 56767 0.77
Ki-67 + DP(CD4 +CD8 +) 681 949 410 916 0.26
T cells (CD3 + CD56 -) 1745891 926820 1591205 867307 0.81
Transitional B cell CD27 - IgM + CD24 + 
CD38high
2351 2592 2488 3581 0.84
Transitional B cells (CD24 + + CD38 + +) 1724 2011 1723 2683 0.84
Regulatory T cells CD25 + CD127low 44191 32339 33788 24706 0.32
Regulatory T cells CD45RA - 26503 13579 21242 15924 0.26
Regulatory T cells CD45RA + 21115 23414 18148 17189 0.51
Regulatory T cells FOXP3 + Helios - 5150 4304 4047 3605 0.26
Regulatory T cells FOXP3 + Helios + 41536 22001 36566 20793 0.31
Regulatory T cells HLA -DR + 10274 7196 7523 5935 0.26
The different immune cell populations in former smokers. (Abbreviations: CD: Cluster of differentia-
tion; Ig: Immunoglobulin; IQR: inter-quartile range; NK: Natural killer; NKT: Natural killer T)
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supplementary table 5. The circulating mediators in peripheral blood from former smokers.
Circulating mediators
former smokers non-smokers
p-valuemedian IQR median IQR
Adiponectin 6.73 0.24 6.63 0.30 0.44
Leptin 3.91 0.63 3.73 0.84 0.44
IL-18 1.69 0.96 1.48 0.96 0.51
IL-1Ra 2.15 0.25 2.20 0.17 0.61
hsCRP 2.76 0.59 2.71 0.53 0.87
AAT 9.04 0.42 9.11 0.35 0.89
IL-18 binding protein 4.41 0.17 4.38 0.16 0.89
IL-18 2.18 0.24 2.17 0.12 0.92
IL-1β 0.92 0.50 0.71 0.50 0.92
VEGF-A 1.48 0.25 1.46 0.26 0.92
IL-6 0.01 0.29 0.02 0.31 0.92
Resistin 4.13 0.21 4.14 0.23 0.92
The circulating mediators in peripheral blood from former smokers. (Abbreviations: AAT: Alpha-1 
Antitrypsin; hsCRP: high-sensitive C-reactive protein; IL: Interleukin; IQR: Inter-quartile range; Ra: re-
ceptor antagonist; VEGF: Vascular Endothelial Growth Factor)
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supplementary table 6. Ex vivo cytokine production upon stimulation with TLR-ligands in former 
smokers.
sample TlR-ligand
Cytokine 
(pg/ml)
formersmokers non-smokers p-value 
(uncorrected)median IQR median IQR
PBMC LPS IL-1β 3.30 0.38 3.39 0.35 0.31
PBMC LPS IL-6 3.81 0.25 3.88 0.26 0.04
PBMC LPS TNFα 2.35 0.58 2.39 0.37 0.49
PBMC LPS IL-1β 2.34 0.83 2.27 1.12 0.24
PBMC LPS IL-6 3.43 0.88 3.43 1.19 1.00
PBMC LPS TNFα 1.89 0.13 1.89 0.09 0.31
Whole blood LPS IFNγ 2.55 0.54 2.57 0.62 0.45
Whole blood LPS IL-1β 3.31 0.22 3.31 0.21 0.91
Whole blood LPS IL-6 3.93 0.18 3.97 0.20 0.27
Whole blood LPS TNFα 2.96 0.39 3.02 0.26 0.25
PBMC Pam3Cys IL-6 3.92 0.26 4.02 0.27 0.07
PBMC Pam3Cys TNFα 2.60 0.62 2.61 0.41 0.58
PBMC Poly I:C IL-1β 1.73 0.29 1.76 0.50 0.14
PBMC Poly I:C IL-6 2.55 0.61 2.66 0.56 0.13
PBMC Poly I:C TNFα 1.89 0.12 1.89 0.16 0.86
Ex vivo cytokine production. (Abbreviations: IL: Interleukin; IQR: Inter-quartile range; LPS: Lipopoly-
saccharide; PBMC: Peripheral Blood Mononuclear Cells; TLR: Toll-like receptor; TNFα: Tumor Necrosis 
Factor-α)
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sUMMARY AnD DIsCUssIOn
Comorbidities play a significant role in COPD and especially cardiovascular comorbidi-
ties have important health consequences.1-4 About half of the admissions of patients 
with COPD are accounted for by CVD.3,5 COPD is a chronic inflammatory condition and 
although the crosstalk between inflammation and coagulation is well known, this cross-
talk has been poorly studied in COPD. Therefore, the main aim of this doctoral thesis 
was to investigate the interaction between inflammation and coagulation in patients 
with COPD and to investigate the potential to modulate their interaction.
Although the presence of pulmonary embolism in patients with an acute exacerbation 
of COPD (AE-COPD) have been repeatedly reported, the exact prevalence still needed 
to be determined. A systematic reviewed about prevalence for pulmonary embolism 
in patients with an AE-COPD was therefore performed (Chapter 2). This is followed by 
studies that investigated pathophysiological mechanisms in which inflammation and 
coagulation interact in COPD (Chapters 3-4). Platelet function was studied both in 
stable disease and in AE-COPD, since platelets play a pivotal role in the development of 
cardiovascular diseases. Chapter 5 investigates the role of STAT3 in platelet function. 
Recent work suggested that STAT3 is involved in the crosstalk between inflammation 
and coagulation, via activation of platelets through the collagen pathway, however, 
further confirmation of its relevance in humans was warranted.
It is increasingly appreciated that vitamin D is able to modulate immune responses. 
For this reason, vitamin D may be used as an additional treatment in COPD patients. 
Currently, the effects of vitamin D supplementation on exacerbation frequency in COPD 
is investigated.6 The association between vitamin D and platelet function is less inves-
tigated. The 500FG, a large cohort study that is part of the Human Functional Genomics 
Project (HFGP, http://www.humanfunctionalgenomics.org/site/) that is aimed at charac-
terizing variations in immune function and platelet function,7,8 offered the opportunity 
to investigate the association between vitamin D and platelet function. Platelet func-
tion assays were performed in 500 healthy volunteers and its association with vitamin 
D is reported in Chapter 6. Lastly, the primary risk factor for COPD is tobacco smoking. 
Long-term tobacco smoke exposure causes not only an inflammatory response in the 
lungs, but also at a systemic level. The latter may contribute to the non-pulmonary 
complications of COPD such as CVD. Immune dysregulation because of smoking has 
been studied extensively, however, a comprehensive analyses of the systemic effects 
of tobacco smoke on peripheral immune cell populations in humans was lacking. Using 
the data from the 500FG cohort, current smokers and former smokers were carefully 
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matched to non-smokers and differences in immune cells were investigated (Chapter 
7).
Pulmonary embolism is common in patients with unexplained AE-COPD.
The risk for myocardial infarction and stroke in COPD patients is extensively studied 
and many studies report a significantly increased risk in this population.9-11 The risk for 
these thrombotic complications increases even further during episodes of increased 
inflammation, such as seen in acute exacerbations of COPD,9-12 suggesting that inflam-
mation contributes to their development. It has also been suggested that venous 
thromboembolism is increased in COPD,13,14 however, the prevalence of VTE during 
acute exacerbations is less well studied. To address this caveat, we have systematically 
reviewed the current literature in order to estimate the overall prevalence of PE during 
AE-COPD.
In Chapter 2, we report that PE is common in AE-COPD and our meta-analysis showed 
an overall pooled prevalence of PE in 16.1% (95%-Confidence Interval 8.3-25.8%) of 
patients with unexplained AE-COPD. Moreover, two-thirds of these emboli were found 
to be located more proximal than subsegmental, indicating that the majority of these 
embolisms have important clinical consequences. These embolisms require anticoagu-
lant treatment and should therefore be recognized.15 Of the 7 included studies, 6 ad-
ditionally reported on the prevalence of deep venous thrombosis and our meta-analysis 
showed a pooled prevalence of 10.5% (95%-Confidence interval 4.3-19.0%) in AE-
COPD. Our study confirms findings from a previous review by Rizkallah and colleagues 
who reported a prevalence of 19.9%.16 Since publication of this previous review 5 
relevant studies have been published and these were included in our meta-analyses.
The risk for venous thromboembolism in AE-COPD is substantial, especially in compari-
son to other inpatient populations that show a prevalence of 5.7 – 6.0%.17,18 These find-
ings merit clinical attention as PE has a 28-day case fatality rate of 21.2% in patients 
with COPD.19 One-third of cases of PE in AE-COPD was limited to isolated subsegmental 
PE. Unfortunately, we were unable to relate outcomes to embolus localization. The clini-
cal relevance of these small emboli is debated as studies report opposite effects.15,20,21 
Future studies are needed to investigate the clinical relevance of these small emboli in 
COPD. In order to improve early identification of PE in AE-COPD, we identified several 
clinical signs that are suggestive of the presence of PE in AE-COPD, in particular pleuritic 
chest pain and signs of cardiac failure. With this study, we aim to increase awareness on 
the venous thrombotic complications of COPD and to underline the clinical relevance of 
the interaction between inflammation and coagulation in COPD.
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Platelet function and plasmatic coagulation in COPD patients.
Inflammation and coagulation are highly integrated biological systems and to further 
explore the relevance of this crosstalk in COPD, several observational studies were 
performed to investigate the pro-coagulative mechanisms. As previously stated, the 
risk for myocardial infarction and stroke are strongly increased in COPD.9-11 Platelets 
play a pivotal role in development of arterial thrombotic events, but are also increas-
ingly recognized as immune cells.22,23 Platelet function was studied both in stable COPD 
patients and in exacerbated COPD patients (Chapters 3-4). In Chapter 3, we investi-
gated platelet-monocyte interaction and platelet function in 30 stable COPD patients 
and 25 control subjects. We showed increased platelet-monocyte interaction in stable 
COPD patients, in absence of increased platelet activation, platelet hyper-reactivity and 
activation of plasmatic coagulation. This study confirms a previous study by Maclay and 
colleagues that also found increased platelet-monocyte interaction,24 however we did 
not find platelet hyper-reactivity. These findings are important as platelet-monocyte 
complexes contribute to development of CVD by augmented development of athero-
sclerosis and involvement in plague instability.22,25,26 
In addition, these findings add to the current debate on the potential benefits of anti-
platelet therapy in patients with COPD.27,28 Since we could not show increased platelet 
activation and hyper-reactivity the benefits of anti-platelet therapy may seem limited 
from a pathophysiological point-of-view. However, P2Y12 receptor blockers, such as 
clopidogrel and ticagrelor, decrease platelet-monocyte interaction and systemic 
inflammation.29,30 On the contrary, for the COX-inhibitor aspirin these effects are not 
clearly demonstrated.31-33 This suggests that beneficial effects of the platelet-inhibitors 
in COPD may be different, depending on their mechanism of action.
Platelet-monocyte complex formation is often used as a surrogate marker for platelet 
activation, however, platelets and monocytes can interact in various ways.22,23,34 The 
best understood interaction occurs via binding of P-selectin on platelets to PSGL1 on 
monocytes and concurrent binding of fibrinogen to GPIIb/IIIa on platelets and MAC-1 
on monocytes, and these interactions are facilitated by platelet activation.35 In stable 
COPD we did not observe increased expression of P-selectin on platelets, nor did we 
observe increased fibrinogen binding. In absence of these platelet function alterations, 
we explored the role of monocyte activation for this interaction in AE-COPD (Chapter 
4). Platelets can interact with activated monocytes via their receptor GPIbα that di-
rectly interacts with MAC-1 on monocytes.36 MAC-1 increases with increased monocyte 
activation and some suggest that during inflammation this interaction is crucial for 
platelet-monocyte interaction.36,37 We hypothesized that MAC-1 plays an important 
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role in platelet-monocyte interaction in COPD patients and this hypothesis is further 
explored in Chapter 4.
Apart from platelet function, several markers for plasmatic coagulation were also as-
sessed in stable COPD patients. In contrast to previous findings in asthma patients,38 we 
did not find a hyper-coagulable state in stable COPD patients. In comparison to control 
subjects, no differences in clotting time, total amount of thrombin generated, maximum 
thrombin generation and plasma d-dimer were found. Majoor and colleagues found an 
important link between hypercoagulability in asthma, and use of glucocorticoids and 
asthma severity were identified as independent risk factors.39 Interestingly, glucocorti-
coids are also regularly used by COPD patients, however, mostly in the context of acute 
exacerbations of COPD. This factor may play an important role in the risk of thrombotic 
events in COPD patients and requires further investigation.
In Chapter 4, we investigated platelet-monocyte interaction and platelet function in 
exacerbated COPD patients and we explored whether MAC-1 expression on monocytes 
correlated with platelet-monocyte interaction. Twenty-two patients were included, of 
which two died during their hospital admission and one patient retracted informed con-
sent. In contrast to our hypothesis, this study showed lower platelet-monocyte interac-
tion in COPD patients during AE-COPD compared to 6 to 10 weeks post-exacerbation. 
This finding challenges a previous study that suggested increased platelet-monocyte 
interaction in AE-COPD.24 Maclay and colleagues investigated platelet-monocyte inter-
action in 12 patients with AE-COPD and compared them to 18 stable COPD patients.24 
In contrast to their study, we assessed platelet-monocyte interaction during and after 
AE-COPD in order to limit differences between the patients groups, and this may explain 
the contradictory nature of the observations. MAC-1 expression, on the contrary, was 
increased during AE-COPD and inversely correlated with platelet monocyte interaction 
post-exacerbation. These findings suggest that MAC-1 does not play a major role in 
platelet-monocyte interaction in COPD.
Similar to our previous study in stable COPD patients, no clear alterations in platelet 
function were observed. Some clinical studies showed increased survival of COPD 
patients that are treated with platelet-inhibitors.27,28 Platelets also exhibit important 
immunological functions23 and these may influence disease pathophysiology in COPD. 
Furthermore, Harrison and colleagues reported increased survival in COPD patients 
treated with platelet-inhibitors, while this was not related to cardiovascular deaths.27 
An important limitation of this study is the small sample size. COPD is a very heteroge-
neous disease and many studies aim to differentiate between different COPD pheno-
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types.4,40 Vanfleteren and colleagues have recently shown that COPD patients can be 
grouped in five different clusters based on comorbidities, thereby distinguishing COPD 
patients that are at risk for CVD from other clusters of comorbidities.40 To date, no clear 
distinction can be made from a immunological perspective and this may have affected 
our observations. Several confounding factors were assessed, such as frequent versus 
infrequent exacerbator phenotypes and the effects of smoking, however, these factors 
did not alter our observations. Together, these findings do not explain the increased risk 
for CVD during AE-COPD and further research on the exact mechanisms is warranted.
signal Transducer and Activator of Transcription 3 (sTAT3) is involved in 
glycoprotein VI (GPVI)-mediated platelet activation.
In Chapter 5, we investigated the involvement of STAT3 in platelet activation. STAT3 
is important for transduction of a variety of cell signals, including signals involved in 
inflammation.41,42 In response to cytokines and growth factors, STAT3 is phosphorylated 
and translocated to the nucleus for transcription of specific genes. Differentiation of T 
helper-17 (Th-17) cells is dependent on STAT3 and is essential for host defense against 
fungal infections.43,44 Additionally, STAT3 function is associated with several in inflam-
matory diseases, including COPD.43,45,46 
Recent evidence suggested that STAT3 function in platelets may provide a potential 
new link between inflammation and coagulation.47,48 Zhou Zhou and colleagues showed 
that signal STAT3 is involved in platelet activation in response to collagen via platelet 
receptor GPVI.47 The functional relevance of this crosstalk in humans is less well studied 
and understood. To investigate its importance in humans, we studied patients with 
dysfunctional STAT3 and healthy human subjects. Patients with autosomal dominant 
Hyper IgE syndrome have dominant-negative mutations in STAT3, resulting in impaired 
function of STAT3. We showed that GPVI-mediated platelet activation is affected by 
STAT3 loss-of-function mutations, thereby confirming functionality of this crosstalk in 
humans.
Involvement of STAT3 in platelet activation may provide a relevant link between inflam-
mation and hemostasis. Increased activation of the STAT3 signaling pathway has been 
described in cancer and many inflammatory diseases, including cardiovascular diseases 
and COPD.43,45,46,49-51 In contrast, platelet numbers were not affected by mutations in 
STAT3 loss-of-function patients nor was there an association with the SNPs in STAT3 in 
healthy human subjects. With the lack of an effect on platelet numbers, we report an 
opposite effect compared to a previous study that suggests an important role for STAT3 
in the hepatocytic production of TPO, the most important regulator of platelet formation 
by megakaryocytes. In addition to a mouse model, it was shown that desialylated plate-
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lets are taken up by a human HepG2 cells and these cells subsequently produce TPO in 
a Janus Kinase-2/STAT3-dependent manner.52 In contrast, we did not find a decrease in 
platelet numbers in patients with defective STAT3 signaling, moreover thrombocytosis 
was observed in STAT3 loss-of-function patients during acute infections. A trend was 
seen for increased IL-6 in patients and this may be another factor that may stimulate 
thrombopoiesis.53,54 Together, our findings suggest that in vivo STAT3 does not play a 
pivotal role in the production of platelets in humans.
Further experiments showed that GPVI-mediated platelet activation was largely depen-
dent on secondary stimulation by platelet ADP release, both in STAT3 loss-of-function 
patients and in healthy subjects. However, the blockade of this mechanism with apyrase 
strongly attenuated platelet responses, particularly in STAT3 loss-of-function patients, 
indicating that STAT3 may be involved in the secondary ADPpathway as a result of plate-
let activation. The relevance of SNPs in STAT3 was further studied in a cohort of healthy 
volunteers and GPVI-mediated platelet activation was not affected by the SNPs studied.
Our study is limited by the fact that it is not known whether the studied SNPs in STAT3 
affect STAT3 functionality in healthy subjects, or whether aberrant STAT3 function only 
becomes apparent when inflammatory diseases manifest. The role of STAT3 activation 
in inflammatory diseases and its consequences for platelet activation needs further 
exploration. Furthermore, blockade of Janus Kinase (JAK) - STAT3 pathway is currently 
being explored as a new therapy for cancer.55-58 It is important that involvement of STAT3 
in platelet activation is recognized as bleeding complications may occur, especially 
in patients that are concurrently treated with platelet inhibitors that target the ADP 
pathway such as Ticagrelor and Clopidogrel.
Involvement of 25-hydroxyvitamin D in platelet activation and reactivity.
Vitamin D has many functions beyond its traditional role in bone health, including a 
regulatory role in inflammation and infection.59-61 Vitamin D deficiency is highly preva-
lent in COPD patients and is estimated to occur in 60% - 77% of patients with COPD 
GOLD stage 3 and 4, respectively.62 Vitamin D supplementation is suggested to have 
a protective effect to respiratory infections, including viral infections,63-65 a common 
trigger for AE-COPD.
In contrast to the immunomodulatory effects of vitamin D, associations between vita-
min D and platelet function are currently scarcely studied. Several studies have shown 
strong associations between low vitamin D levels and cardiovascular diseases66-69 and a 
seasonal variation of CVD incidence.70-73 Moreover, the majority of patients with acute 
myocardial infarction is vitamin D deficient.74,75 
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In Chapter 6, we assessed the association between serum 25-hydroxyvitamin D levels 
and platelet activation and reactivity in a cohort of 500 healthy human subjects. For this 
observational study, data from the 500 Human Functional Genomics Project (500FG) 
were used.8 The 500FG is part of the Human Functional Genomics Project (HFGP) that 
is aimed a characterisation of variations of immune cell function and platelet function 
in healthy human subjects7,8 and thereby provided an unique opportunity to study the 
association between 25-hydroxyvitamin D and platelet function.
The vitamin D pathway has several important functional SNPs that influence bio-
availibility of 25-hydroxyvitamin D and its active metabolite 1,25-dihydroxyvitamin 
D.76-78 Thirty-nine SNPs were identified from literature,78-82 out of which 31 of these SNPs 
were available in the 500FG dataset. This study is the first to show an inverse correlation 
between 25-hydroxyvitamin D levels and platelet fibrinogen binding in unstimulated 
samples and after stimulation with CRP and ADP in a large cohort of healthy subjects, 
whereas no relation with P-selectin expression was found. This association was stronger 
for 25-hydroxyvitamin D levels ≤ 50nmol/L, a commonly used cut-off value for vitamin 
D deficiency. No differences were observed between 25-hydroxyvitamin D insufficiency 
and normal 25-hydroxyvitamin D levels, further supporting the presence of a threshold.
Few studies investigated direct associations between vitamin D levels and platelet 
parameters in different diseases.83-85 An association between low vitamin D levels and 
high-residual platelet reactivity in patients with CVD receiving anti-platelet therapy 
has been reported, as well as antithrombotic activities of vitamin D supplemented to 
haemodialysis patients.83,85 
The strongest association with 25-hydroxyvitamin D was found for platelet fibrinogen 
binding in response to CRP-XL stimulation. Interestingly, 6 of the 9 vitamin D pathway 
related SNPs that were associated with platelet function also showed an association 
with platelet responses to CRP-XL. We among other have shown that the platelet agonist 
CRP-XL signals through the collagen pathway to activate platelets.47 This mechanism is 
dependent on phosphorylation of Signal Transducer and Activator of Transcription 3 
(STAT3).47 Interactions between vitamin D and JAK-STAT signaling pathways have been 
reported.86,87 
Olson and colleagues showed that vitamin D decreases STAT3 phosphorylation and this 
may explain increased platelet fibrinogen binding in response to CRP-XL in vitamin 
D deficient participants.87 On the other hand, VDBP may also play a key role as 5 out 
of 9 SNPs were present in the GC region, encoding VDBP, and involvement of VDBP in 
platelet activation has been suggested.88 
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A causal relationship between the SNPs, vitamin D levels and platelet function param-
eters could not be confirmed. Critics suggest that vitamin D may be just a bystander and 
may reflect a combination of physical inactivity, poor health status and poor variation 
in diet that results in vitamin D deficiency. Vitamin D could be an epiphenomenon and 
may not be causally involved. This hypothesis is further strengthened by supplemen-
tation studies that yield little to no effect on cardiovascular diseases to date.35,89,90 
Furthermore, no association between vitamin D levels and immune cell function was 
found in the 500 human functional genomics projects after correction of seasonality 
effects.8 On the other hand, studies exploring the effect of vitamin D supplementation 
on platelet reactivity are lacking. The PRECOVID trial6 investigates the effects of vitamin 
D supplementation on COPD exacerbations as well as its effects on immune responses 
and platelet function in vitamin D deficient COPD patients. These kind of trials are cru-
cial to further understand the mechanisms of action of vitamin D as well as to identify 
effective therapeutic opportunities.
The impact of cigarette smoking on the human immune system.
Despite global initiatives for tobacco regulation, smoking is still common with an 
estimated 1 billion smokers worldwide.91-93 Smoking impacts nearly every part of the 
human body and contributes to numerous diseases with significant morbidity and 
mortality.94-96 Smoking-related diseases do not only develop locally, such as in COPD 
and lung cancer, but also on a distant level, such as in myocardial infarction.94,95 Immune 
dysregulation by smoking is thought to play an important role in the development of 
smoking-related diseases.97 
Many studies have investigated the immunological effects of smoking, however, their 
study designs vary widely. Some studies aim to explore the effects of specific tobacco 
smoke components,98 some analyse specific local and/or systemic immune cell lineag-
es,99-101 whereas others investigate tobacco effects in specific diseases, while humans 
or non-human species are used.102,103 To the best of our knowledge, a comprehensive 
analyses of the systemic effects of tobacco smoking in healthy human subjects is lacking. 
These data are needed to identify and further study those pathways that are involved 
in the pathophysiology of smoking-related diseases at a systemic level. Therefore, the 
last study in this doctoral thesis, Chapter 7, describes a comprehensive analysis on the 
variation of peripheral blood immune cell population in carefully matched smokers, 
non-smokers and former smokers to investigate the systemic effects of smoking.
In this cross-sectional study, cases (current smokers and former smokers) and controls 
(non-smokers) were identified among 500 healthy volunteers participating in the Hu-
man Functional Genomics Project (HFGP).8 Immune cell populations were determined in 
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peripheral blood and compared among the different study subjects. Furthermore, levels 
of circulating inflammatory mediators and ex vivo cytokine production upon stimulation 
of whole blood and peripheral blood mononuclear cells (PBMCs) were compared.
In current smokers, we observed an increased number of monocytes, mostly classical 
monocytes and these cells correlated with pack years. The production of the monocyte-
derived cytokines TNFα, IL-6, IFNγ and IL-1β to ex vivo LPS challenge, in contrast, was 
lower in current smokers. Also dysregulation of the adaptive arm of the immune system 
was observed in current smokers, with increased numbers of CD4 and CD8 positive 
CM cells and increased numbers of CD4 positive EM cells. These observations were 
accompanied by increased numbers of regulatory T cells that showed a more activated 
and mature phenotype and this also correlated with pack years. IL-6 and hsCRP, mark-
ers for systemic inflammation, were not different between smokers and non-smokers, 
however these markers were positively correlated with pack years in current smokers. 
Together, these findings indicate that tobacco smoking leads to a defective capacity to 
produce cytokines upon microbial stimulation, yet it induces inappropriate systemic 
inflammation.
Our study reports important effects of tobacco smoking on human immune phenotype 
and immune function and confirms separate observations of previous studies, whereas 
it challenges others. Increased numbers of classical monocytes were observed that 
produce less pro-inflammatory cytokines. This supports a previous publication by 
Noakes and colleagues, who compared immune responses from cord blood of neonates 
between maternal smokers and non-smokers, and report decreased TNFα, IL-6 and IL-10 
in cord blood of neonates from maternal smokers.104 Others investigated the effects 
of the tobacco component nicotine and reported decreased cytokine production by 
monocytes via a mechanism dependent on nuclear factor-kappaB transcriptional activ-
ity.105,106 
Furthermore, increased numbers of regulatory T cells were found in smokers. These 
natural suppressor cells of the immune system showed increased activation and 
maturation in current smokers. Opposite effects regarding regulatory T cell numbers 
and function have been reported in the context of smoking, including up- and down-
regulation of regulatory T cells.102,107-109 These findings seem dependent on the tissue 
investigated (peripheral blood, bronchial alveolar lavage fluid) and the population, such 
as healthy (non-) smokers or COPD patients.
These observations co-occur with increased numbers of antigen experienced pro-
inflammatory T cells. T cell differentiation follows along a continuum from naive T cells 
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to antigen experienced CM and EM T cells.110-112 In smokers, CM T cells were increased 
in CD4 and CD8 positive cell lineages and confirm previous studies that investigated 
specific T cell populations in humans,100,113,114 but not in mice.115 Upon antigenic stimu-
lation, CM T cells are able to rapidly proliferate into effector T cells that migrate to the 
tissues to exert their pro-inflammatory effects.112 It has been suggested that T cell dif-
ferentiation is determined by antigen load and persistence in infectious diseases.116-118 
Indeed, several studies found alterations in airway colonization caused by cigarette 
smoke,119,120 and the presence of pathogens may be an alternative source for antigenic 
stimulation.
We found that systemic inflammation was not increased in healthy smokers, whereas 
there was an association between pack years and plasma IL-6 and hsCRP. During 
prolonged and/or intense tobacco smoke exposure the balance may shift to a more 
pro-inflammatory phenotype. Indeed, several studies in COPD have shown increased 
inflammation, together with a decrease in regulatory T cells,107,121,122 while others 
observed merely a dysfunction of the regulatory T cell compartment.123,124 Similar 
observations are reported in cardiovascular diseases; decreased numbers of regulatory 
T cells and regulatory T cell dysfunction were found in patients with coronary artery 
disease and acute myocardial infarction.125-127 
These data are important as they contribute not only to our understanding of the 
immunological consequences of smoking, but may help to identify pathophysiologi-
cal mechanisms that result in the development of smoking-related diseases. Further 
investigation and comprehensive analysis of immune cells in these diseases is pivotal 
to identify which mechanisms prevail in the development of smoking-related diseases 
and may help to identify those at increased risk.
COnClUsIOns
In this doctoral thesis the interaction between inflammation and coagulation in patients 
with COPD and the potential to modulate their interaction was investigated. We found 
that pulmonary embolism is common in patients with unexplained exacerbations of 
COPD and that the majority of these emboli have important clinical consequences. 
Further investigation of the mechanisms responsible for thrombotic complications in 
COPD revealed no differences in thrombin generation and d-dimer, markers for plas-
matic coagulation, in stable COPD patients. Platelet-monocyte interaction, however, 
was increased in stable COPD patients and may augment atherosclerosis and plaque 
instability, thereby contributing to the development of cardiovascular diseases.
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In healthy subjects, we found an increased number of circulating immune cells, includ-
ing monocytes, in smokers compared to non-smokers, which further support the role 
of monocytes in COPD and atherosclerosis. Interestingly, during acute exacerbations 
platelet-monocyte interaction was lower and their interaction may not explain the 
increased risk for CVD during AE-COPD.
Several factors involved in inflammation may also exert effects on platelet function. 
Signal Transducer and Activator of Transcription 3, for example, is involved in glycopro-
tein VI-mediated platelet activation. Similarly, 25-hydroxyvitamin D is associated with 
platelet fibrinogen binding, in particular with glycoprotein VI-mediated platelet activa-
tion, among other platelet activation pathways. Although awareness for the thrombotic 
complications in COPD is increasing, the ability to modulate the interaction between 
inflammation and coagulation needs to be closely studied in COPD in order to prevent 
thrombotic complications in the future.
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COPD is een ernstige ziekte die in de meeste gevallen wordt veroorzaakt door roken. 
Daarnaast spelen nevenaandoeningen, ook wel comorbiditeiten genoemd, een belang-
rijke rol in COPD. Vooral de cardiovasculaire comorbiditeiten hebben een belangrijke 
impact op de gezondheid van COPD-patiënten. Naar schatting wordt ongeveer de helft 
van de ziekenhuisopnames van COPD-patiënten veroorzaakt door cardiovasculaire 
comorbiditeiten en een kwart van de sterfgevallen.
COPD is een inflammatoire aandoening en het is bekend dat er intensieve interactie 
tussen ontsteking en stolling bestaat. Zowel arteriële als veneuze trombose komt vaak 
voor bij COPD en heeft een negatieve impact op de gezondheidstoestand. Deze inter-
actie is in COPD nog niet uitgebreid bestudeerd. Het doel van dit academische proef-
schrift was daarom om de interactie tussen ontsteking en stolling te onderzoeken bij 
COPD-patiënten, alsmede om te onderzoeken of deze interactie kan worden beïnvloed.
In Hoofdstuk 2 van dit proefschrift kijken we naar de aanwezigheid van longembolieën 
bij patiënten met een acute exacerbatie van COPD. In de literatuur is het voorkomen 
van deze longembolieën ten tijde van COPD-exacerbaties verscheidene malen gerap-
porteerd, echter bestaat er nog geen consensus over hoe vaak dit gemiddeld voorkomt. 
In deze studie hebben we een systematische review met meta-analyse uitgevoerd van 
de reeds gepubliceerde studies en gevonden dat de prevalentie van longembolieën bij 
patiënten met een onverklaarde exacerbatie van COPD rond de 16% procent ligt. Bo-
vendien is tweederde van deze longembolieën groter dan subsegmenteel en daarmee 
klinisch relevant. Volgens de huidige richtlijn moeten deze longembolieën behandeld 
worden. Daarnaast hebben we verschillende studies uitgevoerd die het mechanisme 
verantwoordelijk voor het verhoogde risico op cardiovasculaire aandoeningen onder-
zochten, deze zullen in de volgende hoofdstukken besproken worden.
In Hoofdstuk 3 zijn de functie van bloedplaatjes, bloedplaatjes-monocyt interactie en 
verschillende markers voor stolling vergeleken tussen patiënten met een stabiel COPD 
en gezonde proefpersonen. We vonden meer interactie tussen bloedplaatjes en mono-
cyten in COPD-patiënten, in afwezigheid van plaatjeshyperreactiviteit. Deze bevinding 
was opmerkelijk, omdat deze fenomenen normaliter vaak samengaan. Plaatjeshyper-
reactiviteit speelt een belangrijke rol bij arteriële trombose. Bloedplaatjesremmers 
vormen een belangrijke therapie om onder andere hartaanvallen en beroertes te 
voorkomen. Interactie tussen plaatjes en monocyten speelt eveneens een rol, omdat 
deze bijdraagt aan het ontstaan van atherosclerose en plaque instabiliteit. De mate van 
stolling, gemeten met behulp van thrombine productie en D-dimeer, was niet verschil-
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lend tussen COPD-patiënten en gezonde proefpersonen. In afwezigheid van functionele 
veranderingen in bloedplaatjes stelden we dat de interactie met monocyten mogelijk 
veroorzaakt wordt door monocyt-activatie. In bovengenoemde studie is er gekeken 
naar stabiel COPD, we wilden hierna graag verder kijken naar hoe bloedplaatjes en mo-
nocyten precies met elkaar interacteren en hoe bloedplaatjes functioneren gedurende 
acute exacerbaties van COPD.
In de hierop volgende studie, beschreven in Hoofdstuk 4, hebben we bovenstaande 
vragen onderzocht. De hypothese luidde dat onder invloed van ontsteking, meer bloed-
plaatjes-monocyt interactie zou bestaan tijdens exacerbaties van COPD in vergelijking 
met de herstelperiode daarna. Patiënten met een exacerbatie van COPD werden tijdens 
een opname onderzocht en tijdens een poliklinische controle, 6 tot 10 weken later. In 
tegenstelling tot onze hypothese vonden we minder bloedplaatjes-monocyt interactie 
tijdens acute exacerbaties van COPD. Er was tevens sprake van een inverse correlatie 
met monocyt-activatie marker MAC-1, wat het minder waarschijnlijk maakt dat activatie 
van de monocyt via deze receptor een cruciale rol speelt in de bloedplaatjes-monocyt 
interactie. Het beperkte aantal patiënten dat in deze studie geïncludeerd kon worden 
was een belangrijke beperking en daarom moeten we voorzichtig zijn met de interpre-
tatie van de bevindingen van deze studie.
In Hoofdstuk 5 is gekeken naar de rol van Signal Transducer and Activator of Transcription 
3 (STAT3) mutaties in de functie van bloedplaatjes en in de productie van bloedplaatjes. 
Een recente studie liet in een muismodel zien dat STAT3 een cruciale rol speelde in 
bloedplaatjesactivatie via de collageen pathway. In gezonde proefpersonen werd dit 
ook getoond met behulp van een STAT3-remmer. Deze bevinding is interessant, omdat 
STAT3 vaak geassocieerd wordt met inflammatoire aandoeningen, waaronder COPD en 
cardiovasculaire ziekten. Om de relevantie van deze bevindingen verder te valideren 
bij mensen hebben we deze pathway onderzocht in patiënten met een defect in STAT3 
functie en bij gezonde proefpersonen. De patiënten met een defect in STAT3 functie 
lijden aan het autosomaal-dominant Hyper IgE syndroom, een immuunstoornis die leidt 
tot recidiverende infecties met onder andere stafylokokken en schimmels.
We vonden in de patiënten met een defect in STAT3 functie inderdaad minder bloed-
plaatjesactivatie en een lagere respons van bloedplaatjes bij het stimuleren van de 
collageen pathway. Verdere experimenten naar de onderliggende mechanismen liet 
zien dat een andere pathway, de ADP pathway, dit defect grotendeels maskeerde. Na ex 
vivo remming van de ADP pathway met apyrase bleek dat bij de patiënten bloedplaat-
jesactivatie nauwelijks toenam na het stimuleren van de collageen pathway, terwijl dit 
in gezonde proefpersonen veel minder invloed had.
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In een tweede cohort van gezonde proefpersonen hebben we verschillende SNPs in 
STAT3 onderzocht om te kijken of bovenstaande effecten zich ook in de algemene po-
pulatie voordoen. De SNPs in STAT3 beïnvloedden de mate van bloedplaatjesactivatie 
echter niet. Verder onderzoek moet uitwijzen of STAT3 leidt tot meer bloedplaatjesacti-
vatie in inflammatoire aandoeningen, waarvan gesuggereerd wordt dat STAT3 activiteit 
is toegenomen. Indien dit fenomeen optreedt zou het bij kunnen dragen aan de ontwik-
keling van cardiovasculaire aandoeningen bij toegenomen inflammatie.
Onze data zijn tevens relevant in de context van de ontwikkeling van nieuwe geneesmid-
delen die STAT3 of zijn voorloper JAK2 remmen. Deze medicijnen worden momenteel 
in studieverband geëvalueerd voor hun effecten in oncologische aandoeningen. Deze 
middelen zouden potentieel kunnen leiden tot een verhoogd bloedingrisico, zeker bij 
patiënten die gelijktijdig behandeld worden met bloedplaatjesremmers die aangrijpen 
op de ADP pathway, zoals Ticagrelor en Clopidogrel.
Een andere factor die invloed zou kunnen hebben op bloedplaatjesactivatie en reacti-
viteit is vitamine D. Cardiovasculaire aandoeningen gaan vaak samen met een vitamine 
D-tekort en bovendien is er een seizoensgebonden patroon van het voorkomen van 
hartaanvallen die overeenkomt met vitamine D-spiegels in het bloed. In Hoofdstuk 6 
wordt de associatie tussen de bloedspiegel van 25-hydroxyvitamine D en bloedplaat-
jesfunctie onderzocht. Ondanks dat er een duidelijke relatie is tussen 25-hydroxyvita-
mine D en cardiovasculaire ziekten zijn de directe effecten op bloedplaatjes nog niet 
eerder bestudeerd.
We zijn de eerste die een inverse correlatie tussen 25-hydroxyvitamine D en bloed-
plaatjesactivatie van integrin αIIbβ3 laten zien in een groot cohort van gezonde 
proefpersonen, te weten het 500FG cohort. Zowel in ongestimuleerde monsters, als 
in  monsters gestimuleerd met CRP-XL werd een inverse correlatie gevonden met de 
binding van fibrinogeen aan integrin αIIbβ3 op bloedplaatjes. Deze associatie was 
vooral sterk aanwezig bij proefpersonen met een 25-hydroxyvitamine D < 50nmol/L. 
We vonden geen verschil tussen een normaal vitamine D (>75nmol/L) en een relatieve 
vitamine D insufficiëntie (50nmol/L-75nmol/L), wat suggereert dat er sprake is van een 
zekere afkapwaarde. Daarnaast hebben we naar verschillende SNPs gerelateerd aan de 
vitamine D pathway gekeken en 9 van de 31 SNPs die aanwezig waren in de dataset 
hadden een associatie met vitamine D concentraties in het bloed.
De bovengenoemde associatie tussen vitamine D en bloedplaatjesfunctie hoeft niet 
te betekenen dat zij in direct verband met elkaar staan. Causal inference analysis liet 
geen causaal verband zien, echter dit kan te maken hebben met het kleine effect en 
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de omvang van het cohort. Critici stellen dat lage vitamine D concentraties mogelijk 
niet direct betrokken zijn bij het ontstaan van cardiovasculaire aandoeningen, maar 
dat het meer als epifenomeen optreedt. Mensen met een slechte gezondheidsstatus 
komen mogelijk minder buiten, hebben weinig beweging en mogelijk een minder 
gevarieerd dieet; factoren die allen bijdragen aan een vitamine D-tekort. Het risico op 
cardiovasculaire aandoeningen zou dan niet zozeer door het lage vitamine D bepaald 
worden, maar door de bovengenoemde factoren. Daarnaast laten verschillende studies 
die patiënten met vitamine D behandelen om cardiovasculaire ziekten te voorkomen 
niet een onomstreden voordeel zien van behandeling met vitamine D-supplementen.
De laatste wetenschappelijke studie in dit proefschrift beschrijft de effecten van roken 
op het immuunsysteem van gezonde vrijwilligers en is beschreven in Hoofdstuk 7. On-
danks dat verschillende mondiale initiatieven proberen om de tabaksconsumptie terug 
te dringen is het roken van tabak nog steeds veelvoorkomend en er zijn momenteel 
nog ongeveer 1 miljard rokers wereldwijd. Roken beïnvloedt elk deel van het menselijk 
lichaam en ligt ten grondslag aan vele aandoeningen. Sommige aandoeningen ontwik-
kelen zich lokaal, zoals COPD en longkanker, terwijl andere aandoeningen zich buiten 
het bereik van de long ontwikkelen.
Men denkt dat disregulatie van het immuunsysteem ten grondslag ligt aan het ontstaan 
van veel rokengerelateerde ziekten. De effecten van tabaksrook op het immuunsys-
teem zijn uitvoerig onderzocht, echter, studiedesigns verschillen enorm. Sommige 
studies richten zich bijvoorbeeld op specifieke componenten van tabak, zoals nicotine, 
terwijl andere studies naar specifieke cellijnen in de long of in bloed kijken. Daarnaast 
wordt onderzoek zowel in mensen als in dieren verricht. Een uitgebreide studie naar 
de effecten van roken op immuuncellen in bloed van gezonde mensen ontbrak nog en 
deze is door ons verricht in het 500FG cohort, waarin rokers, ex-rokers en niet rokers 
nauwkeurig aan elkaar gematched werden.
We vonden dat bij rokers, in vergelijking met niet rokers, verschillende immuun popu-
laties waren toegenomen. Monocyten, met name klassieke monocyten, waren toegeno-
men in populatie en er bestond een positieve correlatie met het aantal gerookte pack 
years. De productie van monocyt afkomstige ontstekingscytokines TNFα, IL-6, IFNγ en 
IL-1β na ex vivo LPS stimulatie, daarentegen, was gedaald. Ook in het adaptieve im-
muunsysteem waren verscheidene populaties verandert, zoals het aantal CD4 en CD8 
positieve central memory (CM) cellen en CD4 positieve effector memory (EM) cellen.
Tegelijkertijd observeerden we een toename van regulatoire T-cellen, de natuurlijke 
rem op het immuunsysteem. Regulatoire T-cellen waren bovendien meer geactiveerd 
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en vertoonden een verder gedifferentieerd fenotype dan bij niet rokers. IL-6 en hsCRP, 
markers voor systemische inflammatie, waren niet verschillend tussen rokers en niet 
rokers, terwijl er wel een correlatie was met pack years. Deze bevindingen suggereren 
dat er enerzijds sprake is van een zekere mate van immuundeficientie en dat er an-
derzijds sprake is van laag-gradige systemische inflammatie. Tussen ex-rokers en niet 
rokers werden geen signifiante verschillen gezien in immuuncellen, wat het belang van 
het stoppen met roken opnieuw benadrukt.
Samengenomen laat deze studie uitgebreide effecten zien van het roken op het im-
muunsysteem van gezonde proefpersonen en heeft het overlap met eerdere bevin-
dingen in rokengerelateerde aandoeningen. Deze data dragen niet alleen bij aan de 
kennis over de consequenties van roken, maar kunnen mogelijk ook inzicht geven in de 
pathofysiologie van rokengerelateerde aandoeningen. Zo zijn in COPD ook toegenomen 
populaties van CD4 en CD8 positieve cellen gevonden en dit correleerde met GOLD 
stage en exacerbaties van COPD. In cardiovasculaire ziekten zouden CD4 positieve EM 
cellen correleren met markers voor atherosclerose. Verder onderzoek naar immuuncel-
len in deze aandoeningen is belangrijk om in beeld te krijgen welke mechanismen de 
overhand krijgen en resulteren in rokengerelateerde ziekten.
COnClUsIE
In dit academische proefschrift werd de interactie tussen ontsteking en stolling bij 
patiënten met COPD onderzocht en werd onderzocht of deze interactie kan worden 
beïnvloed. We vonden dat longembolieën voorkomen bij 16% van de patiënten met 
onverklaarde exacerbaties van COPD en dat de meerderheid van deze longembolieën 
belangrijke klinische consequenties heeft. Verder onderzoek naar de mechanismen die 
verantwoordelijk zijn voor trombose  lieten geen verschillen zien in thrombine productie 
en D-dimeer, markers van plasmatische stolling, in stabiel COPD. Bloedplaatjes-monocyt 
interactie, daarentegen, was toegenomen in stabiel COPD. Deze interactie versterkt de 
ontwikkeling van artherosclerose en plaque instabiliteit, en draagt daarmee bij aan de 
ontwikkeling van cardiovasculaire ziekten. Daarnaast vonden we bij gezonde mensen 
een toename van verschillende typen immuuncellen, zoals monocyten, in rokers in 
vergelijking met niet-rokers. In onze studie naar bloedplaatjes-monocyt interactie 
tijdens exacerbaties van COPD vonden we dat deze interactie juist minder sterk was 
en dit vormde geen verklaring voor het toegenomen cardiovasculaire risico tijdens 
exacerbaties van COPD.
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Er zijn verschillende factoren die een rol spelen bij ontsteking en tevens de functie van 
bloedplaatjes kunnen beïnvloeden. Zo vonden we dat STAT3 een rol speelt bij glyco-
proteine VI-gemedieerde bloedplaatjesactivatie in mensen. 25-hydroxyvitamin D lijkt 
eveneens een rol te spelen, doordat het een inverse correlatie toonde met fibrinogeen 
binding met integrin αIIbβ3 op bloedplaatjes. Dit effect was het sterkst bij glycopro-
teine VI-gemedieerde bloedplaatjesactivatie. Ondanks dat we ons in toenemende mate 
bewust worden van de trombotische complicaties bij COPD, moet verder onderzoek 
leiden tot methoden om de interactie tussen stolling en ontsteking te beïnvloeden om 
zo cardiovasculaire ziekten bij COPD patienten in de toekomst te voorkomen.
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DAnKWOORD
Met dit proefschrift besluit ik een boeiende en uitdagende reis. Mijn dank gaat aller-
eerst uit naar mijn promotoren en copromotor, voor de kans en het vertrouwen die jullie 
me gaven om deze uitdaging aan te gaan.
Prof. Dr. van der Ven, beste André, mijn dank aan jou is niet eenvoudig uit te drukken. 
Zonder jou zou dit proefschrift er niet zijn en we weten beiden dat het waar is. Het 
enthousiasme waarmee je wetenschap bedrijft, onderwijs geeft én de kliniek draait is 
ongekend en aanstekelijk. Dat maakt je een ware bron van inspiratie en ik ben zeer 
dankbaar dat ik met je mocht samenwerken.
Prof. Dr. Heijdra, beste Yvonne, de kansen die jij me hebt gegeven, een opleidingsplaats 
tot longarts en dit promotietraject, zijn ongekend. Ik ben zeer dankbaar dat je me zo 
vroeg de ruimte, maar ook het vertrouwen, hebt gegeven om vorm te geven aan deze 
ambities.
Dr. de Mast, beste Quirijn, jouw deur staat altijd open voor overleg, maar ook voor 
gezelligheid. Jouw kritische blik en scherpzinnigheid maakt dat je een ontzettend 
waardevolle copromotor bent en, ondanks dat COPD niet jouw grote liefde is, heb ik 
veel van je mogen leren.
Leden van de manuscriptcommissie Prof. van der Hoeven, Prof. bel en Prof. Rongen, 
hartelijk dank voor het plaatsnemen in de manuscriptcommissie en voor het beoordelen 
van dit proefschrift.
Op verschillende wijze hebben veel mensen bijgedragen aan de totstandkoming van dit 
proefschrift. Een aantal van hen wil ik in het bijzonder bedanken.
linda en Femke, dank dat jullie het logistieke brein achter de PRECOVID-studie wilden 
zijn. Jullie steun is cruciaal.
Wouter, lisa, Ajeng en Vesla, many thanks for your endless support and effort to help.
Prof. Netea en Prof. Joosten, beste Mihai en leo, dank dat ik jullie werkwijze van heel 
dichtbij mocht meemaken en dank voor jullie steun bij de verschillende studies. Ik heb 
me nooit een buitenbeentje gevoeld in jullie onderzoeksteam, ondanks het verschil in 
bloedgroep.
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Collega’s van het lab Experimentele Interne Geneeskunde, en in het bijzonder; Cor, 
Mark, Michelle, Maartje, Katharina, Martin, Marije, sanne, Arjan, Rob en Rob en 
natuurlijk de analysten , bovenstaande geldt zeker ook voor jullie. Ik ben blij dat ik ben 
opgenomen in jullie groep en dat ik zo veel van jullie mocht leren.
Beste co-auteurs, dank voor jullie ideeën, correcties en suggesties. In het bijzonder ben 
ik daarbij dank verschuldigd aan Prof. dr. de Groot en Frank van de Veerdonk, dank voor 
jullie intensieve begeleiding bij de verschillende artikelen. 
Prof. Pickkers, beste Peter, dank voor jouw steun en reflectie gedurende mijn onderzoek. 
Ik waardeer het enorm dat je mijn mentor wilde zijn en dat jouw deur altijd open stond.
Jeroen, sami, Hanneke, long-wetenschappers van het 1e uur, dank voor de boeiende 
gesprekken en steun, daar waar nodig.
De longfunctieafdeling, dank voor de oneindige metingen die jullie verricht hebben in 
het kader van de PRECOVID-studie.
Graag wil ik de proefpersonen bedanken die in de diverse studies hebben geparticipeerd. 
Zij hebben zichzelf tot studieobject gemaakt ten behoeve van een meer algemeen belang.
Lieve vriendinnen, Amber, nicky, lindy, Kim, nanette, Chantal, Marianne, sylke, Chris, 
Anne, Caroline, Roline, Caroline, en Anne, dank voor jullie vriendschap en voor het 
accepteren van mijn drukke agenda, zeker in toegenomen mate in het laatste jaar. Jullie 
zijn absolute toppers! 
Mijn lieve paranimfen Rachel en Renée, dank voor jullie steun en rugdekking, van het 
allereerste begin tot aan het einde. Ik kan mij geen sterker team wensen!
Lieve familie stevens, dank voor dat ik zo hartelijk in jullie familie ben opgenomen.
Lieve Martijn, dank voor dat je er bent, en altijd al mijn maatje bent geweest.
Lieve papa en mama, jullie onvoorwaardelijke steun en vertrouwen geeft mij steeds 
de moed om dat stapje verder te zetten. Ik realiseer mij ten zeerste hoe bijzonder onze 
band is. Dit proefschrift is mede dankzij jullie zo geworden.
Lieve boudewijn, waar mijn ouders mij moed geven, geef jij me kracht. De kracht om het 
écht goed te willen doen. Ik ben zo trots op jou!
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Floor Aleva werd geboren op 24 november 1988 in Zwolle, 
als oudste kind van Roel en Dionne. Enkele jaren later 
volgde Martijn, inmiddels in Groningen. Zij verhuisden in 
1994 naar Eindhoven, waar Floor haar Atheneum volgde 
aan het Pleincollege Eckart en tevens deelnam aan het 
Pre-University Program aan de TU/e. Ze behaalde haar 
diploma in 2007, waarna zij in Nijmegen begon met 
de studie Geneeskunde. Gedurende haar studie werd 
het enthousiasme voor wetenschap al vroeg gewekt en 
werkte zij aan verschillende studies voor de afdelingen Pathologie en IQ Healthcare in 
het Radboudumc. In 2012 werd Floor geselecteerd voor het Honours Master Program 
‘Beyond the Frontiers’ en werd ze in de gelegenheid gesteld om enkele maanden onder-
zoek doen aan het prestigieuze Imperial College in Londen. Dit leidde tot haar eerste 
wetenschappelijke publicatie.
Bij terugkomst werd de interesse voor de longziekten en de acute geneeskunde 
gewekt tijdens de coassistentschappen. In 2013 volgde zij haar senior co-schap bij 
prof. dr. Yvonne Heijdra op de afdeling Longziekten van het Radboudumc en werd zij 
aangenomen voor de specialisatie tot longarts. Met veel plezier heeft Floor hierna een 
keuze-coschap Intensive Care geneeskunde gevolgd in het Jeroen Bosch Ziekenhuis te 
‘s-Hertogenbosch, waarna zij afstudeerde in 2014. De wetenschap lonkte nog steeds en 
toen Floor van Prof. dr. Yvonne Heijdra de mogelijkheid kreeg eerst om te promoveren 
alvorens te beginnen met de specialisatie, greep zij die kans direct aan. In samenwer-
king met de afdeling infectieziekten en mede onder supervisie van prof. dr. André van 
der Ven heeft zij promotieonderzoek gedaan wat heeft geresulteerd in dit proefschrift.
Floor volgt op dit moment de vooropleiding interne geneeskunde in het Jeroen Bosch 
Ziekenhuis te ’s-Hertogenbosch. Zij zal na afronding van de vooropleiding haar oplei-
ding tot longarts voortzetten in het Radboudumc.
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AAT  Alpha-1 Antitrypsin 
AD-HIES Autosomal-Dominant Hyper IgE Syndrome
ADP Adenosine 5’diphosphate
AE-COPD Acute Exacerbations of Chronic Obstructive Pulmonary Disease
AF Atrial Fibrillation 
ATS American Thoracic Society
AUC Area Under the Curve
BMI Body Mass Index
CD Cluster of Differentiation
CI Confidence Interval 
CM Central Memory
COPD Chronic Obstructive Pulmonary Disease
COX Cyclooxygenase 
CRP C-Reactive Protein
CRP-XL Cross linked Collagen-Related Peptide
CTPA Computed Tomography Pulmonary Angiography
CVD Cardiovascular diseases
CYP2R1 Cytochrome P2R1
DVT Deep Venous Thrombosis
ED Emergency department
EM Effector Memory 
ERS European Respiratory Society 
ETP Endogenous Thrombin Potential 
FDR False Discovery Rate 
FEV1 Forced Expiratory Volume per second
FG Functional Genomics 
FSC Forward Scatter
FVC Forced Vital Capacity
GP Glycoprotein
GPVI Glycoprotein VI
GOLD Global initiative for Obstructive Lung Diseases
HFGP Human Functional Genomics Project
HLA-DR Human Leukocyte Antigen – antigen D Related 
hsIL-6 High sensitive Interleukin-6
HWE Hardy-Weinberg Equilibrium
Ig Immunoglobulin
IFN Interferon  
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IL Interleukin
IQR Inter-quartile range
JAK Janus Kinase
LC- MS/MS Liquid Chromatography tandem Mass Spectrometry
LPS Lipopolysaccharide 
MAC-1 Macrophage receptor 1
MAF Minor Allele Frequency
MFI Mean Fluorescence Intensity
MPV Mean Platelet Volume 
NK Natural Killer 
NT-proBNP  N-terminal prohormone of Brain Natriuretic Peptide 
PAR-1 Proteinase-Activating Receptor-1 
PBMCs Peripheral Blood Mononuclear Cells
PE Pulmonary Embolism
PMC Platelet-Monocyte Complexes 
PPP Platelet-poor Plasma
PRP Platelet-rich Plasma
PSGL-1 P-selectin Glycoprotein Ligand-1 
RTI Respiratory Tract Infection
SCC Sideward Scatter
SD Standard Deviation
SEM Standard Error of the Mean
SH2 Src Homology 2
SNP Single Nucleotide Polymorphism
STAT3 Signal Transducer and Activator of Transcription 3
STROBE Strengthening The Reporting of Observational studies in Epidemiology
TF Tissue Factor 
Th-17 T Helper-17 
TLR Toll-like receptor 
TNF-α Tumor Necrosis Factor-Alpha
TPO Thrombopoietin
TRAP Thrombin Receptor Activating Peptide-6 
VDBP Vitamin D binding protein 
VDR Vitamin D receptor 
VTE  Venous thromboembolism
